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Abstract
Neuronal nicotinic acetylcholine receptors (nAChRs) are members of the Cys-loop super 
family of ligand gated ion channels. Dysregulation of nAChRs can lead to pathologies such as 
Alzheimer’s disease, Parkinson’s disease, Autism and nicotine addiction. Possible new 
therapeutic avenues are positive allosteric modulators (PAMs).
The natural product desformylflustrabromine (dFBr), a tryptophan metabolite of the 
marine bryozoan Flustra foliacea, was found to be PAM of a4|32 nAChR. Evaluation of our 
synthetic water soluble dFBr salt by two-electrode voltage clamp of Xenopus laevis oocytes 
expressing human nAChR confirmed that synthetic dFBr displayed similar properties as the 
natural product. Low concentrations of the synthetic dFBr enhanced ACh’s efficacy on a4p2 
receptors. At higher dFBr concentrations, dFBr inhibited ACh potentiated responses. On a7 
receptors, dFBr inhibited ACh induced currents.
Further pharmacological characterization of dFBr revealed that dFBr was able to 
enhance partial agonist potencies and efficacies. Evaluation of dFBr on antagonists showed no 
effect on antagonist inhibition. The mechanisms of biphasic modulation (potentiation and 
inhibition) of dFBr on a4p2 nAChR were also investigated. Enhanced efficacy of ACh induced 
currents by dFBr appeared to be accomplished by dFBr stabilization of the open receptor 
conformation by destabilization of the desensitized state. The inhibition of ACh potentiated 
currents by dFBr appeared to involve open-channel block.
To better understand dFBr mechanisms, its putative binding site was examined. Alanine 
mutations were made in non-orthosteric clefts on the P2+ and a4- faces. Results revealed 
residues located on these faces are involved in ACh induced conformational change of the 
receptor. In addition our data supports our hypothesis that allosteric modulation by dFBr interacts 
with residues located on the P2+ and a4- faces.
The new novel actions of (4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid) (HEPES) 
as a a4p2 stoichiometric PAM was discovered and characterized. We showed that HEPES, a 
common buffering agent, potentiated the high ACh sensitivity a4p2 receptor while only inhibiting 
the low ACh sensitivity a4p2 receptor. Mutagenesis results suggested that residue P2D217 is a 
critical residue in the HEPES binding site.
Results from these studies will aid in the development of therapeutic ligands that will 
assist in the treatment of diseases where nAChRs are dysregulated.
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1CHAPTER 1: Introduction
The role of nAChRs in pathological conditions is widespread and monumental. Neuronal 
Nicotinic Acetylcholine Receptors (nAChR) are being found not only in the Central Nervous 
System (CNS) but also in the Peripheral Nervous System (PNS), suggesting that nAChRs are 
important for many physiological processes throughout the body. Therapeutic ligands that 
selectively target nAChRs may be a good treatment strategy for diseases such as Alzheimer’s 
disease, Autism, nicotine addiction and cancer (see Chapter 2 for background of nAChR). 
Chapter 2 is intended to provide an extensive background of nAChR to aid in the understanding 
of the later research based chapters of this thesis and is intended to be submitted as a review 
arcticle in the near future.
The development of allosteric modulators is a potential and valuable treatment strategy in 
pathologies where nAChRs are dysregulated. Positive allosteric modulators (PAMs) affect the 
agonist evoked responses on nAChR. Because of PAMs’ low intrinsic activity, these ligands only 
affect the receptors in presence of agonists such as the endogenous neurotransmitter. This 
allows the spatial and temporal relationship of cholinergic transmission to remain unaltered.
To understand PAMs actions, several studies investigating different components of how 
an allosteric modulator works must be conducted. Characterization of PAMs action in 
combination with orthosteric ligands, including full and partial agonists and antagonists, will lead 
to a better understanding of how PAMs function on nAChR. Studies investigating the timing of 
PAM application can also provide clues to how a PAM is able to alter the stability of various 
receptor states (closed vs. open vs. desensitized). Elucidation of PAM mechanism will facilitate in 
the development of drugs that are selective of nAChR subtypes and stoichiometries that have 
specifically tailored actions.
Identifying ligand binding sites broadens the understanding of nAChR structure and 
function as well as ligand-receptor interactions. Elucidation of ligand-receptor interactions leads to 
the development of selective ligands that are able to shape the receptor response to better treat a 
given pathology. Knowledge gained from characterizing ligand binding sites and understanding 
how a ligand shapes a receptor response will provide refinements to our current receptor models. 
Each step in the process provides a greater understanding of nAChR’s structure and function, 
and facilitates the development of novel allosteric ligands. Allosteric modulators are potentially 
valuable as diagnostic and therapeutic treatment tools for CNS disorders.
In this thesis, we address how the PAMs, desformylflustrabromine (dFBr) and 4-(2- 
hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES) work on various nAChR subtypes and
2stoichiometries in presence of orthosteric ligands to better understand the mechanism of PAMs. 
These studies are then followed by the initial characterization of the binding site. The findings 
from this research will aid in the development and understanding of PAMs as therapeutic and 
diagnostic ligands.
1.1. Gaps in Current Knowledge.
nAChRs have become a heavily investigated subject in the last decade. There are many 
gaps in the current knowledge that need to be investigated including the development of new 
therapeutic ligands for both the diagnosis and treatment of pathologies. Potential therapeutic 
ligands which are selective for subtypes and stoichiometries of these receptors will aid in our 
understanding of how dysregulation of nAChR are associated with ailments. Furthermore 
selective ligands could also aid in the treatment of diseases where the densities of subtypes or 
stoichiometries of nAChR differ from normal brains. Characterization of the parent lead 
compound location and structure of the binding sites on nAChR would aid in the development of 
therapeutic ligands.
One possible therapeutic treatment avenue is the use of Positive Allosteric Modulators 
(PAMs). It is currently known that PAMs alter the apparent affinity and efficacy of agonist evoked 
responses and that PAMs are unable to activate the channels alone. PAMs appear to bind at 
allosteric binding sites throughout nAChRs (see Chapter 2). A more in-depth understanding of 
how PAMs interact with nAChR is needed so that this type of ligand can be used clinically. It is 
unknown if PAMs work by increasing the receptor popen and/or alter the firing rate of the receptor. 
It also seems likely that different PAMs will perform differently on nAChR subtypes and 
stoichiometries. Studies investigating how PAMs interact with different pharmacological agents, 
mechanism of action and elucidation of their binding sites will aid in the understanding of how 
PAMs are able to alter agonist affinity and efficacy.
1.2. Gaps Addressed in Current Project.
This thesis focuses on the development of dFBr and HEPES as potential new therapeutic 
ligands (see Chapters 3-5). The compound dFBr is explored more thoroughly than HEPES. 
Exploration of the pharmacology of dFBr, mechanism of action and binding site location on a4(32 
nAChR is emphasized in this thesis (see Chapter 3 and 4). Chapter 3 is a manuscript that has 
been published (J Pharmacol Exp Ther. 2010 Sep 1;334(3):917-26.) and Chapter 4 has been 
submitted to Journal of Molecular Pharmacology. Results from these studies will aid in the 
understanding of how this parent lead compound interacts with a4p2 nAChR. Information gained 
from these studies will aid in the development of dFBr analogues that are more selective and will 
have increased ACh affinity and efficacy with the lack of ability to inhibit ACh induced currents.
3More importantly, these studies provide supportive evidence for developing dFBr-like molecules 
for therapeutic treatment strategies.
Initial HEPES pharmacology and functional binding site studies are also discussed (see 
Chapter 5). Chapter 5 is a manuscript has been submitted to the Journal of Pharmacology and 
Experimental Therapeutics. Here we present the findings that HEPES is a high-sensitivity (HS) 
a4p2 nAChR ligand. On HS receptors, HEPES is a PAM that is able to enhance the ACh efficacy. 
On low-sensitivity receptors (LS), HEPES is a poor inhibitor of ACh evoked currents. The putative 
binding site of HEPES on HS receptors was found. Findings from these studies will further the 
understanding of a4p2 selective PAMs pharmacology and binding sites.
1.3. General Hypothesis.
Members of LGICs include 5-HT3R, nAChR, GABAAandcR and glycine receptors. On 
GABAaR the allosteric modulators benzodiazepines and barbiturates have been prescribed to 
alleviate the symptoms of depression, epilepsy and anxiolytics. Despite nAChRs wide distribution 
throughout the human body, there are no allosteric modulators used therapeutically to selectively 
target nAChR subtypes. Based on preliminary molecular modeling and sequence comparisons 
between members of LGICs we hypothesize that there are allosteric modulators for a4p2 
nAChRs and they bind in a similar region as benzodiazepines on GABAaRs.
1.3.1. Specific Hypotheses.
1.3.1.1. Desformylflustrabromine is an Allosteric Modulator of the ct4[}2 nAChR.
This hypothesis is based on previous studies by Kim et al. (2007) and Sala et al. (2005), 
that dFBr selective potentiates a4p2 nAChR and inhibits a7 receptors (Sala et al., 2005; Kim et 
al., 2007). In order to prove this hypothesis, three criteria must be met: 1) How does dFBr alter 
a4p2 function in presence of pharmacological agents like full agonist, partial agonist and 
antagonist? 2) What is the mechanism of dFBr potentiation and inhibition? 3) Where does dFBr 
bind?
Results showed that dFBr was able to potentiate full and partial agonist induced a4(32 
nAChR responses (Weltzin and Schulte, 2010a). The inhibition of ACh induced currents by 
antagonists on a4p2 nAChR was unaffected by dFBr. The mechanism of dFBr inhibition was 
shown to be voltage dependent, suggesting that dFBr inhibition of ACh-evoked currents was 
caused by open-channel block. The potentiation of dFBr appears to involve maintenance of the 
receptor open state either by destabilization of the desensitized state or stabilization of the open 
state. The potentiation mechanism of dFBr requires further investigation using more refined
4techniques such as single-channel studies. Question 3 is addressed in specific hypothesis 
number two.
1.3.1.2. Desformylflustrabromine Binds at the /32+/a4- Interface on a4f}2 nAChR.
Chapter 4 of the thesis investigates the putative dFBr binding site on a4(32 receptors. The 
putative binding location of dFBr was hypothesized to be at the p2+/a4- cleft. This region was 
chosen following sequence comparisons between other LGIC binding sites and molecular 
modeling studies. The putative dFBr binding site was explored by making single point alanine 
mutations and evaluating the effects of the mutations on ACh and dFBr induced responses. 
Mutagenesis results suggest that dFBr primarily binds to the (32+ face. Additional results suggest 
that non-orthosteric subunit faces are involved in a4p2 responses to ACh. Results from this study 
begin to elucidate the dFBr binding site on the P2+ face and advances our understanding of a4p2 
nAChR function in response to ACh.
1.3.1.3. HEPES is a positive allosteric modulator ofa4fi2 nAChR.
This hypothesis is based on the observation that the crystal structure of the Acetylcholine 
Binding Protein (AChBP) contains HEPES molecules in a similar region of the protein that binds 
ACh (Brejc et al., 2001). This led us to question the reactiveness of HEPES with nAChR.
The characterization of HEPES actions on a4p2 and a7 nAChR is studied in Chapter 5 of 
the thesis (Weltzin and Schulte, 2010b). Findings from this study demonstrate that HEPES is a 
stoichiometric selective PAM that potentiates and inhibits ACh induced currents on HS receptors. 
A point mutation on the C-loop of the P2+ face eliminated the HEPES potentiation. On LS 
receptors, HEPES inhibits ACh evoked currents. Interestingly on a7 nAChR HEPES appears to 
have no effect on ACh currents. Furthermore this study investigated the use of other buffer 
systems and the how HEPES may have altered the interpretation of other modulators.
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6CHAPTER 2: Neuronal Nicotinic Receptors: Structure, Function and Therapeutic 
Opportunities. 
2.1. Introduction.
Ligand gated ion channels (LGIC) are essential components of the central and peripheral 
nervous system (Taly et al., 2009). Family members of the Cys-loop super family are nicotinic 
acetylcholine (nAChR), GABAaR, 5HT3R and glycine receptors (Gotti and Clementi, 2004). LGICs 
play a critical role in synaptic transmission at the junctions between nerve cells (synapses) and 
between nerve and muscle cells by regulating the passage of ions into the cell (Gotti et al., 
2006b). The regulation of synaptic transmission is important in learning, memory, gene 
transcription and muscle contraction. Dysregulation of nAChRs can lead to neurological disorders 
including Alzheimer’s disease (Court et al., 2001; Nordberg, 2001), Schizophrenia (Adams and
Stevens, 2007), Parkinson’s disease (Aubert et al., 1992), Autism (Martin-Ruiz et al., 2004;
Lippiello, 2006) and nicotine addiction (Picciotto et al., 2001). Using allosteric modulators to target 
ion channels is a promising therapeutic treatment for many neurological disorders.
2.2. A General Description of the Physiological Role of nAChRs.
nAChRs are located in the peripheral and autonomic nervous system (PNS and ANS) at the 
skeletal neuromuscular junction and in the Central Nervous System (CNS) at the neuronal 
synapses, mediating the rapid and brief effects of acetylcholine (ACh) across a wide range of 
acetylcholine (ACh) concentrations (ranging from nM to mM) (Dani and Bertrand, 2007). Neuronal 
synapses are junction points where both pre- and post- synaptic cells meet. The gap between the 
two neurons, otherwise known as the synaptic cleft, is about 100 nM wide. In addition to ACh, 
nAChRs respond to a range of endogenous and exogenous pharmacological agents including 
nicotine and organophosphates. Activation of nAChR produces an enhanced release of other 
neurotransmitters including dopamine, serotonin, glutamate and GABA (y-aminobutyric acid).
The process of synaptic transmission begins with the generation of a wave of 
electrochemical excitation known as an action potential at the axon hillock. The generated action 
potential propagates down the axon of the pre-synaptic neuron until it reaches the synapse. The 
action potential depolarizes the membrane and causes calcium (Ca2+) permeable ion channels to 
open. Calcium ions flow into the pre-synaptic cell producing a rapid increase in calcium 
concentration. The high concentration of calcium triggers activation of calcium-sensitive proteins 
attached to synaptic vesicles that contain neurotransmitters such as ACh. The vesicles fuse with 
the cell membrane by interacting with membrane proteins such as t- and v-SNARES and release
7their neurotransmitters into the synaptic cleft. The neurotransmitters diffuse into the synaptic cleft 
where the molecules can either bind to receptors on the membrane of the post-synaptic cleft, be 
degraded or diffuse away from the cleft. The binding of neurotransmitters to receptors such as 
nAChR on the post-synaptic cell initiates the activation of the receptors allowing ions such as 
Ca2+, Na+ and K+ to flow down their ion concentration gradient into the post-synaptic cell. If the 
translocation of ions results in a membrane potential change of about 15 mV, the action potential 
will be propagated.
The resulting magnitude and sign of the induced action potential depends on the charge and 
influx of the translocated ions. Since the conduction of a single input is passive, it takes multiple 
inputs occurring simultaneously to generate an action potential. A synaptic potential can be 
inhibitory or excitatory depending on the charge of the translocated ions, the receptor type, the 
concentration of permeant ions inside and outside of the cell and the cells action potential 
threshold (Purves, 2004). Inhibitory post-synaptic potentials (IPSP) are caused by the 
conductance of anions and low concentrations of cations. IPSPs reduce the chances of 
generating an action potential by hyperpolarizing the post-synaptic membrane (Purves, 2004). 
The excitatory post synaptic potential (EPSP) are caused by the conductance of cations as in the 
case of nAChR and low concentrations of anions. EPSPs increase the possibility of generating an 
action potential by depolarizing the post-synaptic cell (Purves, 2004).
After a couple of milliseconds, the neurotransmitter will disassociate from the receptor (Dani 
and Bertrand, 2007). The remaining neurotransmitter will either be metabolically degraded or be 
reabsorbed by the pre-synaptic cell for future use.
2.3. The Ligand Gated Ion Channel Superfamily.
2.3.1 Classification of LGICs.
Ligand gated ion channels (LGIC) are divided into three subclasses; Cys-loop, ionotropic 
glutamate and ATP-gated receptors, based on their structure, genetic origin and function. The 
receptors are integral membrane proteins and have three distinct extracellular, transmembrane 
and intracellular domains (Figure 2.1). Cys-loop receptors are pentamers. The ionotropic 
glutamate receptors bind the neurotransmitter glutamate and are usually tetramers. Members 
include AMPA, Kainate and NMDA receptors. ATP-gated receptors respond to the nucleotide 
ATP. The only known ATP-gate receptor is the trimer PX2 receptor.
The Cys-loop superfamily contains a characteristic 15 amino acid loop containing two 
cysteine (Cys) residues forming a disulfide bond. The Cys-loop is located at the bottom of the
8extracellular domain (Figure 2.1). Members of the Cys-loop super family include GABAa and c, 
5HTa-3, glycine and muscle and neuronal types of nicotinic acetylcholine receptors (nAChR).
The Cys-loop superfamily is further divided into anion and cation conducting channels. In 
general, receptors which pass anions are inhibitory, while cation selective channels are 
excitatory. The acetylcholine receptors and the 5HT3R are non-seiective cation (K+, Ca2+ and 
Na2+) conducting channels. The A and C subtypes of GABA and glycine receptors are non- 
selective anion conducting (Cl ) receptors. Unlike types A and C, the B type of the GABAR is a G- 
protein receptor.
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Figure 2.1. A diagram of a receptor belonging to the Cys-loop super family of LGIC 
emphasizing the location and amino acid composition of the cys-ioop.
A representative side view of the receptor showing two of the five subunits is displayed above. 
The pore lumen, the neurotransmitter binding site (NT), the transmembrane topology and the 
conserved disulfide bridge (boldfaced C) are shown. All Cys-loop superfamily receptors share a 
similar amino acid composition of the Cys-loop (shown below). Amino acid sequences are from 
(Limapichat et al., 2010). (Top figure modified and used with permission from (Sunesen et al.,
2006).)
92.4. Structure of the Cys-loop LGIC Family.
The Cys-loop LGICs have similar general structural features typified by the nicotinic 
acetylcholine receptor (nAChR) subfamily. Members of the Cys-loop super family have an 
extracellular or ligand binding domain, a transmembrane domain and a variable cytosolic loop 
(Figure 2.2).
Figure 2.2 Ribbon structure of the Torpedo nAChR showing the extracellular, 
transmembrane and cytosolic domains.
(Image reprinted with permission from (Gay and Yakel, 2007).)
All members of the nAChR family respond to the exogenous agonist nicotine and the 
endogenous agonist acetylcholine, hence the name “nicotinic acetylcholine receptors.” Similarly, 
GABAa and c. 5-HT3 (serotonin, 5-hydroxytryptamine) and glycine receptors respond to their 
respective endogenous neurotransmitter y-amino butyric acid, serotonin (5-hydroxytryptamine) 
and glycine. Figure 2.3 displays the ancestral branch points where new receptors were formed.
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Figure 2.3 The ancestral branch points of the modern day Cys-loop super family of 
LGIC.
(Image reprinted with permission from (Davies et al., 2003)).
The Cys-loop receptors are pentameric receptors composed of different subunits. Muscle 
nAChR are heteromeric receptors composed of four different subunits, a1, (31, 5, y and £, and 
are arranged in a 2a:ip:15:1y or e ratio (Barry and Lynch, 2005) (Table 2.1). The y subunit is 
only expressed in the embryonic form of the receptor while the e subunit is expressed in the adult 
receptor (Barry and Lynch, 2005). The neuronal nAChRs are composed of a broad range of 
combinations of a and p subunits (Gotti and Clementi, 2004). There are nine different a subunits 
(a2-10) and three p (P2-4) subunits found in the CNS, collectively known as “neuronal” type 
subunits (Gotti and Clementi, 2004) (Table 2.1). Both homomeric and heteromeric receptors 
assemble to produce functional receptors. The multiple combinations of a and p subunits produce 
a large number of possible neuronal nAChRs, each with unique properties.
nAChRs are integral allosteric membrane proteins with a molecular mass of -290 kDa 
and encoded by 17 genes (Taly et al., 2009). Of these, nine a and three p subunits are expressed 
in the brain. The various subunit combinations result in different pharmacological and kinetic 
properties and physiological locations.
Serotonin type 3 receptors (5HT3R) consist of five different subunits ranging from A to E 
(Gaddum and Picarelli, 1957) (Table 2.1). 5HT3RA form homomeric receptors while types A and B
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can combine and form hetero pentameric receptors. Types C, D and E have been described, but 
have yet to be characterized. GABAa receptors are composed of combinations of 16 different 
subunits (a1-6, p1-3, y1-3, 5, e, t t  and 0) (Olsen and Sieghart, 2008) (Table 2.1). Zinc activated 
ion channels (ZAC) have just recently been described and are known to consist of one subunit 
(Davies et al., 2003). Glycine receptors consist of a1-4 and a single p subunit (Betz et al., 1999) 
(Table 2.1).
Table 2.1 Currently known members of the Cys-loop super family of LGICs.
Receptor Ligand Permeable Ions Number of subunits known
Muscle nAChR ACh Cations 5
Neuronal nAChR ACh Cations > 16
5-HT3R 5-HT Cations >2
ZAC Zinc Cations 1
GABA RA GABA Anions > 16
Glycine R Glycine Anions >5
2.5. Predominant nAChR Subtypes.
The predominant forms of nAChR found in the Central Nervous System (CNS) are the 
homomeric a7 and heteromeric a4p2 subtypes. The a7 receptors contain five identical subunits 
arranged around a central cation conducting pore (Figure 2.4)(Taly et al., 2009). The a4p2 
receptors contain different combinations of a4 and P2 subunits, depending on the putative 
stoichiometry (Figure 2.4). The a7 receptors are known to desensitize rapidly and have a higher 
Ca2+:Na+ permeability ratio compared to NMDA and other nAChR receptors (Albuquerque et al.,
2009). The a4p2 subtype exhibits slower desensitization kinetics and lower cation permeability 
compared to a7 nAChR (Figure 2.4).
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Figure 2.4 a7 and a4p2 nAChR subunit arrangements and ACh-induced response 
profiles.
Left) Homomeric a7 ACh induced response profile and illustration of subunit arrangement. 
Middle) Heteromeric low ACh sensitive a4p2 nAChR ACh induced response profile and 
illustration of putative subunit arrangement. Right) Heteromeric high ACh sensitive a4p2 nAChR 
ACh induced response profile and illustration of putative subunit arrangement. The plus and 
minus signs designate the principal and complementary faces of each subunit.
Previous studies investigating a4p2 nAChR injected in a 1:1 a:p ration saw two- 
component dose response curves in response to varying concentrations of ACh, suggesting that 
two different populations of receptors existed in the preparation (Zwart and Vijverberg, 1998; 
Buisson and Bertrand, 2001; Moroni et al., 2006a; Zwart et al., 2006b). The estimated EC50 
values were 0.3 - 2.8 pM for the high ACh sensitivity component and 66 - 142 pM for the low 
sensitivity component (Moroni et al., 2006a). Two putative stoichiometries of a4p2 receptors have 
been observed in vitro, but have yet to be observed in vivo. The expression of a4p2 
stoichiometries in Xenopus laevis oocytes can be influenced by injecting 5 - 1 0  times higher 
concentrations of one subunit over the other (Zwart and Vijverberg, 1998; Moroni and Bermudez, 
2006; Moroni et al., 2006a; Tapia et al., 2007). Previous studies have further suggested that the 
high-sensitivity receptor preparation predominantly forms receptors with two a4 and three p2 
subunits in the pentameric arrangement apapp ((a4)2(P2)3) (Nelson et al., 2003; Zhou et al., 
2003; Briggs et al., 2006b; Moroni et al., 2006b; Zwart et al., 2006a; Tapia et al., 2007) (Figure 
2.4). The high ACh-sensitive receptors in the presumed stoichiometry have two a+/p- clefts, two 
P+/a- clefts and one P+/P- cleft. Several studies have suggested that receptors formed in the low- 
sensitivity receptor preparation are composed of three a4 and two p2 subunits in the arrangement 
apapa ((a4)3(P2)2) (Nelson et al., 2003; Zhou et al., 2003; Briggs et al., 2006b; Moroni et al.,
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2006b; Zwart et al., 2006a; Tapia et al., 2007) (Figure 2.4). The low ACh-sensitive receptor is 
thought to contain two a+/(3- clefts, two p+/a- clefts and one a+/a- cleft. It is likely that other 
arrangements are also expressing in both the high and low sensitivity receptor preparations.
The a4p2 stoichiometries differ in their calcium permeability, functional pharmacology 
and pharmacological chaperones (Nelson et al., 2003; Tapia et al., 2007). The Ca2+ permeability 
has been demonstrated to be different between the two stoichiometries. Reversal potential 
experiments showed that the low sensitivity receptor permeates Ca2+ though the channel by 26.9 
± 1.3 mV. The high sensitivity receptor permeates Ca2+ though the channel at a much slower rate 
of 7.3 ± 2.2 mV (Tapia,et al., 2007). The higher Ca2+ permeability of the low sensitivity receptor is 
a result of a glutamate residue in the TM2 region of a4 subunits. The p2 subunits have a lysine 
residue at this position that reduces Ca2+ permeability (Tapia et al., 2007).
The high and low-sensitivity receptors differ in their response behavior to different 
pharmacological agents (Moroni et al., 2006a). Nicotine, epibatidine, TC-2559, A-85380 and 3-Br- 
cytisine produced concentration-dependent inward currents on oocytes expressing high and low- 
sensitivity receptors. Cytisine, 5-l-cytisine, 5-Br-cytisine and 5-CI-cytisine acted as partiai agonists 
and only evoked responses in oocytes expressing the low-sensitivity receptor. Nicotine, 
epibatidine and 3-Br-cytisine behaved as partial agonists on high-sensitivity receptors. TC-2559 
and A-85380 were significantly more efficacious than ACh on high-sensitivity receptors. On low- 
sensitivity receptors epibatidine and A-85380 were significantly more efficacious than ACh 
(Moroni et al., 2006a). In addition, the low-sensitivity receptor stoichiometry appeared to be more 
sensitive to channel blocking drugs such as mecamylamine, chlorisondamine and d-tubocurarine 
(Briggs et al., 2006a), suggesting that the structure of the channel pore may differ from that of the 
(a4)2(P2)3 stoichiometry.
The expression of nAChR can be mediated by pharmacological ligands. The expression of 
high-sensitivity a4(32 receptors has been shown to increase after incubating transfected cells with 
nicotine (Buisson and Bertrand, 2001) and the amplified expression occurred independently from 
protein synthesis (Peng et al., 1994; Wang et al., 1998). Augmented expression resulted from 
increased receptor assembly (Wang et al., 1998) in combination with a reduced turnover rate of 
existing surface nAChRs (Peng et al., 1994). Functional studies have additionally revealed that 
the low-sensitivity receptor expression is mediated by post-translational modification of the a4 
subunit by chaperone protein 14-3-3 and protein kinase A (Exley et al., 2006). 3-24h exposure to 
nicotine caused up-regulation of the high a4(32 sensitive receptors promoting the assembly of 
nAChR subunits from large pools of unassembled subunits (Kuryatov et al., 2005). The newly 
formed receptors had a 5-fold lifetime increase on the cell surface membrane. Membrane-
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permeable ligands such as nicotine and choline (Kuryatov et al., 2005; Gahring et al., 2010) and 
less permeable quaternary amine cholinergic lingads (Kuryatov et al., 2005) can act as 
pharmacological chaperones within the endoplasmatic reticulum aiding the assembly of nAChRs.
2.6. Receptor Structure Described by Biochemical and X-ray Crystallography Studies.
Cys-loop LGICs are found throughout the PNS and CNS (Taly et al., 2009). The Cys-loop 
superfamily of LGICs are composed of five membrane bound subunits arranged around an axis 
perpendicular to the cell membrane and form a pore that conducts ions from the outside to the 
inside of the cell (Figure 2.5). Each subunit contains a large amino terminal extracellular domain, 
a four segment transmembrane domain (TM1-TM4) and a variable cytoplasmic domain (Figures
2.2 and 2.5). Depending on the subunit composition, different types of receptors are formed. 
Homopentameric receptors contain the same subunits while heteropentameric receptors have 
different subunits (Figures 2.4 and 2.5). Different combinations of subunits result in the 
expression of receptor subtypes and stoichiometries with varying ligand selectivity and 
conductances (Figure 2.5) (Albuquerque et al., 2009).
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Figure 2.5 Example of the Cys-loop receptor structure.
A) This diagram shows the general structure of a Cys-loop structure. Note similarity to nAChR. 
The receptor is embedded in the cell membrane and in this example passes cations. B) The 
structure of each subunit. TM1-TM4 are the helices that comprises the transmembrane region. C) 
A general structure of a homopentameric receptor. The + designates the principal face and the -  
designates the complementary phase. D) A general structure of a heteropentameric receptor. The 
a402 heteropentameric receptors can form two different stoichiometries based on the number of 
a4 and 02 subunits expressed (left versus right).
2.6.1 Extracellular Binding Domain.
To date, crystallography studies of nAChR and the Acetylcholine Binding Protein 
(AChBP) have been used to describe the structure of the amino terminal. A 4.6A crystal structure 
of the Torpedo nAChR uncovered that the ion tunnel is framed by seven twisted 0-sheet strands 
(Miyazawa et al., 1999). The recent 1.94A resolution structure of the extracellular domain of the 
a1 nAChR revealed a ten-stranded 0-sandwich and an N-terminal a-helix (Dellisanti et al., 2007) 
(Figure 2.6). The sheet constructed from the strands 01, 02, 03, 05, 06 and 08 is referred to as 
the inner sheet, while 0-strands 04, 07, 09 and 010 are referred to as the outer sheet (Dellisanti 
et al., 2007) (Figure 2.6). Additional structural insights come from the 2.7A crystallization of the 
Lymnaea stagnalis molluscan AChBP (Brejc et al., 2001) (see section 2.6.5).
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Figure 2.6 The 1.94A crystal structure of the extracellular region of the mouse a1 
nAChR.
The crystal structure of mouse a1 nAChR subunit (cyan) bound to a-bungarotoxin. The 
carbohydrate chain is shown as a magenta stick structure. Left) Front view of the inner and outer 
sheets of the extracellular region. Right) The top view of the structure. (Image reprinted with 
permission from (Dellisanti et al., 2007)).
ACh is the endogenous ligand for nicotinic receptors. The location where the endogenous 
neurotransmitter binds is termed the “orthosteric site.” In nAChR, the orthosteric site has been 
shown to bind both agonist and antagonist and is located in the extracellular region between the 
principal face of the a and the complementary face of the a or (3 subunits (Figure 2.7)(Taly et al.,
2009). The “principal” faces (denoted as the + face) comprise loops A ((3-strands P4-(35), B (p- 
strands P7-p8) and C (P-strands P9-P10) (Corringer et al., 1995; Unwin, 2005; Dellisanti et al.,
2007) (Figure 2.7). The complementary face (designated the -  face) contains the P-strands D, E 
and F (Figure 2.7) (Corringer et al., 1995).
Depending on the subunit composition of a nAChR, there are either two 
(heteropentameric) or five (homopentameric) ACh-binding sites within the extracellular domain. 
The ACh binding site is termed the “aromatic box” (Corringer et al., 2000; Brejc et al., 2001) 
(Figure 2.7B) and is primarily formed by five aromatic residues, Y93, W149, Y190 and Y198 
located on the principal face, and W55, located on the complementary face (Figure 2.7B) 
(Corringer et al., 2000; Brejc et al., 2001).
Nicotinic agonists contain a cationic nitrogen and a hydrogen bond acceptor that interact 
with nAChRs (Glennon and Dukat, 2000; Glennon et al., 2004) (Figure 2.7C). In a4p2 nAChR, 
there is evidence of a strong cation-TT interaction between W149 and the ligands ACh and 
nicotine (Puskar et al., 2011). Nicotine also strongly interacts by hydrogen bonding with the
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backbone carbonyl contributed by W149 (Puskar et al., 2011). The a7 nAChR has been shown to 
have a similar binding pattern to those of a4p2 nAChR and it has been suggested that the a7 
nAChR cation-TT interaction is important for ligand recognition (Puskar et al., 2011). In a4p2 
receptors, this interaction is on W149 (Puskar et al., 2011). In a7 nAChR this cation-TT interaction 
occurs with Y93 and the agonist (Puskar et al., 2011). Epibatidine, a nicotine analogue, forms a 
cation-TT interaction with T198 (Puskar et al., 2011). A hydrogen bond involving the backbone NH 
of (32L119 of a4p2 nAChR has been shown to form with the ligands nicotine, ACh, epibatidine 
and carbamylcholine (Blum et al., 2010).
Carbamylcholine Choline
Figure 2.7 Loop labeling and residues involved in the orthosteric binding site in the 
extracellular domain of nAChR.
A) The designation of the loops and P-sheets on the principal (+) and complementary (-) faces. B) 
The orthosteric aromatic box. (Figure B reprinted with permission from (Lester et al., 2004)). C) 
Structures of important nicotinic ligands. Hydrogen bond acceptor groups are colored red and 
cationic nitrogens are colored blue.
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2.6.2 Transmembrane Domain.
2.6.2.1 Transmembrane Domain Structure.
The transmembrane (TM) domain spans the 3 nm or so of the cell lipid bilayer 
membrane. There are four alpha helical transmembrane segments (TM1-TM4) in each subunit for 
a total of 20 transmembrane helices in the holoprotein (Figure 2.8). The TM2 helices line the 
channel pore and contain residues that form the ion channel gate. Crevices filled with water and 
cholesterol are formed between TM1, TM2 and TM3 of each subunit (Figure 2.8) (Wick et al., 
1998; Bera et al., 2002; Bera and Akabas, 2005; Brannigan et al., 2008). The extracellular 
domain is linked to the TM1 domain (see Figure 2.5). There is a short intracellular loop which 
connects TM1 to TM2 (see Figure 2.5). TM2 and TM3 are connected via a short extracellular loop 
termed the TM2-TM3 linker (see Figure 2.5). A long intracellular loop connecting TM3 to TM4 
may interact with cytoskeletal protein within the cell (Barry and Lynch, 2005) (see Figure 2.5).
Figure 2.8 Transmembrane helices in nAChR.
The 20 transmembrane helices in a nAChR modeled after of N. Unwin (2005) 4A template: TM1 
is purple; TM2 is green; TM3 is blue and TM4 is cyan. Cholesterol was clocked into the proposed 
binding sites (sites A (yellow), sites B (orange), sites C (red)). (Image reprinted with permission 
from (Brannigan et al., 2008).)
The ion channel is blocked by a gate constructed of leucines and valines on the TM2 
helices (Figure 2.9). There are two rings, 9’ leucines and 13’ valines, that face into the channel 
and form a 6A in diameter hydrophobic girdle that prevents ion flow (White and Cohen, 1992; 
Banks et al., 2000; Miyazawa et al., 2003; Arevalo et al., 2005; Unwin, 2005). A numbering 
system has been developed to compare TMs of the different subunits to each other (Miller, 1989). 
The conserved positively charged residues at the cytoplasmic end of TM2 are defined as 0’ with
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the numbers increasing toward the extracellular end which is designated as 20’ (Miller and Smart,
2010). Hydrated Na+ and K+ ions (approximately 8A in diameter) cannot pass due to their size. 
Smaller dehydrated ions also cannot pass due to insufficient polarity through the hydrophobic 
girdle (Miller and Smart, 2010). It is believed that the gate opens as a result of the TM2’s tilting 
motion (Unwin, 1995).
The TM2 helix is an important structure that links the binding and gating events of the 
Cys-loop receptors. The TM2 extends two a-helix twists above the extracellular membrane in 
GABAaR (Bera et al., 2002). The position of the TM2 does not parallel the cell membrane. 
Rather, the upper section of the helix tilts away from the helix’s posterior part making it so that the 
top part of the channel (nearest to the extracellular domain) is wider than the bottom of the 
channel creating a ‘kink’ in the middle of each TM2 (Unwin, 1995).
Figure 2.9 The ion channel pore of nAChR.
The pore facing side chains of the TM2 helix. Grey dots are residues that form the gate. The 
molecular surface of the pore domain cross sectional view with the front subunit removed. Red 
and blue colors correspond to areas with high negative (red) and positive (blue) charge. The 
yellow areas are hydrophobic regions containing the gate. Valines and leucines are identified 
(aV255 and aL251). The little light blue sphere located midway down the channel is the 
approximate size of a hydrated sodium ion. (Image reprinted with permission from (Miyazawa et 
al., 2003).
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2.6.2.2 Transmembrane Domain and Receptor Gating.
There are several hypotheses regarding the conformational change within nAChR that 
link the ligand binding and gating events. Using electron microscopic structural studies of 
Torpedo nAChR, Unwin and colleagues proposed a receptor mechanism that links the binding 
and gating events (Unwin et al., 2002). They predicted that the binding of the agonist caused a 
clockwise rotation of each a region (likely the inner (3-sheet) of the extracellular domain 
perpendicular to the cell membrane and through the Cys loop (Unwin et al., 2002) (Figure 2.10A). 
However, due to the tilt of the angle’s rotation on each subunit’s extracellular domain, the 
quaternary structure of the extracellular domain rotates anticlockwise (Bocquet et al., 2009). The 
rotation of each extracellular domain may create contact points between the (31-(32 loop and the 
TM2-TM3 linker (Unwin et al., 2002), a hypothesis that is supported by glycine mutations in the 
linker region (Lynch et al., 1997; Lewis et al., 1998; Shan et al., 2003) and mutagenesis studies 
demonstrating that the TM2-TM3 linker experiences backbone structural changes during gating 
(England et al., 1999; Bera et al., 2002) (Figure 2.10A and C). The movement of the TM2-TM3 
linker (Figure 2.10B) torques the TM2 area, retracting TM2 from the pore and pushes it toward 
TM1, TM3 and TM4 causing the channel to open (Miyazawa et al., 2003). The channel is 
stabilized by contacts between neighboring TM1, TM2 and TM3 helices (Miyazawa et al., 2003). 
A water and/or cholesterol filled cavity separating TM2 from TM1 and TM3 additionally assists 
this movement (Figure 2.8) (Wick et al., 1998; Bera et al., 2002; Bera and Akabas, 2005; 
Brannigan et al., 2008). The TM1-TM2 and TM2-TM3 connecting loops contain conserved 
glycines that allow for increased flexibility of the TM2 movement (Miyazawa et al., 2003).
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Figure 2.10 Illustrations of the contacts and movements that may occur between the 
extracellular and transmembrane domains of nAChR.
A) A model of nAChR structure and gating modeled after Neigel Unwin’s investigations. The 
binding of the agonist induces clockwise rotation of the large shaded region which then torques 
the TM2 region causing the channel to open. The gate is represented by hatched lines in the 
transmembrane domain. B) The transmembrane structure of nAChR illustrates the postulated 
movement of the TM2 helix. Residue 19’ has been shown to rotate into a more hydrophobic 
environment (Dahan et al., 2004). C) Top, Ribbon structure of one nAChR subunit. All the (3- 
sheets are labeled. The red labels indicate the (3-strands that might rotate with agonist binding. 
Bottom, A close up view of the transmembrane domain, postulated contact points and structural 
movements associated with agonist binding. The L251 is thought to lie at the TM2 gate. 
(Permission to reuse image granted by (Lester et al., 2004).
22
The timing of TM2 movement has been investigated by Auerbach and co-workers 
(Purohit et al., 2007). They predicted that the two a-subunit TM2s moved before the non-a 
subunits. The sideways TM2-TM2 interactions that stabilize the gate are possibly disrupted by the 
outward movement of the two a-subunit TM2s. This movement would cause the leucine gate to 
destabilize and move out of the way, allowing the passage of ions (Miller and Smart, 2010).
Recent studies demonstrated that as the channel opens a tagged fluorescent group 
attached near the top of the TM2 helix moves into a more hydrophobic environment (Dahan et al.,
2004). This data is consistent with the clockwise rotation of the TM2 region. The rotation would 
move the chain at position 19’ into contact with several hydrophobic side chains (Miyazawa et al.,
2003). Previous data showing that the water-filled TM2-TM3 pocket changes shape during Cys- 
loop activation (Wick et al., 1998) is consistent with Unwin and colleagues’ theory of 
conformational change (Unwin et al., 2002).
It has been proposed that the Cys loop may be the structural region that contacts the 
TM2-TM3 linker during conformational changes (England et al., 1997; Kash et al., 2003; Leite et 
al., 2003). Unwin has postulated that the p1-p2 loop contacts the TM2-TM3 linker (Unwin et al.,
2002). In the AChBP, these regions are nearby which may explain the differing ideas. It is also 
possible that that both of these regions are involved in gating. Kash et al., (2003) suggested that 
the Cys loop and the TM2-TM3 linker are involved in both the opening and closing events of the 
receptor.
Another theory proposed by Auerbach and co-workers suggests that a gradual series of 
transitions occurs in response to agonist binding (Grosman et al., 2000; Cymes et al., 2002) 
(Figure 2.11). Linear free-energy analysis of single point mutations investigated by single-channel 
recordings may indicate the position of the transition state for the gating event. A cp=0 indicates 
the mutated receptor is in a ‘closed-like state, while a q>=1 indicates the receptor is more ‘open­
like’ (Grosman et al., 2000; Cymes et al., 2002). There is a gradient of cp values from the agonist 
binding site to the transmembrane domain. These results suggest that conformation changes 
occur in a wave rather than a unified single movement (Akk et al., 1996; Grosman et al., 2000; 
Auerbach, 2005; Zhou et al., 2005; Purohit et al., 2007) (Figure 2.11).
Figure 2.11 Auerbach and co-workers (2004) model of a conformational wave 
associated with agonist binding.
Structure is of nAChR a and 5 subunits. The gradient <p value is shown on the left. During gating, 
red colored residues in loop 5 have cp=0.93 and are the first residues to move. Loop 2/loop 7 in 
yellow (cp=0.80) are the next to move, followed by residue aS269 (green (p=0.69) in the TM2-TM3 
linker region. The upper part of the 5TM2 are the next to move (blue, cp=0.32) followed by the 
lower half of the 5TM2 (magenta, cp=0.0). The extracellular domain is the AChBP (Brejc et al., 
2001) and the transmembrane domain is from the Torpedo nAChR (Miyazawa et al., 2003). The 
cp values were estimated independently from Chakrapani et al., 2004. (The image is from 
(Chakrapani et al., 2004) and has been reused with permission).
2.6.3 Intracellular Domain.
The structure of the intracellular domain consists of a cytoplasmic loop that has not been 
extensively studied. Unwin’s 4.6A structure of the nAChR intracellular region predicted that there 
are transverse tunnels formed by a-helices in the channel wall (Miyazawa et al., 1999). However, 
Unwin’s 4A Torpedo nAChR structure did not reveal the cytoplasmic loop and was presumed to 
be disordered (Unwin, 2005).
Amino acid sequence comparison within the LGIC family of the intracellular region has 
revealed that this area is highly variable in amino acid residues and length. This loop of the
24
protein varies in length from 70 residues (in glutamate-gated Cl- channels) to 271 residues (a4 
nAChR) (Keramidas et al., 2004). The diversity of the cytoplasmic loop sequence may suggest 
that this region is important for subunit specific behavior and possible interactions with cellular 
components.
The residues in the TM1 (Wang et al., 2002) and at TM4’s extracellular and intracellular 
ends of a1 nAChR (Roccamo and Barrantes, 2007) have been shown to control the assembly 
and targeting of the receptors to the cell surface. Mutation and delegation of residues near the 
intracellular end of TM4 in the cytoplasmic loop have been shown to reduce the assembly of the 
receptor subunits and cause both enhancement and reduction of ACh induced currents of 
nAChRs (Yu and Hall, 1994b; Valor et al., 2002; Kuo et al., 2005; Castelan et al., 2007). The 
diversity of the cytoplasmic loop sequence may suggest that this region is important for subunit 
specific behavior and the possible interactions with cellular components. It has been 
demonstrated that the cytoplasmic loop interacts with cytoplasmic transport machinery during 
nAChR trafficking to the synapse (Williams et al., 1998; Temburni et al., 2000; Keller et al., 2001; 
Ren et al., 2005; Xu et al., 2006). The mutation of residues in the TM1 (Wang et al., 2002) and at 
TM4’s extracellular and intracellular ends of a1 nAChR (Roccamo and Barrantes, 2007) have 
been shown to reduce the assembly and targeting of the receptors to the cell surface. The 
cytoplasmic loop interacts with the actin cytoskeleton resulting in cell surface expression 
(Bencherif and Lukas, 1993; Yu and Hall, 1994a; Shoop et al., 2000) and the resultant 
phosphorylation (Pacheco et al., 2003; Wiesner and Fuhrer, 2006) may reduce the time the 
receptor is desensitized (Huganir et al., 1986; Fenster et al., 1999), enhance or reduce receptor 
expression (Wang et al., 2004; Cho et al., 2005) and reduces cytoskeletal interactions (Colledge 
and Froehner, 1997). In a7 nAChR, palmitoylation has been shown to aid in the formation of 
functional receptors (Drisdel et al., 2004; Huang and El-Husseini, 2005).
2.6.3.1 Ion Channel Selectivity.
The Cys-loop super family receptors contain ion selectivity filters that screen hydrated 
ions via a partial dehydration mechanism (Corringer et al., 1999b). Charged rings exist at the 
cytoplasmic and extracellular ends of the channels and are important for regulating channel 
conductances (Figure 2.12A) (Miller and Smart, 2010). In nAChR and 5HT3R, the rings are 
negatively charged permitting the passage of cations (Keramidas et al., 2004) while GABAAand c 
and glycine rectors have positively charged rings that allow anions to pass (Keramidas et al.,
2004).
Voltage-gated ion channels have aided our understanding of the movement of ions 
though receptor pores. In voltage-gated channels, ions transverse down the ion channel by
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dehydration of their water molecules by protein residues that mimic the interactions of water. The 
ions are then coordinated by the partial charges of the carbonyl groups found on the protein’s 
backbone and “ping-pong” down the pore (Doyle et al., 1998; Zhou et al., 2001; Dutzler et al.,
2003). Cys-loop receptors appear to have additional ion translocation mechanisms. For example, 
in muscle AChR cations are selected by the anionic residues located on either side of the TM2 
(Imoto et al., 1988) and the transverse tunnels in the cytoplasmic domain (Kelley et al., 2003) 
(Figure 2.12). The hydrophobic a-helices reside in the TM2 form a narrow region of the AChR 
channel, providing little stabilization and thereby minimally slowing the passage of hydrated ions 
(Miyazawa et al., 2003). Studies have shown that in the course of translocation, individual ions 
are transiently stabilized by electrostatic attraction to rings of negatively charged residue along 
the extracellular part of the pore (Imoto et al., 1988; Wang et al., 2008a) (Figure 2.12). The 
cytoplasmic border rings (positions -2 to 2) of TM2 select monovalent cations over anions (Galzi 
et al., 1992; Corringer et al., 1999a; Gunthorpe and Lummis, 2001; Keramidas et al., 2004; 
Sunesen et al., 2006; Wotring and Weiss, 2008). By using molecular dynamics simulations to 
investigate the transport of ions through the muscle nAChR, Wang et al., (2008) suggested that 
ion selectivity is achieved by electrostatic interactions while the translocation is reliant on channel 
hydration (Wang et al., 2008a) (Figure 2.12B). This study demonstrated that selective cation 
translocation may occur in two stages. First, cations are selected through a series of oppositely 
charged residues in the protein vestibule leading down to a narrow hydrophobic constriction 
(presumably the gate). Second, hydration of the narrow region and protein movement enables the 
cation to pass though the pore (Wang et al., 2008a).
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Figure 2.12 ion translocation in nAChR.
A) A homology model of the human adult muscle nAChR. The rings of change are shown. The 
rings and labels in grey describe charged residues that affect conductances and selectivity as 
described in Imoto et al.’s, (1988) functional assay (Imoto et al., 1988). The rings and labels in 
black are identified residues associated with prolonged cation dwell times in molecular dynamic 
studies conducted by Wang et al. (2008) (Wang et al., 2008a). (Image reprinted from (Sine et al.,
2010) and used with permission.) B) Molecular dynamic successive snapshots depict the 
translocation of a single cation though the nAChR channel. The water molecules inside the 
channel are shown in surface representation. The permeating ion is shown in yellow. Water 
molecules outside the channel are shown in line representation and other cations are shown as 
small yellow spheres (Image reprinted from (Wang et al., 2008a) and used with permission).
2.6.4 Comparison of Different Electron Diffraction and X-ray Crystailization of nAChR
Structures.
Structures obtained by electron diffraction and X-ray crystallization techniques have 
contributed substantial information about the architecture and function of LGICs (Unwin, 1995; 
Miyazawa et al., 1999; Unwin, 2005; Dellisanti et al., 2007). Unwin’s 4A resolution of the Torpedo 
AChR is currently the best structure to date and assists in the homology modeling of other 
nAChRs (Unwin, 2005). This structure reveals that the N-terminal extracellular domain of each 
subunit has ten (3-strands and one a-helix at the top of the channel pore, furthest from the cell 
membrane. The subunits are thought to contact each other in the extracellular domain primarily 
through polar contacts (Wells, 2008) while the transmembrane appears to make contacts mainly
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through hydrophobic contacts (Wells, 2008). The Cys-loop and the P1-p2 loop of the N-terminal 
extracellular domain of a subunit interact with the short TM2-TM3 loop of the TM domain (Unwin,
2005). This interaction may be linked to channel gating as described in the above sections.
The mouse a1 nAChR subunit bound to a-bungarotoxin was recently crystalized with a 
resolution of 1.94 A (Dellisanti et al., 2007). In the extracellular region, the Cys loop and the 
previously unknown N-linked glycosylation moiety appeared to interact with the bound a- 
bungarotoxin (see Figure 2.6). Functional studies demonstrated that the carbohydrate chain is 
involved in a-bungarotoxin binding and channel gating (Dellisanti et al., 2007).
2.6.5 X-Ray Crystallography and Molecular Modeling of AChBP.
In 2001, the 2.7A resolution X-ray crystal structure of the acetylcholine binding protein 
(AChBP) from the fresh water snail Lymnaea stagnalis was determined by Brejc et al.., (2001) 
(Figure 2.13). To date, three different AChBP proteins have been isolated from freshwater 
mollusks Lymnaea stagnalis (Brejc et al., 2001), Aplysia californica (Hansen et al., 2004), Bulinus 
truncates (Celie et al., 2005). In the snail, AChBP is secreted into the synaptic cleft and is thought 
to regulate neurotransmission by quenching ACh (Smit et al., 2001). These pentameric water 
soluble proteins lack the transmembrane and cytosolic domains; therefore AChBP may only be a 
model of the binding and not the gating mechanism.
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Figure 2.13 AChBP structure overview.
A) A stereo image of one subunit from the AChBP viewed from outside the pentameric ring. The 
N-terminus is colored blue while the C-terminus is colored red. The disulfide bridge found on the 
C-loop is colored in green ball-and-stick representation. The p-sheets are numbered. B) The 
topology of a AChBP subunit is shown. The Immunoglobulin-like folds have been labeled in 
alphabetical letters. The p-strands have been labeled p1 -10 and the loops have been labeled L1- 
10. The disulfide bridge is labeled as S-S. (Image reprinted with permission from (Brejc et al., 
2001).)
AChBP appears to be a good structural model of nAChR extracellular domain. The 
AChBP backbone is similar to nAChR with a comparative sequence of 20-40% homology (Wells,
2008). However, despite the low sequence homology, many other aspects of the tertiary and 
quaternary structures are similar. For example, nearly all of the conserved residues found in the 
nAChR family are also found in the AChBP (Brejc et al., 2001) and the AChBP binds similar 
agonist and antagonist such as ACh, nicotine, d-tubocurarine and a-bungarotoxin (Smit et al., 
2001).
The Brejc et al., crystal structure of Lymnaea AChBP showed that the amino terminal of 
each subunit consists of an a-helix, two short 3i0 helices and a core of ten p-strands forming a p- 
sandwich (Brejc et al., 2001) (Figure 2.13). The AChBP p-strands are considerably twisted with 
the p-sheets rotated against each other causing two separate hydrophobic cores to be formed 
(Brejc et al., 2001). Presumably, AChBP’s hydrophobic cores are the same structures described 
as the inner and outer P-sheets in nAChR. The 210 amino acid sequence of each AChBP subunit 
is the same and is most similar to the a7 nAChR (Brejc et al., 2001). The Cys-loop contains 14 
residues instead of the usual 15 (Brejc et al., 2001).
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2.6.5.1 AChBP Crystal Structure Bound to Orthosteric Ligands.
In Brejc et al.’s Lymnaea AChBP structure, the ligand binding sites are occupied by 
HEPES, a common buffering agent used in electrophysiological experiments (Brejc et al., 2001) 
(Figure 2.14A). The Lymnaea AChBP crystal structure bound to the nicotinic agonists nicotine 
and carbamylcholine provides insights into the orthosteric binding site (Celie et al., 2004; Karlin,
2004). Usually negatively charged, the orthosteric site facilitates the interactions with the 
positively charged tertiary nitrogen of nicotine and the quaternary nitrogen of carbamylcholine 
(Dougherty and Stauffer, 1990; Dougherty, 1996; Zhong et al., 1998). The negative charges 
within the orthosteric site are formed by the tt  electrons from the aromatic residues W143, Y192, 
Y1185 and W53 and the backbone carbonyl of W143 (Dougherty and Stauffer, 1990; Dougherty, 
1996; Zhong et al., 1998).
The C-loop in AChBP crystal structures suggests that this loop undergoes structural 
movements depending on the ligand bound in the orthosteric site (Figure 2.14B). The HEPES-, 
nicotine- and carbamylcholine- bound structure shows that the C-loop is positioned over the 
ligand (Brejc et al., 2001; Celie et al., 2004; Karlin, 2004). The Lymnaea AChBP with a- 
cobratoxin, an antagonist of nAChR, indicates a movement of the C-loop away from the binding 
site (Bourne et al., 2005). Comparison of AChBP structures free of ligand, agonists ((+)- 
epibatidine and lobeline) and antagonists (a-conotoxin Iml and methyllycaconitine) bound 
structures reveal that agonist binding induced C-loop closure (Hansen et al., 2004; Hansen et al.,
2005) (Figure 2.14).
30
Figure 2.14 AChBP with agonist and antagonist bound.
A) AChBP side view. The ligand binding site (ball and stick representation) is shown between the 
yellow and blue subunits. (Image reprinted from (Brejc et al., 2001) and used with permission.) B) 
Conformational change mechanism and ligand selectivity. Top: The top view of the Iml-bound (C- 
loop red) and epibatidine bound Aplesia AChBP penatmers (C-loop blue). Structure shows how 
distant conformations for the agonists and antagonists bind. Bottom: The overlay of the C-loop in 
the apo (grey), Iml (red), methylcaconitine (green) and epibatidine (blue). The bound epibatidine 
ligand is shown in light grey. The arrow depicts the motion of the opening and closing of the C- 
loop upon antagonist and agonist binding. (Image reprinted from (Hansen et al., 2005) and used 
with permission.)
2.6.5.2 AChBP Crystal Structure Bound to Allosteric Ligands.
The crystal structure of Aplysia AChBP bound to galanthamine and cocaine, positive 
allosteric modulators of nAChRs, demonstrate that these ligands bind deeply into the subunit 
interfaces without contacting the C-loop tip (Hansen and Taylor, 2007). AChBP, from the Bulinus 
truncates, was crystalized using the common biochemistry buffer agent N-cyclohexyl-3- 
aminopropanesulfonic acid (CAPS) (Celie et al., 2005). CAPS molecules were found in four of the 
five ligand binding sites (Celie et al., 2005). These crystal structures may provide insight on the 
different conformational changes that occur in response to binding of different ligands.
2.7. Orthosteric and Allosteric Binding Sites.
The agonist binding site on LGIC is located between two receptor subunits (Figure 2.7). 
The binding site for the endogenous agonist is commonly referred to as the “orthosteric" binding 
site while the binding sites for allosteric modulators are commonly referred to as “allosteric” 
binding sites. The allosteric site includes loops A, B and C on the primary face and p-strands D, E 
and F on the complementary face (Figure 2.7). Both sites include highly conserved aromatic
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residues. In general, the orthosteric site is negatively charged allowing favorable interactions 
between the positive charges of tertiary and quaternary nitrogens on nicotinic ligands (Dougherty 
and Stauffer, 1990; Dougherty, 1996; Zhong et al., 1998) (Figure 2.7). The negative charges 
within the orthosteric site are formed by the tt  electrons from the aromatic residues W143, Y192, 
Y1185 and W53 and W143’s carbonyl backbone (Dougherty and Stauffer, 1990; Dougherty, 
1996; Zhong et al., 1998).
A selective review of well-characterized binding sites and significant therapeutic ligands 
including the serotonin, GABAa and Nicotinic receptors follows. Elucidation and characterization 
of ligand binding sites will lead to a greater understanding of the protein and the development of 
novel therapies.
2.7.1 Characterized Binding Sites on the Serotonin Type 3 Receptor (5-HT3R).
5-HT3R are involved in various physiological functions including cognitive processing, 
sensory transmission, regulation of autonomic function, integration of vomiting, reflex, pain 
processing and control of anxiety (Barnes and Sharp, 1999; Hu and Lovinger, 2008) . 5-HT3 
receptors have two different subunits, 5-HT3A and 5-HT3B. 5-HT3A forms a homomers while 5-HT3B 
only forms a|B heteromers. In the nervous system, 5-HT3R mediates fast excitatory synaptic 
transmission and modulates neurotransmitter release (Hu et al., 2003).
2.7.1.1 The 5HT3R Orthosteric Binding Site.
In 5HT3R, the primary side chain interactions for the orthosteric binding site appear to 
come from loops A, B and C on the principal face (Figure 2.15). On the complementary face, 
amino acids on the D and E p-strands appear to play a role in ligand binding (Figure 2.15). The F 
P-strand has yet to be thoroughly investigated. The chemical structures of the discussed 
serotonin (5-HT) ligands are shown in Figure 2.16.
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Figure 2.15 The orthosteric binding site of 5-HT3AR-
Residues that have been demonstrated biochemically to participate in the binding and/or gating of 
5-HT3 agonist and/or antagonist. Extracellular region modeled after Lymnaea stagnalis AChBP 
(PDB ID 2ZJV). The position of the labeled residues is the approximate location.
In the A-loop, E129 or F130 faces into the binding pocket (Price et al., 2008) (Figure
2.15). Results reveal that a hydrogen bond forms between E129 and the hydroxyl group of 5-HT 
(Price et al., 2008). Other residues in the A-loop such as N128 and F130 may also play a role in 
receptor gating, but they do not participate in ligand binding (Price et al., 2008) (Figure 2.15).
W183 in loop B (W143 in AChBP) is entangled in ligand-receptor interactions and 
appears to be the core of the binding site (Spier and Lummis, 2000; Beene et al., 2002) (Figure
2.15). It has been postulated that W183 forms cation-TT interactions with the amino group of 5-HT 
(B eene et al., 2002) or arom atic interactions with 5-HT (Suryanarayanan et al., 2005).
In the C-loop, residues E225, F226, D229, Y234 and E236 have been shown to be 
important residues in the orthosteric binding site (Figure 2.15). D229 and Y234 in the C-loop 
appear to be important binding residues (Beene et al., 2002; Suryanarayanan et al., 2005). This 
region of the receptor has little sequence homology with AChBP, making it difficult to align the
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protein’s sequences. Y234 appears to align best with AChBP Y192 (Celie et al., 2004). Y234 
appears to play a role in 5-HT binding and/or gating, and is probably the most important residue 
in the binding pocket (Beene et al., 2004). Unnatural amino acid mutagenesis studies suggest 
that 5-HT orients itself so that the primary amine is located between W183 and Y234 (Beene et 
al., 2004). It has also been suggested that an inter-subunit contact forms between Y234 and 
Y143 in loop E (Maksay et al., 2003). D229 in the C-loop is another important residue aligning 
with C187 or Y185 (Celie et al., 2004). Alanine mutations of D229 in 5-HT3R decreased 5-HT and 
granisetron, but not m-chlorophenylguanide (mCPBG) affinity (Suryanarayanan et al., 2005). 
These data suggest that interactions are formed between D229 and the ligands 5-HT and 
gransietron. Residues E225, F226 and E236 in the C-loop also appear to be involved in the 
orthosteric binding site. Mutagenesis studies of E225 have shown that E225 is involved in both 5- 
HT binding and gating of the receptor (Schreiter et al., 2003). F226 (similar in position to Y185 in 
AChBP) appears to be essential to 5-HT binding and receptor gating (Suryanarayanan et al.,
2005). E236 (D194 AChBP equivalent) in 5-HT docking studies have shown that a salt bridge is 
formed between E236 and the 5-HT amino group (Schulte, 2006).
In the A-loop, E129 and F130 are involved in iigand binding (Figure 2.15). These 
residues have been shown to interact with the 5-HT ammonium group by ionic or hydrogen bond 
interactions (Boess et al., 1997; Steward et al., 2000). Residue F130 appears to be important for 
agonist selectivity and when mutated to the a1 nAChR equivalent N, the F130N mutant 5-HT3R 
become responsive to ACh (Steward et al., 2000).
On the complementary face, the binding site consists of the D, E and F (3-strands (Figure
2.15). W90 and R92 reside on the D-p-strand and are involved in maintaining the proper binding 
site structure (Yan and White, 2002). A more recent study suggests that graniestron’s orientation 
is such that the tropane ring interacts with W90 while R92 interacts with the indazole ring (Yan 
and White, 2005). Antagonist may directly interact with R92 (Yan and White, 2005).
In the E-P-strand, residues Y141, Y143, and Y153 are involved in the orthosteric site on 
5-HT3Rs (Figure 2.15). The ligands 5-HT and mCPBG interact with residue Y143, (+)- 
tubocurarine (dTC) with Y141 and lerisetron with Y143 and Y153 (Venkataraman et al., 2002a; 
Venkataraman et al., 2002b; Beene et al., 2004; Price and Lummis, 2004). The effects on 5-HT3R 
antagonist binding affinity suggest that the E-loop region directly affects ligand binding 
(Venkataraman et al., 2002a; Venkataraman et al., 2002b). Residues L112 and M114 may also 
make hydrophobic interactions with nicotine (Celie et al., 2004) and dTC (Gao et al., 2005), 
respectively. Mutations of Y141, Y143 and Y153 have been demonstrated to significantly alter the 
binding of 5-HT3R ligands (Beene et al., 2004). Residues Y142, G148, E149, V150, Q151, N152,
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Y153 and K154 have been implemented to be important for granisetron binding (Venkataraman 
et al., 2002a) (Figure 2.15). Y143 and Y153 have been revealed to play a role in receptor function 
while Y153 is involved in ligand binding (Beene et al., 2004).
The structure of the F-p-strand has yet to be thoroughly investigated. Thompson et al., 
(2005) exhibited that residues W195 and S206 in mouse 5-HT3Rs are critical for ligand binding, 
and may be involved in conformational changes within or close to the binding pocket (Thompson 
et al., 2005; Thompson et al., 2006) (Figure 2.15).
2.7.1.2 The 5-Hydroxyindole Binding Site.
The 5-HT binding site has been previously shown to bind a wide variety of ligands 
ranging from antagonists to agonists and may possibly include allosteric modulators (Kooyman et 
al., 1994; Yan et al., 1999). The positive allosteric modulator 5-hydroxyindole (5-HI) is a serotonin 
analogue (Figure 2.16) that displays biphasic behavior consisting of both competitive inhibition 
and allosteric potentiation actions on the homomeric 5-HT3A receptor. This suggests that there 
are at least two distinct binding sites, one located at the orthosteric site and the other at a 
separate binding pocket (Kooyman et al., 1994). The mutation L293A on 5-HT3A converted 5-HI 
to a partial agonist which was blocked by antagonist binding (Hu and Peoples, 2008). These 
results suggest that either 5-HI binds at the orthosteric site and/or that residue L293 is part of the 
5-HI binding site. Studies have also shown that upon washout of 5-HI, rebound currents occur 
(Hu and Peoples, 2008). Rebound currents have been previously linked to open-channel block 
(Liu et al., 2008b), suggesting that 5-HI may also bind within the channel.
NH.
Serotonin M-chl orophenylguanide 
(mCPBG)
Granisetron
(S-HT)
(+)-tubocurarine
(dTC)
5-hydroxyindole
(SHI)lerisetron
Figure 2.16 Chemical structures of serotonin ligands.
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2.7.2 Characterized Binding Sites on Gamma Amino Butyric Acid (GABA) Receptors.
GABAa receptors mediate synaptic inhibition in the CNS. One of the best characterized 
LGIC binding sites is the benzodiazepine site on GABAaRs. The benzodiazepine binding site was 
reviewed by Sigel in 2002 so only a summary of the important findings discovered in the last nine 
years are discussed here (Sigel, 2002). In addition, the newly characterized neurosteroid and 
general anesthetic binding sites are summarized below.
2.7.2.1 The Benzodiazepine Binding Site.
Classical benzodiazepines (BZ) are positive allosteric modulators of the GABAa receptor. 
BZ act primarily by increasing the affinity of the agonist GABA without affecting the maximal 
induced current amplitude (Sigel, 2002). It has recently been found that GABA evoked currents 
on GABAaRs containing the a4 or a6 subunit can be potentiated by the BZs diazepam and 
flunitrazepam (You et al., 2010). The a and p subunits are sufficient to mediate GABA activated 
Cl' currents while the y subunit is needed for functional modulation by BZ as demonstrated with 
y2 knockout mice (Gunther et al., 1995). Research has demonstrated that the BZ binding site is 
located at the a and y interface (Sigel and Buhr 1997). Non-BZD hypnotics used for treating 
insomnia also bind at the BZ binding cleft (Hanson et al., 2008). Only the key structural 
components of the BZ binding site structure are reviewed here (Figure 2.17). Reviews by Sigel 
and Buhr (1997) and Sigel (2002) are available for a more comprehensive coverage (Sigel and 
Buhr, 1997; Sigel 2002).
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y-Amsnobutync acid Flunitrazepam Diazepam Eszopicione Zolpidem
(GABA)
Figure 2.17 Summary of the residues found benzodiazepine binding site on GABAaR 
and the chemicai structure of the benzodiazepines.
A) A-loop shows residues that have been demonstrated biochemically to participate in the binding 
of benzodiazepines in GABAaR. Extracellular region modeled after Lymnaea stagnalis AChBP 
(PDB ID 2ZJV). The position of the labeled residues is the approximate location. B) B-loop shows 
the chemical structures of the benzodiazepine ligands discussed in the text.
The a1 subunit is the main subunit that is photoaffinity labeled by the BZ flunitrazepam 
(Figure 2.17B for chemical structure). Specifically, H101 in loop A appears to be critical for 
flunitrazepam modulation (Duncalfe et al., 1996) and forms a covalent attachment at the C-7 
position of diazepam as shown by radioactive ligand binding and two-electrode voltage clamp 
methods (Berezhnoy et al., 2004). The pendant phenyl group of flunitrazepam also interacts with 
aH101 (McKernan et al., 1998). When a1Y159 in loop B was mutated to serine an impairment of 
diazepam modulation occurred (Amin et al., 1997). aY159 and aY161 in loop B, aT206 and Y209 
in loop C have significant effects on BZ function whereas S205 and Y210 loop C are important for 
BZ selectivity (Sigel and Buhr, 1997; Wagner and Czajkowski, 2001). Mutating the a1Y209 (C 
loop) residues nearly abolished flunitrazepam current stimulation (Buhr et al., 1997b). Other
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studies show that when a1Y209 is mutated to a serine diazepam’s EC50 is increased by >7-fold 
(Amin et al., 1997). Mutations of a1G200 and a1T206 in loop C alter affinities for BZ suggesting a 
role in the binding pocket (Schaerer et al., 1998) (Figure 2.17).
The region of y2D75, y2l76 and y2l77 in the D-p-sheet has been shown to drastically 
reduce allosteric modulation by flurazepam (Teissere and Czajkowski, 2001) (Figure 2.17). 
Residue y1F77 (D-P-sheet) is important for BZ direct interactions and selectivity (Buhr et al., 
1997a). Displacement studies using the point mutation y2F77Y caused a 250-fold reduction in 
diazepam affinity suggesting that the tyrosine hydroxyl group interferes with diazepam binding 
(Sigel et al., 1998). Using Substituted Cysteine Accessibility Method (SCAM), it has been shown 
that the region around y2A79 (D-p-sheet) in the BZ binding pocket becomes more accessible to 
MTSEA-biotin modification during GABA binding (Teissere and Czajkowski, 2001). These results 
suggest that at least a portion of the BZ binding pocket undergoes conformational change in 
response to GABA binding and channel gating (Teissere and Czajkowski, 2001). Amino acid 
residues y2A79 (D-P-sheet) and y2M130 (E-P-sheet) appear to be required for high affinity 
binding of various BZ, but does not alter BZ efficacy (Wingrove et al., 1997). Amino acid y1T142 
(E-p-sheet) affects BZ efficacy suggesting a role in conformational change, facilitated possibly by 
a hydrogen bond with aY160 (loop B) (Mihic et al., 1994). yM57 and yY58 (F-P-strand) are 
essential determinants for conferring high affinity BZ binding (Kucken et al., 2000) (Figure 2.17).
Alterations in zolpidem, eszopiclone (non-BZD hypnotics used for insomnia) and BZ- 
antagonist binding were studied using cysteine mutants in the BZ binding site (Hanson et al., 
2008). Mutations in the y2 loop D and a1 loop A and B altered the affinity of all tested ligands 
demonstrating that these loops provide a structural framework for the BZ binding cleft. y2 loop E 
and a1 loop C mutants had various effects on ligand affinity suggesting that these loops are 
important for ligand selectivity. Molecular modeling of the binding site showed that docking of 
eszopiclone and zolpidem yielded a model stabilized by several hydrogen bonds. Alternatively, 
zolpidem docking showed the ligand binding via three equally populated orientations with few 
polar interactions. These results suggest that unlike eszopiclone, zolpidem binds in response to 
shape recognition of the BZ binding pocket rather than specific amino acid interactions, and may 
explain why zolpidem is a1 and y2 subunit selective (Hanson et al., 2008).
2.7.2.2 The Neurosteroid Binding Site.
The most potent endogenous modulators of GABAa receptors are neurosteroids, 
specifically allopregnanolone and tetrahydrodeoxycorticosterone, which are synthesized in 
neurons and glia cells from cholesterol (Hosie et al., 2007) (Figure 2.18B for chemical structures). 
At low nanomolar concentrations neurosteroids potentiate GABA responses (Stell et al., 2003)
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and at sub to micromolar concentrations can directly activate the receptor (Majewska et al. 
1986). The putative GABAa neurosteroid binding sites have been recently reviewed (Hosie et al.
2007) and a brief summary follows (Figure 2.18).
HO
Allopregnanolone Tetrahydrodeoxycorticosterone 
CN
(3a,5a,17 )-3-Hydroxyandrostane- 
17-carbonitrile
OhttlWMVXMWWl 7-Nitrobenz-2-oxa-1,3-diazole
Figure 2.18 The neurosteroid binding sites in GABAaR.
A) Top: A homology model for a1 and (32 subunits of the GAE3AaR. The TM2 domain is colored 
cream. The residues Q241, N407 and Y410 are shown in a space-filled layout. These residues 
have been shown to be important for the steroid potentiation site in the a1 subunit (green). 
a1T236 and (32Y284 (blue) are located within the activating site. The 
tetrahydrodeoxycorticosterone molecules are shown docked into each site and viewed from 
within the plane of the membrane. Bottom: Same model of the binding sites, but viewed from a 
bird’s eye perspective of only the transmembrane region. A primary sequence comparison of 
GABAa GABAcp1 and glycine a1 receptors for the major residues involved in steroid binding are 
compared in the tables. Red residues are involved in the activation site and blue residues are 
found in the potentiation site. (This image was modified and reprinted from (Hosie et al., 2007) 
with permission.) B) The chemical structures of the discussed steroids.
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Based on studies using excised patches and the steroids 7-Nitrobenz-2-oxa-1,3-diazole 
and (3a,5a,17(3)-3-Hydroxyandrostane-17-carbonitrile, it appeared that steroids must accumulate 
in the cell membrane for modulation to occur (Akk et al., 2005) (Figure 2.18B). This strongly 
suggests a role of the transmembrane region in neurosteroid modulation (Akk et al., 2005). 
Specifically, mutation of (32G219 located at the N-terminal of TM1 either reduced or enhanced the 
potentiation of GABA currents by various neurosteroids (Chang et al., 2003). Authors reasoned 
that G219 was more likely to be involved in the general mechanism of receptor modulation rather 
than contributing specifically to the binding site because mutations of (32G219 failed to prevent 
direct gating by pentobarbital propofol, etomidate and alphaxalone. Amino acid residue p1l307 
located in TM2 was found to enhance and reduce anesthetic action in addition to altering the 
receptor’s pharmacology suggesting that this residue may be involved in influencing allosteric 
modulation of the receptor function (Belelli et al., 1999; Morris and Amin, 2004) (Figure 2.18A).
Using Drosophila GABAa receptor, the first two transmembrane domains of the a1 
subunit were found to be important regions for potentiation and direct receptor activation by 
various neurosteroids (Hosie et al., 2006a). Mutation of T236 was found to be critical for steroid 
activation. An I mutation of T236 markedly reduced receptor activation by 
tetrahydrodeoxycorticosterone and allopregnanolone, without affecting their potentiation 
responses to GABA (Hosie et al., 2006b). The Q241W mutation removed the potentiation of 
GABA currents and reduced the apparent neurosteroid agonist efficacy without altering the 
agonist EC50 (Hosie et al., 2006b). The transmembrane region aQ241-aN407/aY410 has also 
been proposed to be involved in a neurosteroid potentiation site (Hosie et al., 2007). A 
neurosteroid activating site has been located in the region around aT236-(3Y284 and there is at 
least one site for inhibitory sulphated steroids which likely involves the transmembrane 1 and 2 
domains (Hosie et al., 2007). These results propose that there may be two to four neurosteroid 
binding sites on GABAa receptors (Hosie et al., 2006b; Hosie et al., 2007) (Figure 2.18).
Homology modeling indicated that the polar residues T236 and Q241 are located in two 
discrete hydrophobic cavities that could each contain a steroid molecule implying the possibility 
for two binding sites (Hosie et al., 2006b) (Figure 2.18A). T236 is thought to be located on the 
outer surface of the receptor at the interface between the a and (3 subunits, but within the 
membrane. Q241 is thought to be located at the base of an aqueous pocket formed by the 
transmembranes 1-4 of the a subunit (Hosie et al., 2006b), which has also been proposed to 
interact with anesthetics (Mihic et al., 1997). Molecular modeling estimations of the steroid’s 
molecular dimensions and mutagenesis suggest that N407 and Y410 in the TM4 of the a1 
subunit are involved in ligand binding (Hosie et al., 2006b) (Figure 2.18A). It is considered
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unlikely that the 5 subunit contributes to the potentiation binding site although it may affect the 
efficacy of potentiation (Hosie et al., 2009).
2.7.2.3 The Anesthetic Binding Site.
General anesthetics, such as etomidate and propofol, have been shown to act by 
modulating LGIC such as GABAa receptors possibly by the same putative binding pocket as 
neurosteroids (see Figure 2.18 above). The a1 subunit appears to contribute L232 (TM1), S270 
(TM2), A291 (TM3) as well as Y411, T414 and Y415 (TM4) (Mihic et al., 1997; Krasowski and 
Harrison, 1999; Mascia et al., 2000; Jenkins et al., 2001; Jenkins et al., 2002). In the 02 and 03 
subunits, N265 (TM2) has been shown to be important for etomidate modulation but it is unclear if 
N265 is located within the binding pocket (Belelli et al., 1997; Moody et al., 1997; Moody et al.,
1998) (Figure 2.19 for chemical structure). Using a radioactive etomidate analogue, a1M236 in 
the TM1 and 03M286 in TM3 were photolabeled suggesting the binding site is at the 0 and a 
transmembrane interface (Li et al., 2006).
Figure 2.19 The chemical structures of the discussed anesthetic compounds.
The propofol cavity appears to be located closer to the membrane-extracellular interface 
between TM1 and TM4 (Figure 2.19 for chemical structure). Mutation of M286 to a tryptophan in 
the 02 subunit abolished propofol potentiated GABA responses, but did not affect the direct 
activation of GABAaR in absence of GABA (Krasowski et al., 2001). A hydrogen bond was 
predicted to form between Q224 and the propofol hydroxyl hydrogen atom. A tt - tt  stacking 
interaction may occur between the Y448 phenyl ring and propofol. Other possible important sites 
of interaction include L223, T225 and Y226 in TM1, L285, F289 and F293 in TM3 and Y444 and 
W445 in TM4 (Campagna-Slater and Weaver 2007).
Recently, (Campagna-Slater and Weaver, 2007) used molecular modeling to further 
investigate this binding region in GABAa receptors using the ligands etomidate and propofol. 
Models identified two cavities in the 02 subunit. The etomidate binding sites appeared to be in the 
transmembrane domain between the TM1 and TM4 and between the TM3 and TM4. There 
appeared to be tt - tt  stacking interactions formed between the imidazole ring of W237 (TM1) and
Etomidate Propofol
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the phenyl group of etomidate. Other residues that may be important in etomidate binding include 
I230, L231, T233, I234 and S236 in TM1, M261 in TM2 and F293, L296, L287 and A300 in TM3 
(Campagna-Slater and Weaver, 2007).
2.7.3 Characterized Binding Sites on Nicotinic Acetylcholine Receptors.
nAChR are excitatory receptors found in the CNS. Several allosteric binding sites have 
been characterized on the nAChR. The allosteric compounds physostigmine, divalent calcium, 
NS-1738 and PNU-120586 galanthamine, 17(B-estradiol and zinc are included in the following 
discussion.
2.7.3.1 The Physostigmine Binding Site.
Physostigmine is a cholinesterase inhibitor that stimulates both nicotinic and 
muscarinic receptors (Figure 2.20 for chemical structure). Only a single attempt to characterize 
the physostigmine binding site has been published. Using outside-out patches from cultured 
hippocampal neurons it was shown that a7 nAChR residue aL125 appears to be essential to the 
physostigmine binding site (Pereira et al., 1993).
c h 3
Figure 2.20 Chemical structure of physostigmine.
2.7.3.2 The Divalent Calcium Biding Site.
Divalent calcium (Ca2+) is capable of modulating neuronal nAChRs by enhancing agonist 
affinity, efficacy and cooperativity (Hill coefficients) (Galzi et al., 1996). It has been suggested that 
the ACh and Ca2+ binding sites may be close together but occupy distinct locations (Galzi et al., 
1996). Early work using a7/5-HT3 receptor chimeras revealed that Ca2+ potentiated the chimera, 
but not the 5-HT3 receptor. This observation indicated the allosteric effect of calcium ions was 
mediated by a binding site located on the N-terminus of a7 nAChR (Maricq et al., 1991). Later, 
use of the a7/5-HT3 chimera combined with site directed mutagenesis uncovered ligand binding 
residues in the putative binding site (Galzi et al., 1996; Eddins et al., 2002). Mutations a7E18Q 
and a7E44Q abolished calcium enhanced agonist affinity, but maintained Ca2+ potentiation and 
cooperativity (Figure 2.21). Mutations in the region of a7 (161-172) (F-(3-strand) had a variety of 
effects on Ca2+ modulation. Potentiation was enhanced by D163N and S169E (F-p-strand)
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mutations while E161R, S165E and Y167F reduced or abolished (E172Q) the effects of calcium 
(Galzi et al., 1996; Eddins et al., 2002) (Figure 2.21). Molecular modeling of the a7 extracellular 
domain onto the crystal structure of the AChBP showed that E172 lines the “bottom” of the outer 
vestibule near the interface of the extracellular domain and the transmembrane domains (Figure 
2.21). This model suggested that E172 is accessible to cations in the water filled vestibule 
(Eddins et al., 2002). The mutation E195Q was recently shown to be in the Ca2+ binding site and 
also reduces quercetin mediated enhancement of a7 ACh induced currents (Lee et al., 2010a). 
These results suggest that quercetin may also be binding in the same binding pocket as Ca2+.
Figure 2.21 The putative Ca2+ binding site on a7 nAChR.
This diagram illustrates the location of the Ca2+ binding site on a7 nAChR. Residues labeled have 
been shown to alter Ca2+ potentiation. Residues are located on the F-p-strand on the 
complementary face of the a7 subunit.
2.7.3.3 The NS-1738 and PNU-120596 Binding Sites.
The a7 nAChR positive allosteric modulators (PAMs) 1-(5-chloro-2-hydroxyphenyl)-3-(2- 
chloro-5-trifluoromethylphenyl)urea (NS-1738) and 1-(5-chloro-2,4-dimethoxyphenyl)-3-(5-methyl- 
isoxazol-3-yl)urea (PNU-120596) have recently been shown to selectively potentiate, alter affinity 
and Hill coefficients of ACh-induced currents (Figure 2.22 for chemical structures). NS-1738 is
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thought to be a type I modulator while PNU-120596 alters desensitization kinetics making it a 
type II modulator (Bertrand and Gopalakrishnan, 2007). Type 1 modulators are molecules that 
affect the induced peak current (Bertrand and Gopalakrishnan, 2007). A type II modulator is a 
ligand that alters both the peak current and the time course of the agonist evoked repose 
(Bertrand and Gopalakrishnan, 2007). These two PAMs are structurally similar but have different 
functional effects on a7 nAChR suggesting that these modulators may act at allosteric binding 
sites (Bertrand et al., 2008). By using chimeras of a7 and 5-HT3 receptor domains, the binding 
regions of these two modulators were narrowed down. Results suggested that the extracellular N- 
terminal domain of a7 plays a critical role in NS-1738 modulation while PNU-120596 probably 
interacts with one or more of the transmembrane domains of the receptor (Bertrand et al., 2008).
Figure 2.22 Chemical structures of NS-1738, PNU-120596 and LY-2087101.
Further studies investigating the role of the transmembrane domains in allosteric 
modulation concluded that the TM1-3 are the principal determinates of potentiation by the 
allosteric modulator PNU-120596. Specifically residues Ser222 (TM1), Ala225 (TM1), Met253 
(TM2) and Phe455 and Cys459 (TM4) influenced potentiation by PNU-120596 (Young et al.,
2008). Homology models of a7 and the crystal structure of the Torpedo nAChR showed that 
these amino acid residues are located centrally within the transmembrane helices and point 
towards the intra-subunit cavity located between the four helical domains. In contrast, residues 
that induce no effect on potentiation are positioned away from the central cavity. Blind docking 
studies suggest a role for these residues in binding of PNU-120596 and LY-2087101 (a type I 
modulator) (Young et al., 2008).
2.7.3.4 The Galanthamine Binding Site.
1-{5-chioro-2-hydroxyphsnyl)-3- 1-{5-chtoro-2,4-dimethoxyphenyl)-3-
{2-cbloro-5-tnfluoromethylpheny!)urea (5-methyl-isoxazol-3-yl)urea 
(NS-1738) (PNU-120596)( - )
[2-[(4-Fluorop(ienyl)am(no)-4-methyi 
-5-thiazoiyl]-3-th!enylmethanone 
(LY-2087101 )
Galantamine, an approved drug for the treatment of Alzheimer’s disease, is a dual action 
drug that inhibits acetylcholinesterase and is a allosteric modulator of 03(34, a4(32 and a6(34 
nAChR as demonstrated by whole-cell patch clamp studies using human embryonic kidney-293
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cells (Figure 2.23 for chemical structure) (Samochocki et al., 2003). In an attempt to visualize the 
extracellular regions of heteromeric nAChRs bound to galanthamine and cocaine, the vicinal 
cysteines in the C-loop on AChBP were mutated to be more similar to the non a subunit 
interfaces of nAChR and other Cys-loop receptors (Hansen and Taylor, 2007). The 2.9 A 
resolution crystal structures of Aplysia AChBP exposed galanthamine bound to four of the five 
subunits. In the binding sites that contained galanthamine the C-loop was against the ligand, but 
the vicinal cysteines were positioned away from the ligand. Galanthamine was found to be bound 
in two conformations in equal proportions. Galanthamine’s amine nitrogen was positioned 
between W147 and either Y93 or Y55. The oxygen atom of galanthamine was positioned towards 
the C-loop in both conformations. In the cocaine bound 1.8 A structure of Aplysia AChBP, 
cocaine occupied two of the five possible binding sites. The vicinal cysteines in one subunit 
contacted the benzene ring of cocaine (Hansen and Taylor, 2007).
Figure 2.23 Galanthamine and cocaine chemical structures.
Using X-ray structures of cocaine and galanthamine bound to mutated AChBP revealed 
interactions deep within the non-a subunit interface and maintained little contact with the C-loop 
tip (Hansen and Taylor, 2007). Mutations were only made in the vicinal cysteines of the C-loop 
and results should be interpreted with caution. The data can only illustrate the events that 
occurred when the vicinal cysteines were not present. To further our understanding of the 
interactions occurring within the non-a subunits, this region in the AChBP could be mutated to 
residues found in nAChR and other Cys-loop receptors. Contrary to Hansen and Taylor’s 
conclusions (2007), immune epitope mapping studies and photoaffinity labeling suggested that 
the galanthamine binding site is close to but distinct from the ACh binding site on the a nAChR 
subunit (Schrattenholz et al., 1993; Maelicke et al., 2000).
Galanthamine Cocaine
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2.7.3.5 The 17(i-Estradiol Binding Site.
The steroid 170-estradiol selectively potentiates human a402 neuronal nAChR while not 
potentiating rat a402 nAChR (Figure 2.24 for chemical structure). The sequence AGMI at the end 
of the C-terminus of the human a4 nAChR appears to form the binding site of 170-estradiol 
(Maelicke et al., 2000; Curtis et al., 2002). It appears that the steroid rings and/or the ethynyl 
group bind to the a4 C-terminus and the two steroid hydroxyl groups are free to interact with other 
amino acids elsewhere in the protein (Paradiso et al., 2001).
Figure 2.24 The chemical structure of 17p-estradiol.
2.7.3.6 The Zinc Binding Site.
Zinc modulates heteromeric nAChR and potentiates 0202, a204, a304, a402 and a404, 
but not a3p2. It was proposed that both the a and 0 subunits contribute to the zinc binding site 
(Hsiao et al., 2001). Using site directed mutagenesis, amino acid residues E59 and H162 on the 
rat a4 subunit were identified as potential mediators of zinc potentiation (Hsiao et al., 2006). 
Cysteine mutations at a4E59 (D-0-strand) and a4H162 (F-p-strand) caused a reduction of zinc 
potentiation upon treatment with methanethiosulfonate reagents /V-biotinoylaminoethyl 
methanethlosulfonate (MTSEA-biotin) and [2-{trimethylammonium)ethyl] methanethiosulfonate. 
The mutation a4H162C compared to E59C was more effective at hindering the MTSEA-biotin 
reaction in presence of zinc, suggesting that H162 may participate in the binding site for zinc 
(Hsiao et al., 2006). Less robust effects were seen at the a4E59C mutant, suggesting that a4E59 
may be near the zinc binding site. It was hypothesized that the zinc binding site occurred at the 
non-ACh binding site, the 04-a4 cleft and near the a4 resides H162 and E59 (Hsiao et al., 2006).
The zinc binding site was further elucidated by attempting to express two different a402 
stoichiometries using a high and low ACh sensitive receptor preparation. It was presumed that 
the high-sensitivity receptor preparation formed receptors with the stoichiometry (a4)2(02)3. The 
low-sensitivity receptor preparation was assumed to form receptors with the stoichiometry 
(a4)3(02)2. It was noticed that zinc inhibited the “(a4)2(02)2” stoichiometry and depending on the
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concentration, potentiated or inhibited “(a4)3(P2)2” stoichiometry (Moroni et al., 2008) (Figure 
2.25). These results suggest that the zinc potentiation binding site is located at the a4(-)/a4(+) 
cleft. Alanine mutations of a4H195 on the a4(-) face and a4E224 on the a4(+) face reduced the 
zinc potentiation effects of zinc and a4H195A shifted the zinc IC50 to the right. Authors reasoned 
that these residues are located in the zinc potentiation site. a4H195 (a4 (-) face) interacted with 
both the inhibitory and potentiation zinc binding sites (Moroni et al., 2008). a4H195A deceased 
the zinc IC50 in the high-sensitivity preparation. p2D218A (loop C) decreased the zinc IC50 
receptors expressed using the high-sensitivity preparation. P2D218A receptors expressed in the 
high-sensitivity preparation had enhanced zinc potentiation compared to wild-type receptors. 
Authors reasoned that the p2(+)/a4(-) interface found in both receptor stoichiometries to be the 
location of the putative zinc inhibitory binding site (Moroni et al., 2008) (Figure 2.25). The 
conclusions regarding P2D218 are somewhat surprising. Moroni et al., (2008) reasoned that an 
increase in zinc potentiation indicted that this residue was located in the inhibition binding site. It 
seems more plausible that some other mechanism or ligand may be causing the increase in zinc 
potentiation (see Chapter 5 for further explanation).
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Figure 2.25 The putative zinc potentiation and inhibition sites on a4f32 nAChR.
A) These figures illustrate the zinc potentiation and inhibition sites. The far left diagram is the 
presumed stoichiometric arrangement of receptors formed in the high-sensitivity receptor 
preparation. Middle and right images are the putative potentiation binding site of zinc. B) The zinc 
inhibition site is illustrated below. The far left diagram is the presumed stoichiometric arrangement 
of receptors formed in the low-sensitivity receptor preparation Middle and right images are the 
putative inhibition binding site of zinc. (Images are modified and used with permission from 
(Moroni et al., 2008).)
2.7.3.7 Channel Blockers.
A significant category of nicotinic drugs, channel blocking ligands may have therapeutic 
value in applications ranging from local anesthesia to smoking cessation Channel blockers 
function by sterically blocking the channel pore thereby preventing ion flux and altering the 
allosteric transitions of the nAChR (Taly et al., 2009). Channel blockers have been shown, by 
affinity labeling experiments, to bind to key residues 2, 6 , 9, 13 and 20 within in TM2 (Figure 2.26) 
(Giraudat et al., 1986; Blanton et al., 1998; Corringer et al., 2000). This is the face of TM2 that 
lines the inside of the channel pore. Various channel blocker binding sites have been shown to 
be located throughout the transmembrane channel. Binding sites have been mapped within the
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gate in the closed conformation of the receptor and at the entrance of the ion selectivity filter, 
which consists of rings of hydrophilic residues at the cytoplasmic border.
Figure 2.26 Location of channel blocking ligand binding sites in the TM2.
A diagram showing only the TM2 helix of two nAChR subunits. Channel blocker binding sites 
have been located within the gate in the closed conformation of the receptor and at the entrance 
of the ion selectivity filter. Residues at positions 2, 6 , 9, 13 and 20 in the TM2 have been shown 
by affinity labeling to affect to bind channel blocking residues. (Image used with permission and 
significantly modified from (Miller, 2002).)
2.8. Receptor Mechanism.
2.8.1 Allostery.
Allostery is the property of proteins to adopt conformations or shapes induced by the 
adherence of two or more ligands. The binding events at one location can influence the coupling 
episodes on a different part of a protein through structural changes in the protein that may or may 
not alter the rate of binding of the second ligand to the protein. An increased binding rate of the 
second ligand is considered positive cooperativity. Conversely, negative cooperativity occurs 
when the rate of the second ligand is decreased. The quantification of cooperativity can be 
estimated using the Hill coefficient, which corresponds to a hypothetical number of ligands that 
would have to be bound to the protein in an all-or-none fashion for the protein to exhibit perfect 
cooperativity.
Allostery classically describes the events surrounding the binding of one ligand to a 
protein and provoking a large conformational change that alters the affinity of another site for its 
ligand. Recently Tsai et al., (2008) have shown dramatic backbone deformations are not an
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essential characteristic of an allosteric effect (Tsai et al., 2008). It seems possible that allostery 
may arise from either large conformational changes or fluctuations in protein temporal dynamics. 
The conformational change of a protein is likely to be unique to the number and type of ligand(s) 
binding to the protein and the proteins structural composition.
The process of ion channel activation is a highly complicated mechanism that is only 
beginning to be understood. It is currently hypothesized that ligand binding a LGIC produces a 
conformational change in the protein and different types of ligands (agonists, partial agonists, 
antagonists, allosteric modulators, etc.) can induce different protein conformations. Ligand 
binding leads to an anticlockwise conformational wave (quaternary twist) that propagates through 
the protein causing the channel gate to open transiently and then close. The stabilization of each 
new conformation likely alters the structure of the orthosteric binding site and may modify the 
structure of allosteric subunit clefts as well.
LGICs can exist in at least three distinct conformations with different stabilization 
energies and are referred to as closed, open or desensitized. The closed state is the resting state 
of the receptor and is non-conducting whereas the open state actively conducts ions. The 
desensitized state is non-conducting and is distinct from the resting state. When exposed to low 
concentrations of ligand, it is most likely the receptor will enter an open (active) conformation or, 
although less likely, a desensitized state than remain in the closed state. Receptors have a high 
probability of existing in the desensitized state on continuous exposure to ligand. In the absence 
of ligand, the closed state predominates.
The conformational change of a protein may be driven by entropic effects which can be 
better understood through kinetic models. The process of a ligand binding to a protein may result 
in a decrease in the entropy of the system due to the translational and rotational degrees of 
freedom of the protein and the ligand no longer being independent. To better understand the 
biophysical characteristic of nicotinic receptors, kinetic models of receptor gating have and are 
currently being developed. Auerbach and Akk (1998) developed a kinetic model of the mouse 
muscle nAChR gating though single channel studies (Auerbach and Akk, 1998) (Figure 2.27). 
The receptor in the closed conformation (R) can bind two ACh molecules in two steps. The affinity 
for each site is relatively low but each site has a high forward rate constant 4x1 O'8 M'1s'1. A 125 
pM concentration of ACh half saturates the two equivalent ACh binding sites. Binding of ACh 
produces a massive increase in the probability of the channel opening (O*). In a diliganded 
mouse AChR, the gate will open approximately 50 times faster than the receptor closes. 
Comparatively, spontaneous channel opening events without a ligand can occur but the gate 
opens only about twice as fast as it closes (Auerbach and Akk, 1998). The calculated equilibrium
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constant for spontaneous openings is approximately 3.0 x 10"6 The mean open time of a mouse 
muscle nAChR bound with two ACh molecules is 670 pS. The channel then closes with the two 
ACh molecules bound to the A2D state. At this point, the receptor can either lose one ACh 
molecule or it can reopen with a probability of 0.5. If ACh is constantly present, the receptor can 
also move from the open (A20*) to a desensitized (D) state. As the ACh comes off the channel, 
the receptor goes through a one ACh bound desensitized state and then to the closed state 
(Auerbach and Akk, 1998) (Figure 2.27).
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Figure 2.27 Auerbach and Akk (1998) kinetic model of mouse muscle nAChR.
The small alphabetical letters are the forward and reverse rate constants for the different receptor 
states. The k_ values are the agonist dissociation rate constants and the k+ values are the agonist 
association rate constants. K2ACh and KACh are the equilibrium dissociation constants (Kd) for 
double and single liganded states. Numerical values were taken from (Auerbach and Akk, 1998).
Equilibrium constants determined experimental can be used to calculate the free energy 
differences between the receptor conformations using the relationship AG0 = -RTIn(K) (Auerbach 
and Akk, 1998). The equilibrium constants shown in Figure 2.27 were used to calculate the free 
energy diagram shown in Figure 2.28 (Auerbach and Akk, 1998). The A2D state is -27.3 kT more 
stable than the resting state (C). During the nAChR recovery the receptor passes through the 
desensitized (D) state. The no liganded D state is the only state that is less stable than the resting 
state of the receptor (Auerbach and Akk, 1998).
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Figure 2.28 Free energy diagram of mouse muscle nAChR for activation, 
desensitization and recovery.
Top) The cyclic reaction of the receptor transition between the closed (C), open (O) and 
desensitized (D) states. For simplicity, the two agonist binding steps were condensed. The AG 
sign pertains to the clockwise direction. Bottom) A graphical representation of the calculated free 
energies of the different receptor states. The unliganded closed receptor is the ground state. 
Activation of receptors was accomplished by application of 1 M ACh. The A2D state is the most 
stable conformation. The D state is the only state that is less stable than the C state. (Image 
reprinted from (Auerbach and Akk, 1998) and used with permission).
2.8.2 Conformational Change Models.
The signal transduction mechanism of the nAChR has been proposed to involve a global 
transition of the molecule, referred to as allosteric transition (Koshland, 1963; Changeux, 1964). 
Receptors are thought to transition between conformations by either the concerted or sequential 
models.
The concerted or the Mondo-Wyman-Changeux (MWC) model was developed during an 
investigation of hemoglobin. The liganded and non-liganded forms of hemoglobin differ by 15° 
rotation of one pair of a and p subunits relative to the other two in the a202 tetramer (Baldwin, 
1980). The concerted model suggest that all subunits change conformation simultaneously 
resulting in only two conformational states, tense and relaxed (Monod et al., 1965). In this model 
the two conformations exist even in absence of ligand with the equilibrium constant L between the
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two states. The ligand’s apparent affinity for the protein is controlled by its ability to shift between 
the relaxed and tense states.
The MWC model accounts for signal transduction mediated by the nAChR between 
active, open-ligand bound conformations, resting and closed conformations and cooperative 
ligand binding (Taly et al., 2005). This model predicts that agonists, allosteric modulators and 
antagonists induced distinct conformations and accounts for spontaneous opening of the channel 
in absence of ligand.
The sequential or Koshland-Nemethy-Filmer (KNF) model proposes that each subunit 
can be in a different conformation depending on the number of agonists bound. The KNF model 
assumes that a protein is sufficiently flexible to allow the binding of one ligand to alter the protein 
conformation in a way that affects the affinity of the second site for the ligand. This model allows 
for intermediate states between closed and open to exist.
The two models differ in terms of protein conformations and the affinity of the ligands for 
each binding site. Both models suggest that binding of a ligand changes the protein conformation. 
In the sequential model, conformation change due to ligand binding leads to an effect on other 
binding sites and the ligand affinity for that site. In the concerted model the conformational 
change only alters the equilibrium between the protein’s state (tense versus relaxed for 
hemoglobin or open versus closed for receptors). The models also differ in that the concerted 
model suggests that the two conformations are present (relaxed and tense) even in absence of 
iigand. The sequential model suggests that conformational change only occurs upon ligand 
binding. In general, the concerted model is the more restrictive of the two models particularly 
because it does not predict negative cooperativity. In the sequential model a ligand can only pull 
the conformational equilibrium towards the high affinity conformation.
Whether nAChRs function more like the concerted or sequential model is currently being 
debated. Crystallography studies have shown that the different subunits can exist in different 
conformations from each another with and without ligand being present in muscle nAChR (Unwin, 
1995; Unwin, 2005; Hansen and Taylor, 2007) arguing in favor for the sequential model. Several 
AChBP crystallography studies have shown that different conformations are induced depending 
on the type of ligand bound to the protein (Unwin, 1995). It has also been observed that a change 
in one subunit conformation can affect other subunits causing a conformational wave within the 
protein (Auerbach, 2005), supporting the concerted model. nAChR have been shown to exist in 
open and closed states in absence of ligand (Jackson, 1984; Jackson, 1986), suggesting that the 
concerted model may explain nAChR function. However, nAChRs also experience different 
conformations besides open and closed such as the desensitized and the putative “flip” state
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(Lape et al., 2009), arguing that nAChRs function more like the sequential model. The flip 
conformation is an intermediate conformation between the resting and open states (Lape et al.,
2008) where the affinity and efficacy of a ligand for a receptor is determined by its ability to 
stabilize the conformation. This mechanism is different from the previous models which 
suggested that ligand affinity and efficacy depends on the ligand’s ability to stabilize the open 
conformation.
It is likely that due to the complex nature of nAChR function that neither the sequential or 
concerted model fully explains nAChR conformational changes. A more expansive model that 
allows for conformational changes, variation in subunit conformations, different receptor states, 
etc. would be more appropriate.
2.9. Neurophysiological Role of Nicotinic Receptors.
In the CNS, acetylcholine activated nAChRs regulate processes such as transmitter 
release, cell excitability and neuronal integration (Gotti et al., 2006b). These processes are critical 
for network operations and influence physiological functions such as arousal, sleep, fatigue, 
anxiety, pain processing, food intake and several cognitive functions (Hogg et al., 2003; Gotti and 
Clementi, 2004; Hogg and Bertrand, 2004).
It has been proposed that the majority of the cortical and hippocampal cholinergic release 
sites are non-synaptic and contribute to diffuse volume transmission (Umbriaco et al., 1994; 
Descarries et al., 1997) as has been observed for other modulatory neurotransmitters such as 
monoamines (Vizi, 2000). Other studies have suggested that nAChRs are principally located at 
presynaptic sites where they modulate neurotransmitter release or on cell bodies and dendrites 
where they mediate postsynaptic effects (Hogg et al., 2003; Dajas-Bailador and Wonnacott, 2004; 
Gotti and Clementi, 2004).
Spillover of ACh from the synapse or from non-synaptic release sites into the 
extracellular space is likely to be an important contributor to cholinergic volume transmission 
(Dani and Bertrand, 2007). The spread of ACh from the release site is determined by diffusion 
and the hydrolysis of ACh by the widely distributed CNS enzyme acetycholinesterase (AChE) 
(Kawaja et al., 1990). ACh is synthesized from choline and acetyl-CoA by the enzyme 
acetyltransferase and is broken down by AChE into choline and acetate. The density and location 
of AChE does not always match the location of ACh release sites (Kawaja et al., 1990). 
Cholinergic volume transmission allows ACh to diffuse and act at lower concentrations at some 
distance from the release site. The amplitude, shape and time course of the ACh single depends 
on the local distribution and density of AChE relative to the ACh release sites (Dani and Bertrand, 
2007).
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The hydrolysis of ACh creates choline, which is a nAChR partiai agonist (Castro and 
Albuquerque, 1995; Papke et al., 1996). It is estimated that choline has an EC50 -1 .6  mM and an 
IC50 -370 pM on a l  nAChRs (Alkondon and Albuquerque, 2006). The extracellular choline 
concentrations have been estimated to be around 3-5 pM and reaches concentrations of 20 pM 
or more under pathological conditions (Alkondon and Albuquerque, 2006). At a cholinergic 
synapse, vesicular release produces a millimolar ACh concentration for only a few milliseconds 
before diffusion and AChE removal of the neurotransmitter (Dani and Bertrand, 2007). An area 
that experiences a high frequency of ACh release and plentiful AChE would likely produce 
relatively high choline concentrations. Therefore ACh provides a diffuse, volume signal that 
continues as a choline signal (Dani and Bertrand, 2007).
Different nAChR subtypes are located throughout the CNS and respond differently to 
ACh and choline. a7 nAChRs have a lower ACh affinity (~ 100 pM) compared to a4p2 receptors 
which have two ACh affinities (ACh affinity -  1.6 pM and 62 pM) (Buisson and Bertrand, 2001). 
The two different ACh affinities in a4|32 nAChR may be caused by the putative high- and low- 
ACh sensitivity a4p2 stoichiometries. After neurotransmitter release at the synapse, high- 
sensitivity a4p2 nAChR will open and desensitize with slower response kinetics than the rapidly 
desensitizing a l  nAChRs. Successive synaptic activity and volume transmission of ACh may 
provide a prolonged exposure of low agonist concentrations. This process produces a slow form 
of desensitization (Dani and Bertrand, 2007). Because a4p2 have a high affinity for ACh, these 
receptors have a slower desensitization rate for agonist below 0.1 pM. In comparison, a l 
receptors are not effectively desensitized by agonist at concentrations below 1 pM (Dani et al., 
2000; Quick and Lester, 2002; Wooltorton et al., 2003). nAChRs which are exposed to a slow 
rising by sustained agonist concentrations may contribute to the modulation of the neuron activity 
when the cell is close to its resting potential (Dani and Bertrand, 2007).
Activation of presynaptic nAChRs can cause the release of many different types of 
neurotransmitters (McGehee et al., 1995; McGehee and Role, 1995; Gray et al., 1996; Role and 
Berg, 1996; Albuquerque et al., 1997; Alkondon et al., 1997; Lena and Changeux, 1997; 
Wonnacott, 1997; Guo et al., 1998; Radcliffe and Dani, 1998; Jones et al., 1999; Luetje, 2004; 
Sher et al., 2004). Nicotinic agonists applied exogenously enhance, while nicotinic antagonist 
generally reduce the release of ACh, dopamine (DA), norepinephrine, serotonin, glutamate and 
GABA (McGehee et al., 1995; McGehee and Role, 1995; Gray et al., 1996; Role and Berg, 1996; 
Albuquerque et al., 1997; Alkondon et al., 1997; Lena and Changeux, 1997; Wonnacott, 1997; 
Guo et al., 1998; Radcliffe and Dani, 1998; Jones et al., 1999; Luetje, 2004; Sher et al., 2004). 
The activity of presynaptic nAChRs directly and indirectly begins the intracellular calcium signal 
that enhances neurotransmitter release (McGehee et al., 1995; Gray et al., 1996; Role and Berg
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1996; Wonnacott 1997). nAChRs mediate small direct calcium influx (Vernino et al., 1992; 
Seguela et al., 1993; Vernino et al., 1994; Castro and Albuquerque, 1995) that can cause the 
release of calcium from intracellular stores (Sharma and Vijayaraghavan, 2003). nAChR activity 
can also produce depolarization that can cause activation of voltage-gated calcium channels in 
the presynaptic terminal (Tredway et al., 1999). Presynaptic nAChR activity overall elevates intra­
terminal calcium and causes increased neurotransmitter release.
Glutamate release is enhanced by nicotinic stimulation lasting from seconds to a few 
minutes (Radcliffe and Dani, 1998) and contributes to the ability of a neuronal synapse to change 
its connection strength in response to the usage of the synapse in synaptic pathways also known 
as synaptic plasticity (Wonnacott, 1997; Aramakis et al., 2000; Mansvelder and McGehee, 2000; 
Ji et al., 2001; Ge and Dani, 2005). The glutamate enhancement can last for several minutes or 
more and utilizes intra-terminal calcium elevation as a second messenger to indirectly modify 
glutamatergic synaptic transmission (Dani and Bertrand, 2007). The localized calcium signals, 
mediated by nAChRs, initiates enzymatic activity (i.e. protein kinases and phosphatases) that 
modify the glutamatergic synapse (Fisher and Dani, 2000; Hu et al., 2002). Presynaptic nAChR 
activity arriving just before electrical stimulation of glutamatergic afferents boosts the release of 
glutamate and enhance the induction of long-term synaptic potentiation (Dani and Bertrand, 
2007).
nAChRs are found on preterminal, axonal, dendritic and somatic locations (Lena et al., 
1993; Zarei et al., 1999). Preterminal nAChRs positioned before the presynaptic terminal bouton 
indirectly affect neurotransmitter release by activating voltage-gated ion channels and by possibly 
initiating action potentials (Lena et al., 1993; Alkondon et al., 1997; Albuquerque et al., 2000). 
Axonal, dendritic and somal nAChRs may modulate neurotransmitter release and affect local 
excitability in other ways. Activation of non-synaptic nAChRs alters the membrane impedance 
and changes the space constant of the cellular membrane (Dani and Bertrand, 2007) influencing 
the spread and efficiency of synaptic inputs to activate action potential outputs in the target 
neuron (Dani and Bertrand, 2007). Neuronal excitation can also be altered by directly exciting or 
slowing an action potential at junction, axonal or dendritic nAChRs (Dani and Bertrand, 2007). 
The widespread distribution in non-synaptic locations may also enable nAChRs to influence 
moment-to-moment membrane resting potentials thereby influencing the ease of reaching the 
threshold to generate an action potential (Dani and Bertrand, 2007).
nAChRs also appear to participate in other non-cholinergic neuronal systems. There has 
been mounting evidence that crosstalk occurs between GABA, dopamine and nAChRs. For 
example, by using hippocampal slices and electrophysiological recordings noradrenaline release
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has been shown to be indirectly modulated by a7 nAChR located in glutamate afferents and y- 
amino butyric acid (GABA)-containing interneurons. These results provide strong evidence that 
there is cross-talk amongst neurotransmitters in modulating noradrenalin release (Barik and 
Wonnacott, 2006). Cross-talk between neurotransmitter systems is likely to affect the properties 
of therapeutic ligands.
To summarize, synaptic and volume release of ACh activates and desensitizes nAChRs 
at synaptic and non-synaptic locations. nAChRs located at non-synaptic locations influences the 
excitability of a neuron (Dani and Bertrand, 2007). Continuous cholinergic activity causes 
depolarization of neurons and pushes the membrane potential to move towards the threshold for 
firing an action potential. nAChR activity contributes to calcium signals that regulates intracellular 
enzyme systems which shapes the response of the cell. Signaling by nAChRs causes subtype- 
dependent desensitization which influences the overall signal. The breakdown of ACh by AChE to 
produce choline assists in the shaping of the time and spatial dependence of nAChR signaling.
2.10. Nicotinic Receptor Pharmacology.
Each nAChR subtype has different ligand selectivity, affinity and efficacy. Selectivity 
delineates the specificity of a compound for different types of receptors. Affinity describes how 
tightly the ligand interacts with the receptor while the potency is measured by the EC50 or the 
effective drug concentration which elicits half of the maximum induced response. Efficacy is the 
ligand’s ability to produce the maximum effect. For example, ACh induced responses produce 
100% efficacy on nAChR. Partial agonists induce maximum responses with < 100% efficacy 
while PAMs may produce responses with > 100% efficacy.
There are different types of ligands such as full agonist, partial agonist, antagonist and 
allosteric modulators. Full agonists are ligands that bind to the orthosteric site and activate the 
receptor, displaying full efficacy of the receptor. Partial agonists bind at the orthosteric site, but 
are only able to cause partial efficacy of the receptor. Antagonists are ligands that do not induce a 
biological response, but reduce agonist mediated responses. Allosteric modulators are ligands 
which bind to non-orthosteric sites, resulting in conformational changes that may alter the 
protein’s function. Positive and negative allosteric modulators (PAMs and NAMs) cause 
enhancement and inhibitory effects, respectively (Arias et al., 2006; Bertrand and 
Gopalakrishnan, 2007; Faghih et al., 2008). Modulators can alter a ligand’s affinity and/or 
efficacy. Enhancement of the agonist efficacy is known as potentiation.
Allosteric modulators typically have low intrinsic activity. A ligand which binds at an 
allosteric cleft and activates the channel without assistance would be classified as an allosteric 
non-competitive agonist or allosteric partial agonist. Allosteric modulators must be co-applied with
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an agonist in order for the modulators to have an effect. PAMs selectively potentiate physiological 
activity, shifting the conformation equilibrium towards the receptor open state. There are two 
types of PAMs, type 1 and type 2. Type 1 modulators are molecules that affect the induced peak 
current (Bertrand and Gopalakrishnan, 2007) while a type 2 modulator is a ligand that alters both 
the peak current and the time course of the agonist evoked repose (Bertrand and 
Gopalakrishnan, 2007). NAMs inhibit the agonist activity by shifting the conformation equilibrium 
towards the receptor closed state. The low intrinsic activity of allosteric modulators allows for the 
spatial and temporal synaptic patterning to remain unaltered. The data within this thesis is 
focused on a4(32 nAChR. The following discussion is a brief description of a4(32 nAChR 
pharmacology.
2.10.1 Selective a4(32 Full and Partial Agonists.
2.10.1.1 Acetylcholine.
Acetylcholine (ACh) is a neurotransmitter in the PNS and CNS and acts as a full agonist 
on all nAChR subtypes (Figure 2.29). The ACh affinity on a4(32 nAChR is approximately 21 pM 
(pEC50= 4.7 ± 0.1) (Weltzin and Schulte, 2010) while its efficacy is 100%.
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Figure 2.29 Chemical structure of acetylcholine.
2.10.1.2 Nicotine.
Nicotine, an alkaloid found in the botanical nightshade family (Solanaceae), is an nAChR 
targeted toxin that serves to defend the plant from predation (Albuquerque et al., 2009) (Figure 
2.30). Until recently, nicotine was used as an insecticide. Nicotinic analogues such as 
imidacloprid have been found to be even more effective than nicotine as an insecticide. In 
addition to its toxic properties, nicotine is a highly addictive substance most commonly associated 
with tobacco products. Over the years, the concentration of nicotine has increased ~ 1.6% 
mg/cigarette/year from 1998-2005 to a current concentration of approximately 1 mg of 
nicotine/cigarette (Connolly et al., 2007). The American Heart Association has determined
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nicotine addiction to be one of the most difficult addictions to break (American Heart Association, 
2011).
Figure 2.30 Chemical structure of nicotine.
A partial agonist on a402 nAChRs, nicotine’s affinity on a4(32 nAChR is approximately
2.1 pM (pEC50 = 5.7 ± 0.3) and its efficacy is approximately -38% compared to ACh’s efficacy 
(100%) (Weltzin and Schulte, 2010).
2.10.1.3 Epibatidine.
Epibatidine is an alkaloid found on the skin of the Ecuadorian tree frog Epipedobates 
tricolor (Daly et al., 2000; Dukat and Glennon, 2003) (Figure 2.31). It is a potent analgesic that 
has high affinity (-60 pM) to a402 nAChR, but will also bind to other heterometic nAChR 
subtypes with lower affinity (0.025 - 0.46 nM) (Xiao et al., 2004). Derivatives of Epibatidine are 
being explored for their therapeutic potential to treat diseases such as Alzheimer’s disease 
(Dwoskin and Crooks, 2001).
Figure 2.31 Chemical structure of epibatidine.
2.10.1.4 Cytisine.
Cytisine is a pyridine-iike alkaloid that has similar pharmacological properties to nicotine 
(Figure 2.32). Plants belonging to the leguminoae family synthesize cytisine as a protective 
mechanism against predation (Marion and Cockburn, 1948). Cytisine is a a402 nAChR partial 
agonist that has low efficacy (Coe et al., 2005). In eastern and central Europe, this compound is 
used as a smoking cessation treatment (Tutka and Zatonski, 2006).
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Figure 2.32 Chemical structure of cytisine.
2.10.1.5 Varenicline.
A derivative of cystisine, varenicline is an orally active compound used for smoking 
cessation that has also been shown to reduce alcohol consumption in humans (McKee et al.,
2009) (Figure 2.33). Varenicline is a a4(32 partial agonist (K, value 0.06) (Coe et al., 2005; 
Rollema et al., 2007a).
Mecamylamine is a non-competitive, non-specific nAChR antagonist displaying 
antidepressant-like effects in mice (Rabenstein et al., 2006) (Figure 2.34). Knockout mice lacking 
the 02 or a7 subunits, this antidepressant effect was not observed (Ostroumov et al., 2008). 
Mecamylamine has also been shown to block physiological, behavioural and reinforcing 
properties of nicotine (Martin et al., 1989).
Figure 2.33 Chemical structures of varenicline.
2.10.2 Selective a4(32 Antagonists.
2.10.2.1 Mecamylamine.
Figure 2.34 Chemical structure of mecamylamine.
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2.10.2.2 Methylcaconitine.
An alkaloid derived from the larkspur flower, methylcaconitine or MLA is a potent and specific 
competitive antagonist that inhibits a7, a6 and a3 containing nAChRs (Alkondon et al., 1992; 
Pfister et al., 1999; Mogg et al., 2002) (Figure 2.35). MLA binds at the agonist binding site 
blocking access to the agonist binding site and inhibiting receptor activation. MLA is a selective 
and potent antagonist for a7 nAChR (Ki = 1.4 nM) (Ward et al., 1990).
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Figure 2.35 Chemical structure for methylcaconitine.
2.10.2.3 Conotoxins.
Derived from cone snails (genus Conus), conotoxins are a family of peptides and proteins 
used by the organism to paralyze other animals. These compounds work by disrupting multiple 
components of neurotransmission including voltage-gated Na+ and K+ channels and nAChRs 
(Dutertre and Lewis, 2006). a-Conotoxins are selective antagonists for different nAChR subtypes 
(Azam and McIntosh, 2009). The a-conotoxins share a common structural fold composed of a 
short helix stabilized by a disulfide bond. These ligands bind specifically to nAChR subtypes 
making them potentially useful therapeutic compounds.
2.10.3 Selective a402 Modulators.
Allosteric modulators are ligands that bind at a different binding site than the endogenous 
agonist. Positive and negative allosteric modulators can exert activator or inhibitory effects 
respectively. Allosteric modulators have little or no stimulatory effects themselves, but enhance 
the activity of orthosteric acting agonists. The key advantage to using allosteric modulators is that 
alteration in receptor function only occurs on agonist binding. This allows for the spatial and 
temporal relationships in neurotransmission to remain unaltered, possibly presenting a new
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avenue for therapeutic treatment of CNS disorders. Positive allosteric modulators (PAMs) have 
therapeutic potential in the possible restoration or improvement of nicotinic transmission 
compensating for altered expression of <34(32 nAChR. PAMs can increase a4p2 receptor 
responses and therefore may offset decreased receptor expression. A brief review of important 
nAChR PAMs follows.
2.10.3.1 Galanthamine.
Galanthamine is a drug that is used clinically to treat Alzheimer’s disease symptoms 
(Scott and Goa, 2000) (Figure 2.36). It is an AChE inhibitor with a ICso value ~ 2.8 - 3.2 pM for the 
frontal cortex and hippocampus (Thomsen et al., 1991). By inhibiting AChE, galanthamine 
prolongs the time period in which ACh can interact on cholinergic systems. Galanthamine is not a 
selective PAM that potentiates a3(34, a6(34 and a7 nicotinic receptors. Galanthamine alters the 
apparent ACh affinity without changing the ACh apparent efficacy on a4p2 nAChR (Samochocki 
et al., 2003). In the presence of 0.5 pM galanthamine, the ACh EC50 value decreased from 20 ±
1.7 to 10 ± 1.8 pM. The shift in the dose-response curve indicated that galanthamine may either 
act by increasing the binding affinity of ACh to a4[32 nAChRs and/or facilitate the conversion of 
the ACh-bound receptor to the open conformation (Samochocki et al., 2003).
Figure 2.36 Chemical structure of galanthamine.
2.10.3.2 Physostigmine.
Physostigmine is not a selective PAM that potentiates a7 nAChR and other heteromeric 
subtypes (Figure 2.37). Physostigmine binds to a low affinity ACh binding site on a4p2 receptors 
in presence of low concentrations of ACh (Smulders et al., 2005). Binding experiments have 
shown the potentiating physostigmine acts as a competitive ligand on a4p2 nAChR, suggesting 
that ACh and physostigmine share a common binding site (Smulders et al., 2005).
Figure 2.37 Chemical structure of physostigmine.
2.10.3.3 17-^-Estradiol.
17-p-Estradiol potentates human a4(32 nAChR, but inhibits rat a4p2 receptors (Paradiso 
et al., 2000) (Figure 2.38). The difference in action between human and rat may be the result of 
having two 17-p-Estradiol binding sites on human a4p2 nAChR and one on rat a4p2 receptors. 
On human a4p2 receptor, the 17-p-Estradiol potentiation binding site is located on the a4 subunit 
C-terminal end at the amino acid sequence WLAGMI. Single channel studies showed that 17-p- 
Estradiol works by increasing the opening probability of a4p2 nAChR (Curtis et al., 2002). The 
binding site for 17-p-Estradiol’s potentiation is not the same as its inhibition site. Mutation of the 
key W to an I or S removed the potentiation affect, but had no effect on progesterone inhibition 
(Paradiso et al., 2001). The inhibition site for 17-P-Estradiol may be located at the steroid binding 
site located within the transmembrane domain (discussed in section 2.7.2.2).
Figure 2.38 Chemical structure for 17-P-Estradiol.
2.10.3.4 Zinc.
Zinc (Zn2+) modulates a number of LGIC receptors including GABAaR, glycine and 
nAChRs (Krishek et al., 1998; Harvey et al., 1999). Zn2+ has been shown to inhibit a7 and a3p2 
nAChR subtypes and produces biphasic dose response curves on a2p2, a2p4, a3p4, a4p2 and 
a4p4 (Hsiao et al., 2001). Zn2+ has also been shown to potentiate the a4p4 receptors (Hsiao et 
al., 2008). Low micro molar concentrations of Zn2+ potentiated ACh induced currents on a2p2, 
a2p4, a3p4, a4p2 and a4p4 receptors. At milli-molar Zn2+ concentrations, Zn2+ inhibited ACh 
induced responses on a2p2, a2p4, a3p4, a4p2 and a4p4 receptors. Zn2+ potentiation is
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apparently selective for the putative low ACh sensitivity a4p2 stoichiometry (Moroni et al., 2008), 
while Zn2+ inhibition is non-selective, inhibiting both high and low-sensitivity stoichiometries. ACh 
responses on the low-sensitivity a4p2 receptors were potentiated 260% by Zn2+. The inhibition of 
Zn2+ on high-sensitivity a4(B2 receptors was voltage dependent while it was independent on low- 
sensitivity receptors. Site-directed mutagenesis studies suggested that the p2+/a4- interface 
contains the Zn2+ inhibition site. The putative potentiation site was presumed to be located at the 
a+/a- binding cleft (Moroni et al., 2008).
2.10.3.5 Desformylflustrabromine.
Desformylflustrabromine (dFBr), a new compound extracted from North Sea bryozoan 
Flustra foliacea, has been shown to inhibit the growth of bacteria such as Paenibacillus pabulf, 
Roseobacter sp., Sulfitobacter sp., 01-14-4 (Psychroserpens-like bacterium) and Halomonas 
marina (Peters et al., 2003). In the Flustra foliacea, dFBr is a tryptophan metabolite (Lysek et al.,
2002) (Figure 2.39). Other tryptophan derived metabolites of this organism were shown to have 
muscle relaxant properties (Sjoblom et al., 1983). Radioligand binding of dFBr on a7 and a4p2 
indicates an affinity of > 50 pM on a7 nAChR and an affinity of 3.4 ± 0.5 on a4p2 (Peters et al., 
2004). Functional testing of dFBr on a4p4, a3p2, a3p4, a4p2 and a7 nAChR on Xenopus oocytes 
showed that with ACh, dFBr selectively potentates a4p2 nAChR (Sala et al., 2005). While dFBr 
did not potentiate the other tested subtypes, the compound did inhibit a7 nAChR. The induced 
response of dFBr on a4p2 receptors was sigmoidal in nature. Low nM (up to 30 pM) dFBr caused 
potentiation of ACh induced responses that were reversible and concentration dependent. 
Chapters 3 and 4 discuss our investigation and findings regarding the mechanisms of dFBr 
potentiation and inhibition. The selective nature of dFBr makes it an ideal molecule to probe novel 
binding sites on nAChRs and develop new potential therapeutic ligands. We have begun to 
characterize the dFBr binding site (see chapter 4) and have also begun to characterize analogues 
of dFBr. Results from these studies will be useful in developing a4p2 nAChR subtype selective 
ligands that may be useful in treating pathologies.
Figure 2.39 Chemical structure of desformylflustrabromine.
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2.11. Assembly and Trafficking of Nicotinic Receptors.
nAChR subunits fold and assemble into pentameric receptors in the endopiasmic 
reticulum (ER) (Figure 2.40). A requirement for the proper folding and assembly of nAChR 
appears to be required before the receptors leave the ER (Smith et al., 1987; Gu et al., 1991; 
Kreienkamp et al., 1995; Keller et al., 2001). From there, the assembled proteins are transported 
to the Golgi apparatus and then to the plasma membrane (Figure 2.40). The maturation process 
has been estimated to take 2h (Merlie and Lindstrom, 1983) but the mechanism of nAChR 
maturation is poorly understood. Key proteins known to be involved in the process of nAChR 
maturation (Figure 2.40) are briefly summarized below.
Figure 2.40 Components of nAChR trafficking highlighted in the text.
2.11.1 Assembly.
Several chaperones have been identified that are associated with and/or influence 
maturation of nAChRs. The most widely studied proteins include Ric-3 (Jeanclos et al., 2001; 
Halevi et al., 2002; Cheng et al., 2005), 14-3-3 (Jeanclos et al., 2001), BiP (Connolly et al., 1996) 
and Lynx-1 (Miwa et al., 2006) (Figure 2.40). These chaperones associate with immature nAChR 
subunits and enhance protein folding, assembly and surface expression. Ligands have also been 
shown to alter nAChR expression (Figure 2.40).
The protein Resistant to Inhibitors of Cholinesterase (RIC-3) has been identified as the 
first protein discovered that is specifically required for AChR maturation in Caenorhabditis 
elegans and has been hypothesized to function in the folding, assembly and/or transportation of 
nAChRs from the ER to the Golgi apparatus (Halevi et al., 2002; Treinin 2008) (Figure 2.40). RIC- 
3 has two transmembrane domains as well as extensive coiled-coil domains (Halevi et al., 2002)
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and is expressed in both muscles and neurons within cell bodies. The RIC-3 protein appears to 
be localized in the ER where unassembled receptors accumulate and AChRs are assembled and 
miss-folded (Smith et al., 1987; Halevi et al., 2002). RIC-3 has additionally been shown to be an 
effective facilitator of aJ nAChR expression (Halevi et al., 2002; Treinin, 2008). However, 
contradictory results have been shown for RIC-3 in a4|32 nAChR maturation (Halevi et al., 2003; 
Lansdell et al., 2005).
The 14-3-3 protein has also been shown to assist in nAChR trafficking. An adapter 
protein located at nicotinic synapses, the 14-3-3 protein binds at the cytoplasmic domain of the 
a4 nAChR subunit (Lin et al., 2002). The 14-3-3 protein allows or promotes the forward trafficking 
of multimeric membrane proteins, an action resulting from the 14-3-3 protein’s masking or 
overriding the COPI recognition signals ensuring the protein’s retention in the ER (Mrowiec and 
Schwappach, 2006) (Figure 2.40). COPI, or coat protein, is a protein complex that transports 
proteins back from the Golgi and preserves the proteins in the ER (Figure 2.40). In addition, the 
COPI protein allows the trafficking of unassembled subunits from the ER to the Golgi (St. John,
2009). Phosphorylation of the a4 nAChR subunit at the PKA consensus promotes the binding of 
14-3-3 proteins and aids in the stabilization of a4 subunits in the ER (Bermudez and Moroni, 
2006). This stabilization promotes the assembly of complete a4(32 nAChRs which then releases 
the multimeric proteins from the ER and permits trafficking to the plasma membrane. While it is 
unknown if the 14-3-3 protein interacts with a7 nAChR, its involvement in the clustering of a3- 
containing nAChRs has recently been determined (Rosenberg et al., 2008).
The immunological heavy chain-binding protein (BiP) is another chaperone protein that 
contributes to protein degradation (Plemper et al., 1997) and assists in the translocation of newly 
synthesized proteins across the ER membrane (Corsi and Schekman, 1997; McClellan et al.,
1998) (Plemper et al., 1997; Brodsky et al., 1999) (Figure 2.40). BiP functions by ATP driven 
cycles of “binding to” and “release o f  substrate proteins requiring ATP hydrolysis by BiP ATPase. 
The binding and release cycles promote protein folding by preventing aggregation (Gething,
1999).
The protein Lynx-1 may also play a role in the assembly and trafficking of LGICs (Figure 
2.40). Lynx-1 is a GPI-anchored protein that co-localizes with nAChR and modulates nAChR 
affinity and desensitization (Miwa et al., 2006). Some associated proteins, such as HSP90 and 
P2X7i may also exert the opposite effect by activating as negative regulators of receptor 
expression (Adinolfi et al., 2003).
Endogenous and exogenous ligands have also been shown to prompt changes in nAChR 
protein expression through up-regulation (Figure 2.40). For example chronic exposure to nicotine
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causes up-regulation of nAChR by promoting the oligomerisation and maturation of high- 
sensitivity receptors (Kuryatov et al., 2005; Sallette et al., 2005). SLURP (secreted mammalian 
Ly-6/urokinase plasminogen activator receptor-related protein) -1 and -2 can modulate nAChR in 
non-neuronal tissues (keratinocytes, epithelial cells and immune cells) (Chimienti et al., 2003; 
Arredondo et al., 2006b; Moriwaki et al., 2007). SLURP-1 is a potent allosteric potentiator of 
human a7 nAChR (Chimienti et al., 2003). On a3 containing nAChR, SLURP-2 acts as a 
competitive antagonist (Arredondo et al., 2006b). The actions of SLURPs are thought to be 
important in modulating the autocrine cholinergic regulation of cell proliferation.
2.11.2 Trafficking and Cell surface Localization.
Synthesis, maturation and targeting have been comprehensively studied for muscle 
receptors yet the specifics of AChR ontogeny remain unknown. Muscle type nAChR subunits are 
translated by ER membrane-associated ribosomal complexes and co-transnationally inserted into 
the ER membrane by the translocon (Johnson and van Waes, 1999; Alder and Johnson, 2004) 
(Figure 2.40). The nascent subunit subsequently undergoes cleavage of its signal sequence, 
oxidation of its disulfide bonds (Mishina et al., 1985; Blount and Merlie, 1990) and N-glycosylation 
of specific residues (Merlie et al., 1982; Smith et al., 1987; Blount and Merlie, 1988). Chaperones 
like the binding protein BiP (Blount and Merlie, 1991; Paulson et al., 1991; Forsayeth et al., 1992) 
and calnexin (Gelman et al., 1995; Keller et al., 1998) promote the proper folding and maturation 
of AChR subunits (Figure 2.40). Miss folded and unassembled nAChR subunits are targeted for 
degradation by the ER-associated proteasomal degradation machinery (Wanamaker et al., 2003) 
and are then exported from the ER to the Golgi in vesicles coated in protein complex II (COPII) 
(Keller et al., 2001; Wang et al., 2002) (Figure 2.40). The trafficking from the ER to Golgi occurs 
presumably after the masking of specific ER retention signals and recognition of ER export motifs 
in properly folded and oligomerized AChR subunits.
Several trafficking motifs have been identified (Nishimura and Balch, 1997; Barlowe, 
2003; Robinson, 2004) but little is known about the location or composition of these motifs in 
nAChR subunits. Alignment of the cytoplasmic domain of nAChR subunits reveals a large degree 
of conservation of hydrophobic residues (Ren et al., 2005). Mutagenesis studies have shown that 
these highly conserved hydrophobic residues are critical structural determinants for ER export of 
fully assembled nAChRs (Ren et al., 2005). Specifically mutations of leucine resides (L351A, 
L357A and L358A) in the a4 subunit attenuated nAChR cell surface expression, whereas 
mutations L342A, L343A, L349A and L350A in the (32 subunit were sufficient to nearly abolish 
nAChR cell surface expression. These results suggest that the a4 AChR subunit has a
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cooperative or regulatory role and the 02 subunit has a role in functional interactions with the ER 
export machinery (Ren et al., 2005).
Clustering of nAChR at muscle endplates has shown nAChRs to be less susceptible to 
disassembly during maturation and increases the life time of the receptors in the membrane from 
hours to several days (Fambrough, 1979). Agrain activates the transmembrane receptor tyrosine 
kinase (MuSK) which can cause the clustering of nAChR by rapsyn, (Araud et al., 2010) a 43 kDa 
protein, that binds to nAChR and may tether receptors to the cytoskeleton (Antolik et al., 2007) 
(Figure 2.40). Studies have further suggested that rapsyn binds to the cytoplasmic loops of 
nAChR subunits (Lee et al., 2009).
The cytoplasmic loop on nAChRs is also an important regulator of cell surface 
expression. Co-localization of a l  nAChR with “lipid rafts” may be a determinate of nAChR surface 
expression (Figure 2.40). In PC12 cells, lipid rafts are essential for the co-localization of a 
receptors and adenylyl cyclase within the plasma membrane and for other regulation activities 
involving Ca2+ influx through a nAChR (Oshikawa et al., 2003).
2.11.3 Post Translational Modifications.
Post translational modifications are reversible modifications that can alter LGIC function, 
assembly, stability, etc. Phosphorylation, palmiityoylation, sumoylation and ubiquitination are 
examples of post translational modifications that occur on nAChRs, although very little is known 
about palmiiyoylation and sumoylation of nAChRs.
Phosphorylation is a rapidly reversible modification that acts as a switch to influence 
LGIC function (ex. desensitization rate), subunit assembly, receptor aggregation, stability and 
synaptic strength (Araud et al., 2010). Attaching or removing phosphate groups on the receptors 
transpires by kinases or phosphatases (Figure 2.40). Phosphorylation at serine/threonine or 
tyrosine occurs at the intracellular loop. Tyrosine phosphorylation of the a7 nAChR by src-kinase 
on the receptor’s cytoplasmic loop reduced ACh-evoked currents (Charpantier et al., 2005).
2.12. Distribution of nAChRs in the Central Nervous System.
nAChR are widely distributed in both the nervous system and non-neuronal tissues.. 
nAChRs are critically important during early pre- and post-natal circuit formation and age-related 
cell degeneration and are found along cholinergic pathways (Woolf, 1991; Gotti et al., 2006b). 
Cholinergic neurons in the basal forebrain generally located in an axis running from the cranial 
nerve nuclei of the brain stem to the medullary tegmentum and ponomesencephalic tegmentum 
continuing rostrally though the diencephalon to the telencephalon (Woolf, 1991) (Figure 2.41). In 
the brain there are three cholinergic systems that reach from the brain steam to nearly every
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neural area. The first major cholinergic system is found in the pedunculopontine tegmentum (ppt) 
and laterodorsal pontine tegmentaum (Idt) providing a widespread innervation to the hindbrain, 
thalamus, hypothalamus, basal forebrain and midbrain dopaminergic areas and descending to 
the caudal pons and brain stem (Dani and Bertrand, 2007) (Figure 2.41). The second major 
system arises from various basal forebrain nuclei (the nucleus basalis group; nucleus basalis, 
substantia innominata and horizontal diagonal band: bas, si, hdb) that project throughout the 
neocortex, parts of limbic cortex and the amygdala (Dani and Bertrand, 2007) (Figure 2.41). 
These projections provide an extensive and sparse innervation throughout the brain. The third 
cholinergic system is composed of the medial septal group (medial septal nucleus and vertical 
diagonal band: ms and vdb) that project cholinergic axons to the hippocampus and 
parahippocampal gyrus (Dani and Bertrand, 2007) (Figure 2.41). In addition, this system makes 
up approximately 2 % of the striatal neurons and innervates the striatum and olfactory tubercle 
(Zhou et al., 2002).
nAChRs are principally located at presynaptic or pre-terminal sites where they modulate 
neurotransmitter release or on ceil bodies and dendrites where they mediate postsynaptic effects 
(Hogg et al., 2003; Dajas-Bailador and Wonnacott, 2004; Gotti and Clementi, 2004). Other 
studies suggest that nAChR are not found in abundance at the synapse and are more involved in 
diffuse volume transmission (Umbriaco et al., 1994; Descarries et al., 1997). It is not uncommon 
for structural studies to underestimate synaptic contacts due to the difficultly of observing every 
contact from every angle. It is becoming increasingly evident that alteration of nAChR 
neurotransmission can lead to pathologies during development, adulthood and aging.
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Figure 2.41 The three major cholinergic pathways found in the brain.
The cholinergic systems are located as described: (1) Cholinergic neurons in the 
pedunculopontine tegmentum (ppt) and laterodorsal pontine tegmentaum (Idt) project into the 
hindbrain, thalamus, hypothalamus, basal forebrain and midbrain dopaminergic areas and 
descend to the caudal pons and brain. (2) Neurons located in the basal forebrain nuclei (the 
nucleus basalis group; nucleus basalis, substantia innominata and horizontal diagonal band: bas, 
si, hdb) extend throughout the neocortex, parts of the limbic cortex and the amygdala. (3) 
Cholinergic cells located in the medial septal group (medial septal nucleus and vertical diagonal 
band: ms and vdb) extend cholinergic axons to the hippocampus, parahippocampal gyrus, 
striatum and olfactory tubercle. The brain illustration is modeled after a rat brain. (Image was 
used with permission from (Woolf 1991) and was modified.)
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In situ hybridization results of a4, P2 and a7 indicate subunit mRNA is widely distributed 
throughout the brain with receptor location and varies among different vertebrate species (Gotti et 
al., 2006b). a-bungarotoxin sensitive receptor subtypes (a7-10) are highly expressed in the 
cortex, hippocampus and subcortical limbic regions and are expressed at low levels in the 
thalamic regions and basal ganglia (Gotti et al., 2006b) (Figure 2.42).
The a-bungarotoxin sensitive a9 and a10 subtypes have not been found in the brain. 
Their co-expression as a9 homomers and a9a10 heteromomers appears to be limited to the 
cochlea and a few ganglia (Gotti et al., 2006a).
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Figure 2.42 Locations of nAChR in the rat brain.
(Image reprinted from (Gotti et al., 2006b) and used with permission.)
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2.12.1 a4p2 Expression.
The a4|32 subtype appears to found in subregions such as the cortex, striatum, superior 
colliculus, lateral geniculate nucleus and cerebellum (Picciotto and Zoli, 2002; Gotti and Clementi, 
2004; Gotti et al., 2005; Turner and Kellar, 2005) (Figure 2.42). In mice, radioligand binding using 
L-[3H]nicotine has shown high levels of binding in the interpeduncular nucleus, medial habenula, 
thalamic nuclei, ventral lateral and dorsal lateral geniculate nuclei and optic tract nucleus. 
Moderate binding was found in many areas of the brain including the parietal cortex, cingulated 
cortex, subiculum, substantia nigra, superior colliculus, medial geniculate nucleus, optic nerve 
dorsal raphe, laterodorsal tegmental nucleus and retrospenial cortex. Low levels of binding have 
been found in the medial septum, nucleus accumbens, caudate putamen, hippocampus and 
olfactory tubercle. Virtually no binding was found in the cerebellum (Marks et al., 1992).
The L-[3H] nicotine labeling correlates well with a4 mRNA expression in the CNS (Wada 
et al., 1989; Marks et al., 1992). Discrepancies might be due to the protein being localized to 
axons and synaptic terminals while mRNA resides in the soma. (32 nAChR subunit MAb270 
immunolabeling displays a similar expression pattern to the L-[3H]nicotine labeling (Clarke et al., 
1985; Swanson et al., 1987). MAb270 immunolabeling indicates discrete expression at all levels 
of the rat brain and spinal cord with strong labeling in the interpeduncular nucleus, medial 
habenula, thalamus and superior colliculus.
Both a4 and 32 subunit mRNA are detected in the CNS and PNS as early as E11 in rats. 
The expression of a4 is down-regulated in the PNS to undetectable levels by E15 whereas 32 
mRNA expression levels are maintained until adulthood (Zoli et al., 1995).
It has been found that GABAergic and dopaminergic neurons express similar nAChR 
mRNA (Klink et al., 2001). Both a4 and 32 mRNAs are expressed in nearly all dopaminergic and 
GABAergic neurons in the vental tegmental area, whereas a2 are not expressed (Klink et al.,
2001). Specifically, the a7 nAChR subunit mRNA is found in 40% of the dopaminergic and 
GABAergic neurons while 34 is sparsely found in the GABAergic (25%) and dopaminergic (12%) 
neurons. The a5, a6 and 33 mRNA expression levels are lower in GABAergic (< 25%) than 
dopaminergic (> 70%) neurons.
The vental tegmental area and substantia nigra pars compacta contain moderate to high 
levels of a432 nAChR mRNA (Wada et al., 1989). Antibody labeling of a4 and 32 subunits in the 
soma and dendrites of the substantia nigra pars compacta shows co-localization in > 90% of 
dopaminergic neurons (Arroyo-Jim nez et al., 1999; Jones et al., 2001). Immunoelectron 
microscopic studies have shown that a4 subunits are located in the perikarya and dendritic
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shafts, but not in the spines and are scarcely found in postsynaptic membranes of dopaminergic 
neurons (Arroyo-Jimenez et al., 1999). The 32 subunit shows a similar localization pattern in 
dopaminergic neurons found in the substantia nigra pars compacta and in presynaptic 
membranes of dopaminergic axonal terminals in the dorsal striatum (Jones et al., 2001).
2.12.2 Other Heterpentameric nAChR.
Studies have shown that the same neuronal population can express multiple nAChR 
subtypes. The nAChR subunits a2, a3, a6, 32 and P4 can either form heteropentameric complex 
subtypes. For example, a4a6p2* are found in the striatum and visual pathways, a3a432 or 
a3a4p4 in the cerebellum (Turner and Kellar, 2005) and a2a4p2* in the retina (Moretti et al., 
2004; Marritt et al., 2005). Reasons for this heterogeneity are only partially understood. Specific 
characteristic of the subtypes, like high versus low Ca2+ permeability or slow versus fast 
desensitization rates, might make co-expression of the various subtypes relevant. Alternatively, 
the various subtypes may be critical for preferential targeting to different cell compartments (Gotti 
et al., 2006b).
2.13. Pathological Conditions Associated with nAChRs.
Implicated in many pathological conditions, nAChR subtypes and densities change 
depending on the disease. Neurological conditions with strong nAChR components include 
Alzheimer’s disease (AD), Parkinson’s disease, Autism, Schizophrenia, alcohol addiction and 
nicotine addiction. Not surprisingly there are many clinically used drugs targeting nAChR. These 
drugs are usually administered for months and typically produce long-term changes in receptor 
properties and/or numbers (Taly et al., 2009). Chronic exposure to nicotine, for example, can 
cause a two fold up-regulation in the total number of high-affinity receptors (Sallette et al., 2005).
nAChR are involved in the pathogenesis or symptomatology of several diseases of the 
CNS. These diseases are subdivided into two groups: those in which a nAChR subunit gene is 
mutated and the receptor subtype function is altered (as is the case for autosomal dominate 
frontal lobe epilepsy); and those involving modification in nAChR expression densities (such as 
schizophrenia, Tourette’s syndrome, attention deficit hyperactivity disorder, autism, depression 
and anxiety) and neurodegenerative Alzheimer’s and Parkinson’s disease (Hogg et al., 2003; 
Gotti and Clementi, 2004; Hogg and Bertrand, 2004).
Mutations in the channel region of the a4 or 32 subunits have been found in some 
families suffering from autosomal dominate frontal lobe epilepsy. The expression of these 
mutated receptors causes a gain (a4) or loss (32) of function, but in both cases results in 
functional receptors with a higher ACh sensitivity (Gotti et al., 2006b).
74
2.13.1 Alzheimer’s Disease.
Alzheimer’s disease is characterized by progressive cognitive decline and neuronal 
death. The cholinergic synapses in the basal, forebrain, cerebral cortex and hippocampus were 
especially reduced (Kasa et al., 1997) as were muscarinic and nicotinic AChR expression (Court 
et al., 2001). Differences in receptor subtypes have also been observed. In the cerebral cortex, it 
has been reported that there was a massive reduction in predominantly the a4|B2 subtype while 
the a7 nAChR appears to be spared (Bourin et al., 2003) and in the hippocampus, the expression 
of a7 nAChR was reduced (Whitehouse and Kalaria, 1995; Nordberg et al., 1997; Burghaus et 
al., 2000; Guan et al., 2000; Nordberg, 2000).
It has been suggested that the a7 nAChR subtype may play a large role in memory. In 
the hippocampus, a critical region for memory formation, there is a high level of a7 nAChR 
expression. Gene knockout and antisense RNA studies have indicated a role for a7 nAChR in 
learning, memory, attention (Wehner et al., 2004; Keller et al., 2005; Curzon et al., 2006) and 
working-episodic memory (Fernandes et al., 2006; Young et al., 2007). In addition, 
pharmacological studies have shown that a7 nAChR selective agonists or PAMs improve 
cognitive deficits associated with AD.
The selective a7 partial agonist, AR-R17779, has been shown to improve scopolamine- 
elicited deficits in social recognition. AR-R17779 also enhanced the long-term learning and 
attenuated working-memory deficits in rats (Taly et al., 2009). Two a7 partial agonists, GTS-21 
(also a a4p2 antagonist) and MEM-3454 (also a 5HT-3R antagonist) showed precognitive action 
(Rezvani et al., 2009). In preclinical studies, MEM-3454 enhanced episodic, spatial and working 
memory. The precognitive effect of MEM-3454 on episodic memory was completely blocked by 
the a7 specific antagonist methyllycaconitine. In a phase I clinical trial, GTS-21 improved episodic 
secondary memory tests including word recall and picture and word recognition (Kitagawa et al.,
2003). High concentrations of GTS-21 have been shown to reduced cell survival, suggesting a 
risk of over-stimulation (Meyer et al., 1998).
The toxic peptide Ap1-42 involved in AD has recently been shown to bind to a7 nAChR 
(Wang et al., 2000). Controversial reports suggest that Ap1-42 may act either as an agonist or as 
an antagonist on a7 receptors (Dineley et al., 2001; Pettit et al., 2001; Spencer et al., 2006). 
Other papers have suggested that Ap1-42 does not bind to a7 nAChRs (Lamb et al., 2005; Small 
et al., 2007).
Currently, partial agonists are receiving more attention as drug development targets than 
full agonists because of their similar properties and reduced ability to activate the receptors,
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possibly leading to a reduced risk of cytotoxicity by Ca2+ entry. Allosteric modulators are also 
being heavily investigated as potential therapeutics due to their ability to alter the amplitude of the 
receptor response while maintaining the spatial and temporal organization of signal transmission.
Since a7 nAChR play a role in cognitive function (Curzon et al., 1996; Hahn et al., 2003), 
this subtype has also been a target for drug development. ABT-418, a selective a4(B2 full agonist 
has been shown to have cognitive-enhancing activity in preclinical and Phase II studies (Potter et 
al., 1999; Arneric et al., 2007). Ispronicline a full agonist on a4(32 nAChR has been tested in 
clinical trials but failed to demonstrate cognitive improvements.
2.13.2 Autism Spectrum Disorder.
The observation that individuals who suffer from autism spectrum disorder are typically 
non-smokers suggests that nicotinic receptor expression or function may be altered in autistics 
(Glennon, 2005). A more recent study has demonstrated that prenatal exposure to nicotine may 
be linked to infantile autism (Lippiello, 2006). The expression of nAChR appears to be altered in 
autistics in several brain regions. In the cortical regions, epibatidine binding was shown to be 
reduced by nearly 30% with little change in a-bungarotoxin binding (Perry et al., 2001). These 
results indicated that the a4(B2 nAChR expression was decreased while expression of a7 nAChRs 
remained unchanged (Martin-Ruiz et al., 2004).
A possible genetic link also exists. Behavior and linkage analysis studies disclosed that 
there is an autism susceptibility gene on chromosome 1, which contains the (32 nAChR gene 
(Ferretti and Gianandrea, 1954; Anand and Lindstrom, 1992) as well as chromosomes 6 and 19 
(Buxbaum et al., 2004). 02 knockout mice provide further evidence for a genetic link through 
typical autistic behavioral displays, such as a decreased ability for conflict resolution and social 
interaction (Granon et al., 2003). Larger decreases (> 50%) in epibatidine binding are also 
observed in the thalamus and striatum while a7 receptors are unaffected (Court et al., 2000; 
Perry et al., 2001; Martin-Ruiz et al., 2004; Ray et al., 2005). Increases in a7 expression have 
been shown to occur in cerebellar granule cells (Martin-Ruiz et al., 2004). Chromosome 15 is 
near another locus thought to be a genetic marker for autism and contains the a7 nAChR gene 
(Chini et al., 1994; Lamb et al., 2000).
Due to the putative role of nAChR in autism, nicotinic ligands may be useful in treating 
autistic spectrum disorders (Lichtner et al., 1988; Dani and Bertrand, 2006; Lippiello, 2006; 
Nicolson et al., 2006) and several nicotinic ligands, such as Galantamine (Razadyne®), are in 
clinical trials for the treatment of behaviors such as aggression, uncontrollable behavior and 
inattention (Nicolson et al., 2006). A cholinesterase inhibitor and a non-specific potentiator,
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Galantamine enhances nicotinic responses at nicotinic subtypes. Galantamine additionally 
inhibits nAChRs at concentrations only slightly higher than its peak potentiating concentrations, 
thus narrowing its therapeutic range. Mecamylamine (Targacept®) is also currently being 
examined as an autism therapy (Lippiello, 2006). Mecamylamine is a a304 nAChR antagonist 
and has had positive effects in treating Tourette Syndrome and Attention Deficit Disorder (Shytle 
et al., 2000; Silver et al., 2000).
The current nicotinic treatment ligands are not the ideal treatment strategies for Autism. 
Non-selective ligands act on all nAChR populations, not just the dysregulated nAChRs. Selective 
allosteric modulators may be better suited for treating aspects of Autism such as aggression and 
antisocial behavior. A selective PAM would cause an increase in activity in down-regulated 
receptors and would only act on the receptors when the endogenous ligand was present 
maintaining the spatial and temporal relationship within the nicotinic system.
2.13.3 Nicotine Addiction.
nAChR levels in human smokers are higher than nonsmokers as verified by functional 
magnetic resonance imaging and post mortem measurements (Breese et al., 1997; Perry et al., 
1999; Staley et al., 2006; Mamede et al., 2007). The a402 nAChR and other subtypes are 
selectively up-regulated (Nguyen et al., 2003) and active rather than desensitized (Nguyen et al., 
2004; Nashmi et al., 2007). The extent of up-regulation appears to be regional and cell sensitive 
(Nashmi et al., 2007). Up-regulation of highly-sensitive nAChR is partially the biological basis for 
tolerance, locomotor sensitization and cognitive sensitization associated with chronic nicotine 
administrations (Buisson and Bertrand, 2002; Gentry and Lukas, 2002; Nashmi et al., 2007; 
Tapper etal., 2007).
Nicotine’s major addictive effects are thought to be mediated through the dopaminergic 
mesocorticolimbic pathways (Nashmi and Lester, 2006). Dopaminergic neurons originate in the 
vental tegmental area and project to the nucleus accumbens and prefrontal cortex. In the vental 
tegmental area, the dopaminergic neurons, GABAergic neurons and glutamateric axonal 
terminals all contain nicotinic receptors (Mansvelder and McGehee, 2000; Mansvelder et al.,
2002). Chronic nicotine exposure selectively up-regulates receptor number in the midbrain. Up- 
regulation occurs in the GABAergic neurons in the vental tegmental area but not in the somata or 
the dopaminergic neurons. Dopaminergic neurons are the postsynaptic targets and are inhibited 
by the GABAergic neurons. As a result, chronic nicotine increases both the basal firing rates and 
the excitatory effects of nicotine in GABAergic neurons. On dopaminergic neurons chronic 
nicotine decreases baseline firing rates and attenuates the excitatory effects of nicotine (Nashmi 
et al., 2007; Lester et al., 2009). It is thought that the balance of excitatory and inhibitory inputs
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onto the vental tegmental area dopaminergic neurons affects domain dopamine release in the 
nucleus accumbens and is likely critical for the reinforcing effects of nicotine (Nashmi and Lester,
2006).
Compared to wild-type, (32-knockout mice no longer self-administer nicotine (Picciotto et 
al., 1998), demonstrating a role for the (32 subunit in nicotine addiction. Self-administration of 
nicotine is also reduced in rats given dihydro-p-erythroidine (DHpE) (a selective a4p2 antagonist) 
(Watkins et al., 1999). It has been hypothesized that partial agonist may substitute the desired 
effects of nicotine while also antagonizing nicotine reinforcing properties (Hogg and Bertrand, 
2007; Rollema et al., 2007b).
The metabolism of nicotine occurs at a much slower rate than ACh. Nicotine is 
metabolized only by liver enzymes and has a half-life of about ~120min1 (Matta et al., 2007). In 
contrast, ACh is hydrolyzed by acetylcholinesterase with a turnover rate of about ~104 s'1 
(Gyermek, 1996). Simulations of synaptic transmission conclude that ACh remains near receptors 
for < 1ms (Wathey et al., 1979; Bartol et al., 1991). Due to nicotine’s long half-life, it desensitizes 
receptors and permeates cells. Unlike ACh which has slight membrane permeability (> 3h), 
nicotine’s high permeability allows it to act at the cell surface membrane as well as at the 
endoplasmic reticulum and Golgi. This process could be a mechanism of up-regulation of nAChR 
associated with nicotine addiction (Lester et al., 2009). The up-regulation of a4p2 receptors 
appears to be more geared towards the high-sensitivity stoichiometry ((a4)2(p2)3) at the expense 
of the low-sensitivity channel ((a4)3(P2)2) (Lester et al., 2009).
Treatment options for smoking cessation include nicotine and bupropion (a non­
competitive antagonists on a4p2 nAChR) (Fiore et al., 2004). These ligands have limited efficacy 
so the development of more effective therapeutic options is needed. The most recently approved 
drug for smoking cessation is Varenicline, a a4(32 partial agonist and a full agonist on a7 nAChR 
(Rollema et al., 2007b). The US Food and Drug Administration and the European Medicines 
Agency have recently warned of serious side effects including changes in mood and social 
ideation. It is possible that long-term chronic exposure can lead to modified levels of nAChR 
densities (Besson et al., 2007).
The National Institute of Health is funding a major effort to find a better solution for 
nicotine addiction. PAMs are one treatment strategy being explored. The use of PAMs entails a 
smaller dosage of nicotine needed to satisfy cravings allowing the nicotine addicted individual to 
gradually reduce their dependence until they no longer need the drug. The major drawback to this 
approach is that the treatment strategy still targets the reward pathways, which may cause the 
therapeutic ligand to become an abused drug. Another problem with using PAMs as a possible
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nicotine addiction treatment is the ability of some PAMs to reactivate desensitized receptors. 
Large populations of desensitized receptors are present in the brains of nicotine addicted 
individuals and the addition of a PAM could cause activation of these desensitized receptors 
leading to a huge population of activated receptors. The dosage of the therapeutic ligand would 
aid in the prevention of too many receptors being activated.
2.13.4 Cancer and Angiogenesis.
Genomic studies have shown that chromosome regions 15q24-25 (Hung et al., 2008; Liu 
et al., 2008a), 15q15.33 (McKay et al., 2008) and 6p21.33 (Wang et al., 2008b) appear to have 
common sequence variants that may convey a higher risk for developing lung cancer. The 15q24- 
25 region encompasses the nAChR subunits a3, a5 and (34 genes, all of which play a role in 
nicotine addiction (Spitz et al., 2008; Weiss et al., 2008).
Airway epithelial cells produce and degrade ACh (Proskocil et al., 2004). Human 
bronchial epithelium (HBE) express a3, a5, a7, (32 and (34 nAChR subunits (Zia et al., 1997; 
Maus et al., 1998). The a5 and a9 nAChR have been shown to also express in lung and breast 
cancers (Lee et al., 2010b). An increase in a9 nAChR expression has been seen in other cancer 
cells (Lee et al., 2010b).
Nicotine and the tobacco specific nitrosamine 4-(methylnitosamino)-1-(-3-pyridine)-1- 
butanone (NKK) are agonists for nAChR. In an epithelial cell culture model addition of nicotine 
derivatives (NKK and A/-nitrosonornicotine) caused a temporary (1-2.5 hr) up-regulation of the a l  
nAChR subunit (Plummer et al., 2005). An increase in proliferation was observed also then 
reduced by nicotine antagonist (aBTX) (Arredondo et al., 2006a). Nicotine incubation of bronchial 
epithelial cells caused a production of granulocyte-macrophage colony stimulating factor and 
stimulated inflammatory cells (Klapproth et al., 1998). In nonmalignant human bronchial epithelial 
cells, apoptotic effects by damaging agents (such as etoposide, UV irradiation or hydrogen 
peroxide) were attenuated by nicotine and NKK (West et al., 2003). Thus, in epithelial cells, 
nicotine and NKK have a stimulatory effect on growth, inflammation and cell survival.
In breast cancer, exposure to nicotine caused an increase in a9 nAChR expression (Shih 
et al., 2010; Chen et al., 2011). Nicotine itself is not a carcinogen but it does promote the growth 
of cancer cells and proliferation of endothelial cells. Lee et al., (2010b) indicated that increased 
expression of a9 nAChR enhances proliferation and colony formation (Lee et al., 2010b).
In small cell lung cancer (SCLC) and non-SCLC (NSCLC) a3, a5, a l  and |34 nAChR 
subunits are expressed (Chini et al., 1992; Tarroni et al., 1992; West et al., 2003). Both NSCLC 
and SCLC cell lines synthesize and release ACh (Song et al., 2003). In squamous cell carcinoma
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(SqCC), the choline acetyltransferase is strongly up-regulated whereas cholinesterase is down- 
regulated (Martinez-Moreno et al., 2006; Song et al., 2008). This reaction results in an increase in 
ACh concentration in SqCC compared to normal lung, providing an increased level of 
endogenous ACh stimuli to nAChR.
In lung cancer, nicotine induces proliferation of tumor cells by binding to the a7 nAChR, 
leading to the activation of Src and Rb-Raf-1/pERK/p90RSK pathway (Dasgupta et al., 2006b; 
Carlisle et al., 2007). Stimulation of nAChR by nicotine results in Ca2+ influx within seconds. 
Nicotine additionally induces an increase in fibronectin production (Zheng et al., 2007). 
Extracellular fibronectin binds to a5(31 integrin which subsequently leads to increased proliferation 
through ERK, PI3-K and mTOR pathways.
In SCLC and NSCLC cell lines, nicotine diminishes apoptosis (Maneckjee and Minna, 
1994; Dasgupta et al., 2006a). The anti-apoptotic effects of nicotine appear to be mediated by the 
a3 nAChR and required the AKT pathway, leading to an increased recruitment of E2F1 and 
concomitant dissociation of retinoblastoma tumor suppressor protein. The binding of E2F1 to the 
promoter of survivin and XIAP genes resulted in the up-regulation of apoptopic inhibitors 
demonstrating nicotine has a prolonged effect on tumor cell survival by preventing apoptosis.
Individuals diagnosed with smoking-related lung cancer and who continue to smoke have 
a negative correlation with lung cancer survival (Videtic et al., 2003; Sardari Nia et al., 2005). The 
lack of survival may be a result of nicotine’s positive effects on tumor growth and survival.
Studies have shown that nAChR play a major role in breast and lung cancers. The a7 
nAChR are implicated in lung cancer while the a9 nAChR play a major role in breast cancers. 
nAChR antagonists may decrease the survival of tumor cells and provide a novel avenue for 
cancer therapy.
The proliferation of tumors involves the formation of new blood vessels, also known as 
angiogenesis, through the growth factors, intergrins, angioproteins, adhesion and gap junction 
proteins, transcription factors and other components (Risau, 1997). There are three main steps in 
angiogenesis. First, vascular endothelial cells (ECs) activation is mediated by hypoxia and/or 
cytokine release. Second, the basement membrane (BM) is degraded by the matrix 
metalloproteinases (MMPs). Third, vascular endothelial growth factor (VEGF)- and intergrin- 
dependent EC migration, proliferation and differentiation. In pathological conditions, endothelial 
angiogenesis can contribute to neoplastic and non-neoplastic transformations including cancer, 
atherosclerosis, rheumatoid arthritis and diabetic retinopathy (Folkman, 2006). The initial prompt 
for pathological angiogenesis may be EC proliferation/dysfunction by VEGF up-regulation and 
though the release of stored ACh (Parnavelas et al., 1985).
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AChRs are involved in angiogenesis, predominantly subtypes a7 and a3(34 nAChR and 
the subunits a3, a5, P2 and P4 (West et al., 2003). Bronchial epithelial cells (Carlisle et al., 2004), 
endothelial cells of blood vessels (Wang et al., 2001), skin keratinocytes (Chernyavsky et al.,
2004), lymphocytes, microglial and astrocytes contain neuronal nAChRs containing a3, a5, a l, 
p2 and P4 subunits (Conti-Fine et al., 2000; Heeschen et al., 2002).
Angiogeneisis and increased vascular permeability are important factors in wound 
healing, a tightly controlled process involving re-epithelialization, macrophage accumulation, 
fibroblast infiltration, matrix formation and re-vascularization. Whether nicotine promotes or 
delays wound healing is a topic of debate (Jacobi et al., 2002; Galiano et al., 2004; Morimoto et 
al., 2008). In one study non-diabetic mice experienced improved wound heaiing with the use of 
topical 100 pM nicotine (Morimoto et al., 2008) whereas in another study, non-diabetic mouse 
wounds treated with a lower dosage of nicotine (1-10 nM) displayed no improvement in wound 
health when compared to phosphate buffered saline (PBS) treated wounds (Jacobi et al., 2002). 
These results suggest that improvements in wound healing by nicotine may be concentration 
dependent.
Initial tumor formation requires oxygen and nutrients. Further tumor growth requires 
communication with the vascular ECs and new blood vessels. Tumor malignancy is dependent on 
an “angiogenic switch”, a combination of an imbalance of pro- and anti-angiogenic factors 
influenced by hypoxia, low pH, hypoglycemia and inflammatory cytokines (Carmeliet and Jain, 
2000; Pandya et al., 2006). A large variety of angiogenic factors are secreted by tumor cells 
which can overwhelm endogenous angiogenic inhibitors. The ECs migrate towards these 
angiogenic stimuli, proliferate and form new vessels. In hypoxic microenvironments, tumor ECs 
proliferate 2-2000 times faster than normal ECs (Griffioen and Molema, 2000).
Nicotine can induce tumor cell proliferation and angiogenesis through nAChRs expressed 
in cancer cells (Chini et al., 1992; Egleton et al., 2008). The a l  nAChR is the primary receptor 
subtype that mediates nicotine-mediated tumor cell proliferation. a3p4 containing nAChRs may 
also play a role in this process (West et al., 2003). Nicotine enhances cell proliferation of cancer 
cells in small and non-small cell lung carcinomas, pancreatic, colon and bladder cancer cells 
(Shin et al., 2004; Ye et al., 2004; Wong et al., 2007; Chen et al., 2008).
Nicotine has also been shown to increase the levels of different growth factors such as 
VEGF, brain derived neurotropic factor (BDNF), epidermal growth factor (EGF), hepatocyte 
growth factor (HGF), PDGF and transforming growth factor-a (TFG-a) and p (TGF-P) and their 
respective receptors (Conti-Fine et al., 2000). Alterations in these growth factors influence both 
the tumor and normal ECs.
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One cancer treatment avenue is the use of angiogenesis inhibitors. Heeschen and co­
workers demonstrated a decrease in a mouse lung tumor model with the non-specific nAChR 
antagonist mecamylamine (Heeschen et al., 2002). This decrease in tumor growth included a 
lower capillary density and a decreased systemic VEGF levels. Mecamylamine is currently in 
phase II clinical trials. The development of novel inhibiting ligands such as antagonists or NAMs 
may aid in the inhibition or prevention of tumor growth.
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CHAPTER 3: Pharmacological Characterization of the Allosteric Modulator 
Desformylflustrabromine and its Interaction with a4|32 nAChR Orthosteric Ligands1
3.1 Abstract.
Neuronal nicotinic acetylcholine receptors (nAChRs) are members of the Cys-loop superfamily of 
ligand-gated ion channels. nAChRs are involved in modulating nicotinic based signal 
transmission in the CNS and are implicated in a range of CNS disorders. Desformylflustrabromine 
(dFBr) is a positive allosteric modulator which potentiates a4p2 nAChRs. Sala et al. report that 
dFBr is selective for the a4|32 receptor relative to other common nAChR subtypes (Sala et al.,
2005). Co-application of dFBr with acetylcholine produces a bell-shaped dose response curve 
with a peak potentiation of over 265% (Kim et al., 2007) at dFBr concentrations <10 pM and 
inhibition of responses at concentrations >10 pM. The potentiation and inhibition components of 
dFBr modulated responses were examined using two-electrode voltage clamp and human a4p2 
nAChRs expressed in Xenopus laevis oocytes. Currents to both partial and full agonists were 
potentiated by dFBr. Responses to low efficacy agonists were potentiated significantly more than 
responses to high efficacy agonists. Antagonist plC50 values were unaffected by co-application of 
dFBr. In addition to its potentiating effects, dFBr was also able to induce current spikes when 
applied to desensitized receptors suggestive of a shift in equilibrium from the desensitized to 
open conformation. In contrast to potentiation, inhibition of ACh responses by dFBr is dependent 
on membrane potential and is likely the result of open-channel block by dFBr and acetylcholine. 
Our data indicate distinct mechanisms for the potentiation and inhibition components of dFBr 
action. dFBr could prove useful for therapeutic enhancement of responses at a4p2 containing 
synapses.
1 Weltzin, M. M. and Schulte, M. K. 2010. Pharmacological Characterization of the Allosteric 
Modulator Desformylflustrabromine and its Interaction with a4(32 nAChR Orthosteric Ligands. J 
Pharmacol Exp Ther. Sep 1;334(3):917-26.
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3.2 Introduction.
The CNS expression of neuronal nicotinic acetylcholine receptor (nAChR) subtypes are 
altered in many neurological disorders including Alzheimer’s disease (Court et al., 2001; 
Nordberg, 2001), Autism (Martin-Ruiz et al., 2004; Lippiello, 2006), Parkinson’s disease (Aubert 
et al., 1992) and Schizophrenia (Woodruff-Pak and Gould, 2002; Friedman, 2004; Adams and 
Stevens, 2007). In Alzheimer’s disease, multiple subtypes of nAChRs decline producing a 
decrease in cholinergic tone (Court et al., 2001; Nordberg, 2001). Post-mortem studies of 
Autistics have shown both decreases and increases in nAChR subtypes (Court et al., 2001; 
Nordberg, 2001; Martin-Ruiz et al., 2004; Lippiello, 2006). Increases in receptor populations 
should be amenable to remediation with antagonists but treatment of disorders involving 
decreases in receptor number are more difficult. Treatment strategies aimed at increasing activity 
of cholinergic systems have focused on acetylcholinesterase inhibitors and partial agonists 
(Corey-Bloom, 2003; Nicolson et al., 2006). While agonists are potentially useful therapeutically, 
the rapid desensitization of nAChRs produced by chronic exposure to agonists limits their 
usefulness.
Positive allosteric modulators (PAM) represent an alternative treatment strategy. Since 
PAMs typically enhance agonist responses without activating receptors, synaptic currents remain 
linked to endogenous neurotransmitter release. In disorders where differential changes in nAChR 
densities occur, non-selective compounds may improve some symptoms while exacerbating 
others. The development of subtype selective PAMs is an important step in developing 
therapeutic treatments for neurological disorders involving alterations in nicotinic tone.
Desformylflustrabromine (dFBr) is a novel PAM that potentiates ACh induced whole cell 
responses of the a4p2 nAChR subtype by greater than 265% (3 pM dFBr co-applied with100 pM 
ACh). Previous studies have shown no apparent potentiation of other subtypes including a7 and 
a3p4 (Sala et al., 2005; Kim et al., 2007). On a4p2 receptors, co-application of increasing 
concentrations of dFBr with a fixed concentration of Ach produces a bell-shaped dose response 
curve containing both stimulatory (<10 pM dFBr) and inhibitory components (>10 pM dFBr) (Kim 
et al., 2007). On a7 receptors, only the inhibitory component is present. Previous studies using 
dFBr extracted from Flustra foliacea suggested potentiation may be a result of altered channel 
gating kinetics (Sala et al., 2005). At inhibitory concentrations of dFBr “rebound” or “hump 
currents” have been observed suggesting dFBr inhibition may be attributable to open-channel 
block (Kim et al., 2007).
The current study aims to better understand the mechanisms of dFBr potentiation and 
inhibition. We investigated both the inhibitory and potentiating actions of dFBr using a series of
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full agonists, partial agonists and antagonists. Our data suggest that inhibition and potentiation 
are mediated by distinct mechanisms at different binding sites. Inhibition appears to be the result 
of channel block by both dFBr and the stimulating agonist. dFBr was determined to potentiate low 
efficacy agonists greater than high efficacy agonists and was capable of recovering receptors 
from desensitization. This supports the hypothesis that dFBr inhibition is caused by open- 
channel block while potentiation is due to a change in the equilibrium between open and 
desensitized conformations.
3.3 Methods.
3.3.1 Receptors and RNA.
The cDNA for human a4 and |32 nAChR subunits was generously provided by Dr. Jon 
Lindstrom (University of Pennsylvania). This cDNA was inserted into a pcDNA3.1/Zeo (Invitrogen, 
Carlsbad, CA) mammalian expression vector to produce mRNA for receptor expression in 
Xenopus laevis oocytes. Xenopus laevis frogs and frog food were purchased from Xenopus 
Express (Homosassa, FL). Ovarian lobes were surgically removed from Finquel anesthetized 
Xenopus laevis frogs and washed twice in Ca+2-free Barth’s buffer (82.5 mM NaCI; 2.5 mM KCI; 1 
mM MgCI2; 5 mM HEPES, pH 7.4) then gently shaken with 1.5 mg/mL collagenase (Sigma type 
II, Sigma-Aldrich, MO) for 20min at 20-25°C. Stage V and VI oocytes were selected for 
microinjection (University of Alaska Institutional Animal Care and Use Committee: 08-71). 
No more than four surgeries were conducted on each frog. A recovery period greater than six 
weeks was allowed between repeat surgeries on the same animal. Synthetic cRNA transcripts for 
human a4p2 were prepared using the T7 mMESSAGE mMACHINE™ High Yield Capped RNA 
Transcription Kit (Ambion, Austin, TX). Oocytes were injected with a total of 50 nL cRNA at a 
concentration of 300 ng/pL and incubated at 19°C for 24-72h prior to their use in voltage clamp 
experiments. At least two different batches of oocytes were used per experiment. dFBr-HCI was 
synthesized by Dr. Richard Glennon (Virginia Commonwealth University) (Kim et al., 2007) and 
dissolved in ND-96 buffer prior to use.
3.3.2 Two-Electrode Voltage Clamp.
Recordings were performed using an automated two-electrode voltage-clamp system 
incorporating an OC-725C oocyte clamp amplifier (Warner Instruments, Hamden, CT) coupled to 
a computerized data acquisition (Datapac 2000, RUN technologies, Mission Viejo, CA) and 
autoinjection system (Gilson, Middleton, Wl). Recording and current electrodes with resistance 1­
4 MQ were filled with 3 M KCI. Details of the chambers and methodology employed for
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electrophysiological recordings have been described earlier (Joshi et al., 2004). Oocytes were 
held in a vertical flow chamber of 200 pL volume, clamped at a holding potential of -60 mV and 
perfused with ND-96 recording buffer (96 mM NaCI; 2 mM KCI; 1.8 mM CaCI2; 1 mM MgCI2; 5 
mM HEPES; pH 7.4) at a rate of 20 mL/min. For voltage step experiments, the holding potential 
was varied from -100 mV to +20 mV. Test compounds (Sigma-Aldrich, Natick, MO and Tocris, 
Ellisville, MO) were dissolved in ND-96 buffer and injected into the chamber at a rate of 20 
mL/min using a Gilson auto-sampler injection system.
3.3.3 Electrophysiology Dose/Response Experiments.
Dose/response curves for the full agonist (Acetylcholine Cl, (ACh) [Sigma-Aldrich]) and 
the partial agonists ((-)-nicotine [Riedel-de-Haen, Germany], choline-CI [Sigma-Aldrich] and 
cytisine [Sigma-Aldrich]) were evaluated at concentrations ranging from 0.01 pM-300 pM for ACh, 
nicotine and cytisine and 0.1 pM-30 mM for choline. The effects of dFBr on agonist efficacies 
were determined by co-exposure of varied concentrations of agonist with 1 pM dFBr.
The competitive antagonists (Dihydro-p-erythroidine-HBr [Tocris], DMAB- 
anabaseine-2HCI [Tocris] and tropisetrone-HCI [Tocris]) were evaluated for their ability to inhibit 
responses to 1 mM ACh at antagonist concentrations ranging from 0.001 pM-100 pM. The effect 
of dFBr on antagonist inhibition was determined by co-exposing receptors to antagonist, 1 mM 
ACh and 1 pM dFBr.
In order to permit comparison of responses from different oocytes, Individual responses 
to drug application were normalized to control responses elicited using 1 mM ACh. Data were 
collected from at least four replicate experiments using oocytes obtained from at least two 
different frogs.
3.3.4 Exposure of dFBr Prior to Agonist Activation and During Agonist Induced 
Desensitization.
To study the effects of dFBr prior to agonist activation (pre-exposure) on a4(32 nAChR, 1 
pM dFBr was bath applied at a rate of 4 mL/min 30s prior to application of agonist. Following pre­
exposure to dFBr, 1 mM ACh, was applied at a 20 mL/min perfusion rate for 3s. The slope of the 
rising phase of the response was determined from current data during the linear portion of the 
response prior to the peak current. Slopes for pre- and co-exposure experiments were compared 
using these data and p values were calculated based on the null hypothesis using an unpaired t- 
test.
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dFBr was also applied during the desensitization refractory phase of the agonist 
response. In these "post-exposure" experiments, saturating concentrations of agonists (1 mM 
ACh, 10 mM ACh or 100 pM cytisine) were bath applied at a rate of 4 mL/min prior to exposure to 
dFBr. One pM dFBr was applied at a rate of 20 mL/min in repeated 3s pulses once the agonist 
response entered the refractory desensitized phase of the response. Responses were 
normalized to currents obtained by using the appropriate ACh concentration in the absence of 
dFBr. The slope of the rising phase of the response was determined from current data during the 
linear portion of the response prior to the peak current. The agonist and dFBr induced currents 
were compared using p values calculated based on the null hypothesis using an unpaired t-test.
The effects of long-term exposure to 1 pM dFBr on activated receptors were also 
investigated. One mM ACh or 100 pM cytisine were bath applied at a rate of 4 mL/min. Eight mL 
of 1 pM dFBr with and without agonist was perfused at a rate of 10 mL/min for 48s to 
desensitized receptors. As a control, 1 mM ACh was bath applied while 1 mM ACh was perfused 
for 48s at the onset of the maximum induced response. Alterations in the response currents were 
examined.
3.3.5 Voltage Step Experiments.
The voltage dependence of both dFBr potentiation and inhibition was determined by 
using a4|32 expressing Xenopus laevis oocytes and two-electrode voltage clamp. The membrane 
potential was incrementally increased in 10 mV steps ranging from -100 mV to +20 mV. Cytisine 
was chosen as the stimulating ligand for these experiments since it has been previously shown to 
not induce channel block of nAChRs at 100 pM (Liu et al., 2008). dFBr at either 10 pM 
(potentiating concentration) or 30 pM (inhibitory concentration) was co-applied with a fixed 
concentration of 100 pM cytisine (saturating concentration) at each voltage step. Responses 
were normalized to the response obtained at a membrane potential of -60 mV and 1 mM 
acetylcholine applied alone. The membrane potential (Vm) was plotted against the normalized 
current. The slope of the Vm vs I plot was determined using linear regression.
3.3.6 Data Analysis.
Concentration/response curves were fit using non-linear curve fitting and GraphPad 
Prism Software (San Diego, CA) with standard built-in algorithms. Values for the log EC50 and nH 
were determined by fitting the concentration response data to a single site binding model:
j  _ b + (7max -  b)
1 + 10 (LoSEC50-io«[i])*n// '  ’
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Where I is the current elicited on application of agonist, b is the baseline current in the absence of 
ligand, L is the ligand concentration and nH is the Hill slope. The EC50 value is the concentration 
of agonist producing currents equal to one half the maximal current (lmax)- The pEC50 values 
reported in the data tables reflect the negative log of the EC50. EC50 values were also calculated 
from the logEC50 and are included in the tables for convenience. Imax values for different partial 
and full agonists were compared to evaluate relative apparent efficacies and apparent efficacy 
changes as a result of dFBr co-application. In order to permit comparison of full and partial 
agonist data from different oocytes, responses for all test compounds were normalized to the 
currents obtained with 1 mM ACh in the absence of dFBr.
For inhibition experiments, plC50 (-log IC50) and IC50 values were determined by fitting 
concentration/response data to a single site competition model:
j  = fr +  Qfmax ~ b )  (2]
1 +  IQ (~ l ° 8 W - l °SI C 5o )  '  ’
Where I is the current at a specific inhibitor/agonist concentrations, b is the baseline current in the 
absence of agonist and L is the ligand concentration. The IC50 value is the concentration of 
antagonist that reduces the current to one half that obtained by the identical concentration of 
agonist alone. The pICso values reported in the data tables reflect the negative log of the IC50. 
pICso values were typically determined at agonist concentrations equal to the EC50 for the agonist 
used. In order to compare data from different oocytes, currents were normalized to those 
obtained from application of 1 mM ACh alone. For experiments involving co-perfusions of both an 
antagonist and agonist with dFBr responses were normalized to those obtained by co-perfusion 
of 1 pM dFBr with 1 mM ACh.
Comparisons of pEC50 or plC50 values were conducted using an unpaired t-test and p 
values calculated based on the null hypothesis.
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3.4.1 dFBr Inhibition Involves Open-Channel Block.
Understanding the nature of dFBr inhibition is essential to correctly interpreting overall 
response kinetics. Clues to the mechanism of dFBr inhibition come from previous studies of dFBr 
that show the presence of hump currents during washout of dFBr and agonist (Kim et al., 2007). 
Hump currents, also known as rebound currents, are inward currents which occur during the 
desensitized phase of the response on washout of the ligand. Hump currents have been 
previously linked to open-channel block (Liu et al., 2008) and are thought to be induced when an 
agonist binds with high affinity to the orthosteric site and with lower affinity in the channel. During 
washout of the ligand, the ligand bound to the channel dissociates more rapidly thus removing the 
channel block and producing transient increases in the observed response. The observation of 
hump currents suggests dFBr inhibition may involve channel block. To explore this possibility, we 
evaluated the inhibition of cytisine induced currents at a series of different membrane potentials. 
Cytisine was chosen for these experiments since it’s a known partial agonist that does not appear 
to act as a channel blocker (Liu et al., 2008) (Figure 3.1). While other more efficacious agonists 
could have been used for these experiments, the ability of these agonists to channel block would 
have complicated analysis of the results making it difficult to determine if any observed channel 
block is due to the stimulating agonist or dFBr. Increased membrane potential will typically reduce 
channel block thus increasing conductance at higher potentials as indicated by increased slopes 
in plots of voltage vs current (V/l). Figure 3.1 shows a V/l plot obtained by co-application of dFBr 
with 100 pM cytisine at both potentiating and inhibiting dFBr concentrations. At concentrations of 
dFBr that are potentiating rather than inhibiting (10 pM) co-exposure of 100 pM cytisine 
(saturating concentration of cytisine) produces a V/l plot that is linear over the entire range of 
membrane potentials tested. This verifies the lack of channel block by cytisine. In contrast, co­
application of a higher, inhibitory concentration of dFBr (30 pM) with 100 pM cytisine produces a 
V/l plot that is non-linear over the range of membrane potentials tested.
3.4 Results.
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Figure 3.1 Voltage dependence of potentiation and inhibition by dFBr.
Membrane potential was increased in 10 mV steps from -100 mV to +20 mV using two-electrode 
voltage clamp on a4|32 nAChR expressing oocytes. Responses were obtained as discussed in 
the methods section and were normalized to those elicited by application of 1 mM ACh at -60 mV 
from the same oocyte. At least two batches of oocytes from different frogs were harvested for the 
experiments. Each data point represents at least n>4 replicates with error bars shown as ± SEM. 
For the control group (100 pM cytisine) the relationship between the induced response and the 
applied membrane potential is linear over the entire range of membrane potentials. Potentiating 
concentrations of dFBr (10 pM) co-applied with 100 pM cytisine show a similar linear relationship. 
Co-application of 30 pM dFBr (inhibitory concentration) with 100 pM cytisine shows a nonlinear 
relationship between membrane potential and the induced response.
3.4.2 dFBr Potentiates Low Efficacious Agonists More Than Full Agonists.
Partial agonists are useful tools in studying mechanisms of allosteric modulators. Changes in 
response profiles, lmax and pEC50 values for partial agonists that result from the addition of a 
modulator, such as dFBr, can provide clues to the mechanism underlying the actions of the 
modulator. We investigated dFBr’s influence on the full agonist ACh and the partial agonists 
nicotine, choline and cytisine. ACh and choline were examined to explore possible physiological 
effects of dFBr within the synapse. While choline has not previously been considered a partial 
agonist at a4(32 receptors, the observed effects of dFBr on agonist efficacies led us to consider 
whether choline might be revealed as an agonist for a4(32 receptors in the presence of dFBr. 
Nicotine, a common substance of abuse, was selected because of its pathological significance in 
drug addiction. Cytisine was chosen because it is a a4|32 partial agonist that does not induce 
channel block (Liu et al., 2008). In addition, the smoking cessation drug varenicline is a derivative 
of cytisine allowing us to explore dFBr’s potential influence on this therapeutic treatment (Coe et 
al., 2005). dFBr’s alterations of response profiles, pECso (-log ECe®), lmax and Hill coefficients (nH) 
for full and partial agonists are shown in Figure 3.2, Figure 3.3 and Table 3.1 respectively.
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Figure 3.2 shows responses of a4p2 receptors to different concentrations of agonist 
applied alone (left series of traces) or with increasing concentrations of dFBr at a fixed (EC75) 
concentration of agonist or partial agonist (right series of traces). Agonist control responses show 
increases in the rise time and peak responses with increasing agonist concentrations (Figure 
3.2). The desentization profiles remain unaltered, although this is difficult to determine from 
responses obtained using the weak partial agonists choline and cytisine. Co-application of 
increasing concentrations of dFBr altered the profile of responses induced by agonists and partial 
agonists (Figure 3.2). As dFBr concentration is increased responses to ACh, nicotine, choline and 
cytisine show marked increases in the rise time of the response and peak currents. 
Desensitization rates are initially unchanged at low dFBr concentrations but increase as the 
concentration of dFBr is increased. This increase in the desensitization rate does not appear to 
occur with cytisine. Changes in responses resulting from application of dFBr were identical 
whether dFBr was co-applied or applied before addition of ACh (results not shown).
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Figure 3.2 dFBr modulated responses to nAChR agonists and partial agonists.
Responses were obtained from Xenopus oocytes under voltage clamp conditions (Vm = -60 
mV). Responses to agonists alone are shown in the left column. The right column show traces 
obtained at increasing concentrations of dFBr co-applied with fixed concentrations of either A. 
acetylcholine, B. nicotine, C. choline or D. cytisine. The legend for each panel shows the 
concentration of agonist applied alone (left) or the concentration of dFBr and co-applied (right). 
The solid bar above the response traces indicates the time the oocyte was exposed to the 
agonist and/or dFBr. All traces for each set of responses (left, right, A, B, C or D) were recorded 
from a single oocyte expressing a4p2 receptors (mRNA injected at a ratio of 1a:ip). Similar data 
obtained at varied agonist concentrations were pooled and the data plotted to produce the dose 
response curves shown in Figure 3.3 and the data shown in Table 3.1.
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The apparent pEC50, efficacy and Hill coefficients (nH) for each agonist were determined 
from concentration response data and are showed in Figure 3.3 and Table 3.1. The pECso values 
for the tested agonist were not altered by co-application of 1 pM dFBr. Choline invoked 
extremely small currents making determination of pEC50 values in the absence of dFBr difficult; 
thus making it impossible to determine if the pEC50 changed as a result of dFBr application.
Lax values increased significantly in all cases and appeared to increase more 
substantially for weak partial agonists compared to the stronger partial agonist nicotine and the 
full agonist ACh (Table 3.1, Figure 3.3). A 2.70 fold increase in the Lax was observed for ACh in 
the presence of 1 pM dFBr (p<0.0001) while an increase of over 9.0 fold was observed for the 
weak partial agonists choline and cytisine (p<0.0001). Increases in Lax for ACh are consistent 
with previously reported data for ACh (Sala et al., 2005; Kim et al., 2007). Lax values obtained for 
nicotine indicate a non-significant increase of 7.6 fold in the presence of 1 pM dFBr (p=0.0069) 
compared to nicotine aione. The maximum potentiated responses to weak partial agonists failed 
to reach similar amplitudes to potentiated responses of the full agonist ACh (Table 3.1). Hill 
slopes were not significantly altered for any of the four agonists tested.
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Figure 3.3 Dose response curves for agonists and partial agonists in the 
presence and absence of 1 pM dFBr.
dFBr and the appropriate concentration of agonist or partial agonist were co-applied to Xenopus 
oocytes expressing a4(32 receptors (mRNA injected at a ratio of 1a:1(3). The peak current was 
measured and responses normalized to currents elicited by 1mM ACh applied alone to the same 
oocyte. Each data point represents the combined data from at least four different experiments 
from a minimum of two different oocytes harvested from different frogs. Error bars indicate ± 
SEM. pEC50, Lax and Hill slope (nH) were calculated using non-linear curve fitting algorithms and 
are shown in Table 3.1.
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Table 3.1. dFBr induced effects on response kinetics for agonists and partial 
agonists.
The data were obtained using non-linear curve fitting algorithms from the dose response curves 
shown in Figure 3.3. Since individual responses were normalized to the response elicited by 
1mM ACh alone, the lmax value shown represents the maximum current elicited relative to that 
obtained with 1mM ACh in the absence of dFBr. Values in brackets indicate the fractional 
change in the value resulting from co-application of 1 pM dFBr. The statistical significance of 
observed differences in pEC50, lmax and nH as a result of 1 pM dFBr co-application were evaluated 
using a paired student t-test. p-values are given in parentheses under the fold change. Values 
were considered statistically different at p < 0 .00 01.
pE C 50 ±  S EM  
E C jo [pM ]) lmax ±  S EM nn ±  SEM
Ligand 0 gM dFBr
1 gM dFBr 
[Fold 
Change]
0 gM dFBr 1 gM dFBr [Fold Change] 0 gM dFBr
1 gM dFBr 
[Fold 
Change]
ACh 4.7 ±0.1 (2 1 )
4.8 ±0.3 
(15) 
[1 .0]
(p = 0.58)
1.3 ± 0.10
3.3 ±0.6 
[2.7]
(p< 0 .0001)
1.4 ±0.5
0.6 ± 0.2 
[0.43]
(p = 0 .2 1 )
Nicotine
5.7 ± 0.3 
(2 .1 )
4.9 ±0.5 
(14) 
[0.9]
(p = 0.15)
0.38 ± .05
2.9 ± 1.0 
[7.6]
(p = 0.0069)
1.1 ± 0.8
0.5 ± 0.4 
[0.45]
(p = 0.55)
Choline N.D.*
3.7 ±0.1 
(220)
(p = N.D.)
0.015 ± 
0.003
0.14 ±0.008 
[9.3]
(p< 0.0001)
N.D* 1.7 ±0.5 (p = N.D.)
Cytisine
5.3 ± 0.5 
(4.6)
5.4 ± 0.3
(4.0)
[1 .0]
(p = 0.91)
0.053 ± 
0.01
0.53 ± 0.06 
[9.9]
(p< 0.0001) 0.94 ± 0.98
1.0 ± 0.6 
[1 .1]
(p = 0.95)
*Value could not be accurately determined due to low efficacy of choline.
3.4.3 dFBr Does Not Appear to Alter Inhibition by Antagonists.
Since antagonists are typically thought to bind to the closed state of the receptor and do 
not stabilize the open conformation, they can be used to determine if application of dFBr 
produces a conformational change in the orthosteric binding site of the antagonist bound 
conformation. It is also possible that known antagonists might only weakly stabilize the open state 
and act as very poor partial agonists (similar to choline). These compounds might reveal 
themselves as agonists in the presence of modulators such as dFBr. We evaluated the effects of 
dFBr on three different nAChR antagonists Dihydro-(3-erythroidine (DHpE), DMAB-anabaseine 
and Tropisetron. Compounds with diverse actions, selectivity and structures were chosen. DMAB-
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anabaseine is a partial agonist on a7 nAChRs but a competitive antagonist on other nAChRs 
including the a4p2 subtype (Stevens et al., 1998). DHpE is a neuronal nAChR a4 selective 
competitive antagonist (Harvey et al., 1996), and tropisetron is a 5-HT3 and a4p2 nAChR 
receptor competitive antagonist (Middlemiss and Tricklebank, 1992).
Antagonists were evaluated for their ability to inhibit responses to 1 mM ACh on a4p2 
nAChR expressing oocytes in the presence and absence of 1 pM dFBr (Figure 3.4). pICso (-log 
IC50) values were determined from these data and compared (inset, Figure 3.4), No significant 
change in pICso was observed for DHPE or tropisetron (Figure 3.4, table insert). In the presence 
of dFBr, the DMAB-anabaseine plC50 was increased significantly (p<0.0001). The dose-response 
curve of co-application of dFBr and DMAB appears biphasic, however; fitting the data to a two 
site model did not produce any improvement compared to the single site model (single site, 
^=0.77; two site, r*= 0.77). It is possible that a biphasic curve could be produced as a result of 
expression of both high and low affinity a4p2 stoichiometries. It has been shown that DHpE has 
different inhibitory effects on the two different receptor stoichiometries (Moroni et al., 2006). 
DMAB-anabaseine may have similar effects, but to our knowledge this ligand has not been tested 
on high and low affinity a4p2 nAChRs.
To determine if dFBr could stimulate an agonist-like response with antagonists, 1 pM 
dFBr was co-applied in the absence of ACh at antagonist concentrations up to 100 pM. No 
currents were observed under these conditions.
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Figure 3.4 Co-application of dFBr with nAChR antagonists.
Xenopus oocytes expressing a4|32 receptors (mRNA injected at a ratio of 1 a:1 (3) were exposed to 
1 mM ACh and responses inhibited by co-application of increasing concentrations of A. DHpE,
B. DMAB-anabaseine or C. troposetron. Since individual peak amplitudes were normalized to 
those elicited by 1 mM ACh applied alone on the same oocyte, lmax values express peak currents 
relative to those obtained with 1mM ACh. plC50 values (inset table) were determined using non­
linear curve fitting as described in the methods. Data points represent at least 4 replicate values 
obtained from a minimum of two oocytes harvested from different frogs. Error bars indicate ± 
SEM.
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3.4.4 dFBr Can Reactivate Desensitized Receptors.
To examine the effect of dFBr on desensitized receptors, dFBr was applied to a4(32 
receptors desensitized with saturating concentrations of ACh (Figure 3.5). In the absence of 
dFBr, repeated application of 10 mM ACh during the desensitization period of the response elicits 
no additional current (Figure 3.5A Top). This is consistent with the presence of a large number of 
desensitized receptors in the preparation that are resistant to reactivation by ACh. Application of 
3s pulses of dFBr applied during the desensitized phase produced large inward currents (Figure 
3.5A Bottom). Repeated 3s applications of dFBr produced a series of responses with 
progressively decreasing peak currents (Figure 3.5B and C). When responses were elicited using 
1 mM ACh (Figure 3.5B), rather than 10 mM ACh, activation with 1 pM dFBr produced hump 
currents immediately following the 3s dFBr pulse. The activation slope for the first dFBr pulse 
obtained during the desensitization period was -190 ± 9 nA/s for 1 mM ACh induced responses 
and -1020 ± 130 nA/s for 10 mM ACh induced responses. Activation slopes for responses in 
which dFBr and ACh were co-applied to non-desensitized receptors as shown in Figure 3.2 were 
also determined: 1mM ACh + 1 pM dFBr, -13 ± 2 nA/s and 10 mM ACh + 1 pM dFBr, -66 ± 6 
nA/s. Thus, the activation slope of the response to a dFBr pulse applied during desensitization is 
15 times faster than co-application of ACh and dFBr to non-desensitized receptors. This is a 
significant change in the activation slope (p<0.001). When 100 pM cytisine was used as the 
stimulating agonist and dFBr was applied during the desensitizing phase, a similar effect was 
observed (Figure 3.5C). Repeated 3s applications of 1 pM dFBr along with continuous 
application of 100 pM cytisine produced repeated responses that decline only slightly in 
amplitude with each repetition. The activation slope for the first dFBr pulse applied during the 
desensitization phase of responses to 100 pM cytisine was -66 ±26 nA/s compared to -0.66 
±0.18 nA/s for co-application of 1 pM dFBr and 100 pM cytisine to non-desensitized receptors. 
This is a significant increase (p<0.01) in the activation slope of approximately 100 fold.
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A. 10mM ACh B. 1 mM ACh
Continuous 10 mM ACh + repeated 10 mM ACh
Continuous 10 mM ACh + repeated 1 pM dFBr
C. 100 pM Cytisine
Continuous 100 pM cytisine ♦ repeated 1 pM dFBr
Figure 3.5 dFBr reactivates desentized receptors.
Acetylcholine or cytisine were bath applied to Xenopus oocytes expressing a4p2 receptors at a 
rate of 3 ml/min for 30s. During the desensitized portion of the response, 3s pulses of either 
acetylcholine (A) or dFBr (B and C) were repeatedly applied at a perfusion rate of 20 ml/min in 
the continued presence of agonist. Solid bars above the traces show the application of ACh or 
cytisine (continuous bar) and the repeated pulsed application of 1 pM dFBr (short lines on B and 
C plots). A Top. Control trace showing repeated pulses of 10 mM acetylcholine applied during 
the desensitization period of a response to bath applied 10 mM ACh. Minimal current was 
observed under these conditions. A Bottom. Application of 3s pulses of 1 pM dFBr during the 
desensitization period produces large currents that decline back to baseline with repeated pulses 
of dFBr. B. Application of 3s pulses of 1 pM dFBr during the desensitization period of responses 
to 1 mM ACh produces similar effects to A Bottom except pulses are broadened and show 
possible hump currents. C. Application of 3s pulses of 1 pM dFBr during the desensitization 
period of responses to 100 pM cytisine. Large currents were observed similar to those shown in 
A Bottom but with a slower rate of decline. Each experiment (A-C) was repeated at least four 
times on different oocytes harvested from at least two different frogs. The slope of the rising 
phase of the first peak generated by application of dFBr during the desensitizing period in each 
case was determined (activation slope): A Bottom. -1020 ±130 nA/s, B. -190 ± 9 nA/s and C. - 
66 ± 26 nA/s.
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3.4.5 dFBr Induced Currents Elicited on Desensitized Receptors Decline with
Continuous Exposure to dFBr.
The data shown in Figure 3.5 demonstrate the effect of a quick pulse of dFBr applied 
during the desensitization phase of the response. It was unclear from these experiments whether 
dFBr elicited responses on desensitized receptors would show typical desensitizing kinetics 
during longer exposures to dFBr. To determine if receptors desensitize in the continued 
presence of dFBr, we conducted experiments in which desensitized nAChR preparations were 
exposed to dFBr for longer time periods. Figure 3.6 shows the effects of application of 1 pM dFBr 
for 48s to receptors pre-exposed to ACh. Co-exposure of oocytes to 1 mM ACh and 1 pM dFBr 
for 48s produces a typical dFBr potentiated response (Figure 3.6A). As in Figure 3.5A, bath 
application of a control pulse of 1 mM ACh for 48s after the response peak produces no 
additional current (Figure 3.6B). Application of 1 pM dFBr for 48s immediately after the ACh 
response peak and in the continued presence of 1 mM ACh (Figure 3.6C) produces a response 
similar in shape and amplitude to that resulting from co-exposure to ACh and dFBr (Figure 3.6A). 
A similar experiment in which 1 pM dFBr was applied concurrent with termination of the ACh 
perfusion produced a different response (Figure 3.6D). When 1 mM ACh was replaced rapidly by 
1 pM dFBr after the response peak, a more rapidly desensitizing and sharper response peak was 
observed. When 1 pM dFBr was again replaced with 1 mM ACh a similar sharp peak was 
observed although with an apparently slower rate of desensitization. In all cases, where 1 pM 
dFBr was applied, either in conjunction with 1 mM ACh or after the 1 mM ACh peak (Figures 3.6 
A, C and D) removal of dFBr returned the response to its appropriate non-potentiated level. 
Thus, application of 1 pM dFBr produces peak responses that appear superimposed on the 1 mM 
ACh response.
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Figure 3.6 The amplitude of dFBr Induced currents on desensitized receptors 
decline during long exposures to dFBr.
Responses in each panel were elicited by bath application of 1 mM ACh on Xenopus oocytes 
expressing a4p2 receptors. The top solid line above each trace indicates the time period during 
which the oocyte was exposed to ACh. The bottom line above the trace indicates the period of 
application of either ACh (A) or dFBr (B, C, or D). A. Co-application of 1 mM ACh and 1 pM 
dFBr for 48s at a flow rate of 8 ml/min (No pre-exposure to ACh). B. Control trace resulting from 
exposure to 1 mM ACh at a rate of 4 ml/min with 1 mM ACh applied during the desensitization 
period for 48 s at 8 ml/min. C. Application of 1 pM dFBr at the peak of a response elicited by 
exposure to 1 mM ACh. ACh was present before, during and after application of dFBr. D. 
Application of 1 pM dFBr at the peak of a response elicited by exposure to 1 mM ACh. Unlike the 
experiment shown in C, perfusion of 1 mM ACh was discontinued during the application of 1 mM 
dFBr then restored at the end of the 48s dFBr exposure. The responses shown were obtained 
from different oocytes. Due to different levels of receptor expression, no comparison of peak 
amplitudes was possible under these conditions.
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Previous studies demonstrate that the potentiating effects of dFBr and its apparent 
selectivity (based on previous studies) for the a402 subtype of nAChRs make it an ideal 
candidate for the development of novel positive allosteric modulators (PAMs) for a4(32 nAChRs 
(Sala et al., 2005; Kim et al., 2007). The work described here addresses three elements of dFBr 
modulation on a4p2 nAChR important to its ultimate development as a therapeutic agent: a. The 
nature of its bell-shaped response profile; b. Its effect on the action of a4p2 nicotinic full agonists, 
partial agonists and antagonists; and c. Its effects on receptor kinetics.
3.5.1 The Bell-Shaped Dose/Response of dFBr.
We have previously demonstrated the ability of synthetic dFBr to potentiate ACh induced 
responses at concentrations less than 10 pM and inhibit responses at concentrations greater than 
10 pM dFBr (Kim et al., 2007). The observation of rebound currents on washout of dFBr/agonist 
led us to hypothesize that dFBr produced inhibition of ACh responses though a mechanism 
involving open-channel block (Kim et al., 2007; Liu et al., 2008). The non-linear V/l relationship of 
dFBr inhibition observed in voltage step experiments strongly supports our hypothesis that dFBr 
inhibition results from open-channel block.
ACh has been previously demonstrated to inhibit its own responses by blocking the ion 
channel at high concentrations. To determine if dFBr could also block the channel, we conducted 
experiments with the non-channel blocking partial agonist cytisine as the stimulating agonist (Liu 
et al., 2008). The non-linear V/l relationship at dFBr concentrations > 10 pM suggests that dFBr 
itself is capable of channel block. The linear V/l relationship a dFBr concentrations < 10 pM 
supports our hypothesis that potentiation and inhibition are mediated by different mechanisms. 
This suggests that future analogs of dFBr could be developed that do not inhibit a402nAChRs 
and are better able to potentiate agonist responses with less effect on the apparent 
desensitization kinetics.
3.5.2 The Effect of dFBr on the Action of Nicotinic Agonists and Partial Agonists.
We examined the ability of dFBr to enhance the action of other compounds involved in 
nAChR signaling including choline, nicotine and cytisine. Both nicotine and verenecline (a 
derivative of cytisine) are being explored and/or utilized as therapeutic agents. dFBr did not alter 
the pECso of ACh, choline, nicotine and cytisine. Imax values for all three partial agonists were 
increased with a much more substantial enhancement obtained for the low efficacy partial 
agonists choline (9.3X) and cytisine (9.9X) then for the higher efficacy agonist nicotine (7.6X).
3.5 Discussion.
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dFBr co-applied with choline produced a response of approximately 12% of the non-potentiated 
ACh response. While it is difficult to extrapolate the effects on synaptic function from receptors 
expressed in Xenopus oocytes, it is likely that increased activation by choline would alter the time 
course for synaptic currents. The nicotine response during dFBr co-application was equivalent to 
a non-potentiated response to ACh. This raises the possibility of future therapies combining a 
lower nicotine dose with a dFBr class compound.
dFBr co-application did not alter the pECso values for ACh, nicotine or cytisine. These 
observations, along with the enhanced affinity for the antagonist DMAB-anabaseine lead us to 
conclude that dFBr may alter relative stabilities of receptor conformations involved in channel 
gating (channel opening and desensitization).
3.5.3 The Effect of dFBr on Inhibition of Responses by Nicotinic Antagonists.
We evaluated the ability of three structurally different competitive antagonists (DH(3E, 
DMAB-anabaseine and tropisetron) to inhibit responses to ACh in the presence and absence of 
dFBr. No significant changes in inhibition kinetics were observed for the DHpE and tropisetron. 
DMAB-anabaseine, a a7 partial agonist, produced a 1.4 fold increase in its pICso value with the 
application of 1 pM dFBr. The effect of dFBr on antagonist plC50 values appears to be minimal.
Conformational changes induced by allosteric modulators could alter the orthosteric 
binding site causing an antagonist (or poor agonist) to become a functional agonist. The 
benzodiazepine (BZD) flurazepam induces conformational rearrangements in the GABA binding 
site on GABAaR, demonstrating shared allosteric interactions between the GABA and BZD 
binding sites (Kloda and Czajkowski, 2007). To determine if a similar action might occur with 
nicotinic antagonists, we examined the effects of dFBr co-application with antagonists in the 
absence of stimulating ACh. We did not observe any currents for any antagonist tested; including 
the a7 partial agonist DMAB-anabaseine. The lack of any change in antagonist action suggests 
that dFBr does not produce its effects through alteration of the unbound, closed receptor 
conformation. This further supports our hypothesis that dFBr potentiation is the result of 
alterations in gating rather than ligand binding.
3.5.4 Recovery of Desensitized Receptors by dFBr.
Several possible mechanisms could produce the observed changes in partial agonist 
apparent efficacies. Agonist efficacy has been correlated to varying degrees of C-loop closure 
over the ligand seated within the orthosteric binding pocket in ionotropic glutamate (iGLuR),
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glycine receptors and AChBP (Armstrong and Gouaux, 2000; Hogner et al., 2002; Armstrong et 
al., 2003; Furukawa and Gouaux, 2003; Jin et al., 2003; Celie et al., 2004; Han et al., 2004; 
Hansen et al., 2005). Further studies suggest that efficacy of agonists at both iGLu and glycine 
receptors are determined by the ability of the agonist to stabilize the active receptor conformation 
(Furukawa and Gouaux, 2003; Han et al., 2004; Inanobe et al., 2005; Robert et al., 2005; Mayer,
2006). In a model for glycine and nAChRs, agonist efficacy differences are suggested to originate 
in the agonist affinity for a hypothesized flipped state relative to the closed state (Lape et al., 
2008). Stabilization of the open conformation could also shift the equilibrium from the 
desensitized to the open state. One implication of the latter mechanism would be the possibility 
that application of dFBr to a desensitized receptor population would elicit currents by reactivating 
desensitized receptors. This ability has previously been reported for type II PAMs including PNU- 
120596 and TQS (Hurst et al., 2005; Bertrand and Gopalakrishnan, 2007; Gronlien et al., 2007) 
but not for dFBr.
To determine if dFBr could reactivate desensitized receptors, dFBr was applied during 
the desensitization period of a 1 mM ACh elicited response. Large currents were observed in 
response to dFBr application that were similar in magnitude to those obtained for a control 
exposure of ACh to non-desensitized receptors. These responses decline rapidly on removal of 
dFBr. With longer exposures, responses desensitized in the continuous presence of dFBr and 
ACh; returning to the pre-dFBr level on removal of the modulator. The decline in the dFBr elicited 
response over time could be the result of open channel block by both ACh and dFBr as described 
earlier but could also reflect the existence of a desensitized-open conformation that relaxes to a 
new desensitized state in the continued presence of dFBr as has been proposed for ivermectin 
(Krause et al., 1998; Gronlien et al., 2007). The observed decline in the response is similar to that 
observed when dFBr is co-applied with ACh to non-desensitized receptors but the time to peak is 
significantly shortened. This would be consistent with either independent binding of ACh and 
dFBr or a requirement for ACh to bind first.
When dFBr is applied to desensitized receptors with the simultaneous removal of ACh, a 
large peak is elicited that quickly returns to the pre-dFBr amplitude. A second switch from 
perfusion with dFBr back to ACh produces an ACh elicited peak in the absence of dFBr that also 
desensitizes rapidly back to the baseline response amplitude. These data suggest that ACh and 
dFBr bind independently with no requirement for ACh to bind before dFBr or vice versa. The 
rapid rise of the response peaks in Figure 3.6D appears to be the result of either ACh bound first 
followed by dFBr (first peak) or dFBr bound followed by ACh activation (second peak). The rapid 
decline of the first peak (Figure 3.6D) is likely the result of ACh dissociation from the receptor 
during dFBr application and the decline of the second peak represents dissociation of dFBr from
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the receptor. Thus the rate of decline in Figure 3.6D may be reflective of the dissociation rates 
for either ACh (left trace) or dFBr (right peak).
It has been postulated that the ability to re-open desensitized receptors could be a 
common feature of type II modulators (Galzi et al., 1992; Briggs et al., 1999). Thus, dFBr could be 
classified as a a4(32 type II PAM. Some concern has been expressed regarding alterations in 
desensitization rates by type II PAMs since such changes might adversely affect cell viability due 
to increased Ca2+ permeability. This remains a concern with dFBr, particularly due to its ability to 
reopen desensitized receptors. The balance between potentiation and channel block may be an 
important consideration therapeutically since channel block could reduce the problem of Ca2+' 
entry through the channel. The combined channel block and potentiation with dFBr produces 
sharper, more rapidly desensitizing responses rather than prolonged openings as have been 
observed in type II PAMs. The enhancement of partial agonist activities presents the possibility 
for combination therapies between dFBr like compounds and therapeutic partial agonists.
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CHAPTER 4: Non-orthosteric Subunit Faces are Involved in alpha4beta2 nAChR 
Responses to Acetylcholine and Desformylflustrabromine in High- and Low-sensitivity 
Receptor Preparations.
4.1 Abstract.
Alterations in expression patterns of a4(32 nicotinic acetylcholine receptors (nAChR) 
have been demonstrated to alter nicotinic neurotransmission and have been implicated in 
neurological disorders including Autism, nicotine addiction, Alzheimer’s and Parkinson’s 
disease. Positive allosteric modulators (PAMs) represent promising new leads for the 
development of therapeutic agents for the treatment of these disorders. This study investigates 
the involvement of non-orthosteric subunit interfaces of a4p2 receptors in the potentiation of 
acetylcholine (ACh) induced responses by the PAM desformylflustrabromine (dFBr). Amino 
acids on the non-orthosteric P2+ and a4- subunit faces were mutated to alanine and receptors 
expressed in Xenopus laevis oocytes. Acetylcholine induced responses in the presence and 
absence of dFBr were recorded with two-electrode voltage clamp techniques. Three 
fundamentally different results were observed. Several mutations altered the ACh dose- 
response curves, supporting a role for these amino acids in mediating agonist induced 
conformational changes in a4p2 nAChRs. A second group of mutations selectivity altered the 
ability of dFBr to potentiate ACh induced responses but had minimal effect on responses to 
ACh alone (low-sensitivity preparation: P2W176A, P2T177A, P2D179A, p2D217Aand a4W88A; 
high-sensitivity preparation P2T177A, P2D116A and P2Y120A). The remaining mutations had 
no effect on either dFBr or ACh effects. Our data supports our hypothesis that allosteric 
modulation by dFBr involves its interaction within the p2+/a4- cleft and suggests that its effects 
may involve alterations in subunit interactions involving P2+ and a4-. In addition to supporting 
a putative binding site for dFBr, these data also demonstrate the importance of this region in 
normal receptor kinetics.
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Nicotinic acetylcholine (nAChR), GABAa, 5HT3 and glycine receptors are members of the 
Cys-loop super family of ligand gated ion channels (LGIC). nAChRs are integral membrane 
proteins involved in cholinergic transmission in the central and peripheral nervous systems (Taly 
et al., 2009). Dysregulation of nAChRs has been postulated to be involved in neurological 
disorders including Alzheimer’s disease (Court et al., 2001; Nordberg, 2001), Schizophrenia 
(Adams and Stevens, 2007), Parkinson’s disease (Aubert et al., 1992), Autism (Martin-Ruiz et al., 
2004; Lippiello, 2006) and nicotine addiction (Picciotto et al., 2001).
The predominant nAChRs subtypes found in brain are the homomeric a7 and the 
heteromeric a4(32 receptors (Mudo et al., 2007). Recent studies have suggested that a4p2 
nAChRs can form high- (HS) and low- (LS) ACh sensitivity receptors (Nelson et al., 2003; Zhou et 
al., 2003; Briggs et al., 2006; Moroni et al., 2006; Zwart et al., 2006; Tapia et al., 2007). Altering 
the a:p subunit injection ratio in Xenopus oocytes has been demonstrated to alter the relative 
ratios of a HS to LS a4p2 receptors expressed, presumably a result of different a4p2 
stoichiometries. Studies have provided suggestive evidence that similar HS and LS a4p2 nAChR 
stoichiometries are expressed in the mammalian brain (Marks et al., 2000; Butt et al., 2002; Gotti 
et al., 2008) and can be altered by chronic exposure to nicotine (Moretti et al., 2010). The precise 
arrangement of the a4 and P2 subunits within the different a4p2 receptors is unknown.
Ligands, such as Positive Allosteric Modulators (PAMs) that selectively target nAChRs 
are potentially important therapeutic agents that could prove useful for the treatment of 
pathologies involving alterations in nAChR expression. PAMs are ligands which bind at allosteric 
sites and alter responses to agonists such as the endogenous agonist ACh although they have 
no agonist properties of their own and have different effects on agonist responses. PAMs have 
been identified that modify peak currents of the agonist induced responses (Type I profile) or alter 
both the peak current and time course of the agonist evoked response (Type II profile) (Bertrand 
and Gopalakrishnan, 2007). The development of PAMs that are selective for specific receptor 
subtypes and stoichiometries would be potentially beneficial for the treatment of pathological 
conditions where only one receptor subtype or stoichiometry is deregulated and would provide 
useful pharmacological probes for identification of specific subtypes in CNS function. The design 
and development of different classes of PAMs will be facilitated by identification and modeling of 
the respective allosteric binding sites.
Desformylflustrabromine (dFBr) is a recently discovered PAM that potentiates ACh 
evoked currents on a402 nAChRs and inhibits ACh induced currents on other common nAChR 
subtypes (Sala et al., 2005; Kim et al., 2007; Weltzin and Schulte, 2010b). The synthetic form of
4.2 Introduction.
139
this natural compound has been shown to increase maximal currents induced by ACh on a4(B2 
nAChRs by 265% without altering the EC50 for ACh. Similar effects are observed when dFBr is 
co-applied with partial agonists although increases in efficacy are greater for partial agonists 
compared to ACh (Kim et al., 2007; Weltzin and Schulte, 2010). In addition, dFBr has been 
shown to induce currents when applied to desensitized receptors continuously exposed to ACh. 
While the mechanism of dFBr potentiation is unknown it has been proposed that dFBr potentiates 
a4(32 nAChRs and “rescues” receptors from desensitization by altering the equilibrium between 
open and desensitized receptor conformations (Sala et al., 2005; Weltzin and Schulte, 2010b) . 
Inhibition of agonist induced responses by high concentrations of dFBr (> 10 pM) appears to 
involve open channel block by dFBr (Weltzin and Schulte, 2010).
The current study investigates the mechanistic role of the p2+ and a4- subunit faces in the 
potentiation of ACh induced responses by dFBr. Using site-directed mutagenesis, amino acids 
within the p2+/ a4- subunit interface were mutated to alanine and mutant receptors were 
expressed in Xenopus laevis oocytes. The effects of each mutation were evaluated using two- 
electrode voltage clamp techniques on both HS and LS a4p2 receptors. HS and LS receptors 
were expressed by altering the injection ratios of a4 and p2 as described previously by Nelson et 
al. (2003). The putative binding site for dFBr at the P2+/ a4- subunit interface relative to the 
orthosteric binding site on a4p2 receptor is similar to the position of the benzodiazepine binding 
site on GABAa receptors relative to the GABA orthosteric binding site. We thus used homology 
between the P2+/ a4- subunit interface and the GABAa benzodiazepine as a guide for 
mutagenesis. Eight P2+ amino acids and two a- face amino acids were selected and are shown 
in Figure 4.1. The data suggest that non-orthosteric subunit faces are involved in receptor 
conformational changes in response to ACh in the absence of allosteric modulation and data 
obtained in the presence of dFBr support the conclusion that the dFBr binding site is located on 
the P2+ face. Binding of dFBr to the allosteric binding site appears to utilize amino acid 
interactions in this region equivalent to binding loops A, B and C previously described for the 
orthosteric binding site (Sigel 2002; Lester et al., 2004).
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Figure 4.1. DNA sequence alignments for AChBP and nAChR subtypes.
Alanine mutations are made on amino acids on the loops A ((B2D116, 02Y12O and 02Y127), B 
(02W176, 02T177 and 02D179) and C (02D217 and 02D218) located on the 02+ face (black 
boxes) and on the 0-sheets D (a4W88) and E (a4K140) of the a4- face (grey boxes).
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4.3 Materials and Methods. 
4.3.1 Receptors and mRNA.
The cDNA sequences for human a4 (NCBI Reference Sequence: NM 000744.5), p2 
(NCBI Reference Sequence: NM_000748.2) and a7 (NCBI Reference Sequence: NM_000746.3) 
nAChR subunits were used to synthesize a full length cDNA for each subunit. cDNA synthesis 
was conducted by GeneArt Inc. (Burlingame, CA). The 02 cDNA was inserted into the 
pcDNA3.1/Zeo(+) mammalian expression vector with restriction enzymes Not I and Xho I and the 
a4 cDNA was inserted into the pcDNA3.1/hygromyocin mammalian expression vector with 
restriction enzymes Hind III and BamHI (vectors procured from Invitrogen, Carlsbad, CA; 
restriction enzymes purchased from New England Biolabs). The cDNAfora7 nAChR subunit was 
inserted into the pBudCE4.1 expression vector (Invitrogen) with restriction enzymes Sai I and 
Xba. All constructs were fully sequenced and confirmed to be identical to the published 
sequences for each subunit. Synthetic DNA was used to transform AG1 super-competent cells 
(Stratagene) for production of cDNA. Synthetic cRNA transcripts for wild-type and mutant 
subunits were prepared using the T7 mMESSAGE mMACHINE™ High Yield Capped RNA 
Transcription Kit (Ambion, Austin, TX).
Mutatant cDNA was created using commercial mutagenesis services (DNA 2.0, Menlo 
Park, CA). All mutations were confirmed by DNA sequencing. The resulting DNA was inserted 
into the pcDNA3.1/Hygromyocine vector (Invitrogen, Carlsbad, CA) and used to transform NEB 
10-beta E. coli (DNA 2.0) cells.
4.3.2 Experimental Chemicals and Test Compounds.
Acetylcholine (ACh), other salts and buffering agents were obtained from Sigma-Aldrich, 
Inc (MO). Desformylflustrabromine-HCI (dFBr) was synthesized by Dr. Richard Glennon (Virginia 
Commonwealth University) according to a previously published procedure (Kim et al., 2007).
4.3.3 Xenopus laevis Oocytes and Receptor Expression.
Xenopus laevis frogs and frog food were purchased from Nacso (Fort Atkinson, Wl). 
Ovarian lobes were surgically removed from Finquel anesthetized Xenopus laevis frogs and 
washed twice in Ca2+-free Barth’s buffer (82.5 mM NaCI; 2.5 mM KCI; 1 mM MgCI2; 5 mM 
HEPES, pH 7.4) then gently shaken with 1.5 mg/mL collagenase (Sigma type II, Sigma-Aldrich 
Inc., MO) for 20min at 20-25°C. Stage V and VI oocytes were selected for microinjection. No 
more than four surgeries were conducted on each frog. A recovery period greater than six weeks 
was allowed in between surgeries (Xenopus protocols conform to those approved by the
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University of Alaska Fairbanks Institutional Animal Care and Use Committee; approval number 
08-71).
For expression of a4p2 nAChRs, oocytes were injected with 50 nL cRNA. Injected 
oocytes were incubated at 19°C for 24-72h prior to their use in voltage clamp experiments. For 
the high-sensitivity receptor preparations (HS), oocytes were injected with 50 nL of a mixture 
containing 250 ng/pL of a4 cRNA and 50 ng/pL of [32 cRNA (5:1 ratio of a4 to P2). For the low- 
sensitivity receptor preparation (LS) oocytes were injected with 50 nL of a mixture of 50 ng/pL a4 
cRNA and 250 ng/pL p2 cRNA (1:5 ratio of a4 to P2). The EC50 values obtained for ACh induced 
currents on the HS and LS receptor preparations obtained from these injection ratios were 
verified by electrophysiology assays as described below and found to compare well with 
published values for the high ACh-sensitive and low ACh-sensitive receptors (Zwart and 
Vijverberg, 1998; Moroni et al., 2006). EC50 values and response profiles indicated the expression 
of predominantly the HS or LS subtypes although it is likely that both are present in each 
experiment.
4.3.4 Two-Electrode Voltage Clamp.
Current recordings were performed using an automated two-electrode voltage-clamp 
system incorporating an OC-725C oocyte clamp amplifier (Warner Instruments, Hamden, CT) 
coupled to a computerized data acquisition (Datapac 2000, RUN technologies, Mission Viejo, CA) 
and autoinjection system (Gilson, Middleton, Wl). Recording and current electrodes with 
resistance 1-4 MQ were filled with 3 M KCI. Details of the chambers and methodology employed 
for electrophysiological recordings have been described earlier (Joshi et al., 2004). Oocytes were 
held in a vertical flow chamber of 200 pL volume, clamped at a holding potential of -60 mV and 
perfused with various ND-96 recording buffers. A phosphate ND-96 recording buffers was used 
in these experiments due to the findings that HEPES modulates the HS receptors (Weltzin, 
2010). The phosphate ND-96 recording solution is similar to HEPES in all regards except with the 
omission of HEPES and the addition of phosphate (96 mM NaCI, 2 mM KCI,1.8 mM CaCI2, 1 mM 
MgCI2, 2 mM phosphate). Test compounds were dissolved in buffer and injected into the 
chamber at 20 mL/min using a Gilson auto-sampler injection system (Joshi et al., 2004).
4.3.5 Electrophysiology Dose-Response Experiments.
Dose-response curves for the endogenous nAChR agonist Acetylcholine-CI, (ACh) 
(Sigma-Aldrich) were determined for both wild-type and mutant receptors expressed in HS and 
LS receptor preparations at ACh concentrations ranging from 0.1 pM - 3 mM. Broader 
concentration ranges were used when necessary to fully define the ACh dose/response curves.
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For wild-type and mutant receptors expressed in the LS preparation, dose-response curves for 
dFBr were determined by co-application of 100 pM ACh (EC75) with varying concentrations of 
dFBr (0.001 -  100 pM). For wild-type and mutant receptors expressed in the HS preparation, 
dFBr dose-response curves were determined by co-application of 10 pM ACh (EC75) with varying 
concentrations of dFBr (0.001 -  100 pM).
In order to compare responses from different oocytes, individual responses to drug 
application were normalized to control responses elicited using 10 pM ACh for receptors 
expressed by the HS receptor technique for both wild-type and mutated receptors. For wild-type 
and mutant receptors in the LS preparation responses were normalized to those obtained using 
100 pM ACh. Data were collected from at least four replicate experiments using oocytes obtained 
from at least two different frogs.
4.3.6 Data Analysis and Statistics.
Dose-response curves were fit using non-linear curve fitting and GraphPad Prism 
Software (San Diego, CA) with standard built-in algorithms. pEC50 (-log EC50) and EC50 values 
were determined by fitting concentration/response data to a single site binding model:
j  =  fr +  C fm ax-fr)
1  +  1  Q(LogEC,(i-Log[L\)*nH  ( 1)
Where I is the current elicited on application of agonist, b is the baseline current in the absence of 
ligand, L is the ligand concentration and nH is the Hill slope. The EC50 value is the concentration 
of agonist producing currents equal to one half the maximal current (Lax)-
Mutant (32D179A and a4W88A receptors which displayed dFBr potentiation with no 
inhibition at higher dFBr concentrations were also fit to equation 1 rather than equation 2 (bell 
shaped dose/response). For consistency with the bell-shaped dose response curves used for 
other dFBr experiments, the Hill slope (nH) was constrained to 1 in these experiments.
PAMs often produce bell shaped dose-response curves with both potentiating and 
inhibiting phases. dFBr displayed this typical dose-response profile on wild-type and some mutant 
receptors. The pEC50 (-log EC50) and plC50 (-log IC50) values were determined in these cases by 
simultaneously fitting both the potentiation and inhibition phases using equation 2 and GraphPad 
Prism Software (San Diego, CA). Similar equations have been used previously to examine bell­
shaped PAM data (Harvey et al., 1999; Hsiao et al., 2001; Hsiao et al., 2006; Kim et al., 2007; 
Weltzin and Schulte, 2010a). Mutant receptors that did not display a bell shaped response to 
dFBr were fit with other algorithms (see equation 1 and equation 3).
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I is the current elicited on application of agonist, lmaxcaic is the calculated maximum induced 
current of both the potentiation and inhibition curves. Plateau 1 is the initial current prior to 
addition of the modulator and Plateau 2 is the plateau after the inhibition of the agonist response 
at high concentrations of the modulator. The EC50 value is the concentration of modulator 
producing currents equal to one half the calculated maximum current ( lm a x c a i c )  during co­
application with agonist. The IC50 is the concentration of modulator required to inhibit the 
response to 1/2 l m a X c a ic  • The responses elicited from different oocytes and different 
concentrations of potentiator are typically normalized to the response to a control concentration of 
ACh to account for differences in expression between preparations. In potentiation experiments 
the current elicited by a specific concentration of the potentiating ligand + ACh ( l re s p o n s e )  is divided 
by the current elicited by an identical concentration of ACh in the absence of the potentiating 
ligand. Thus, in the absence of a potentiator the response amplitude is equal to 1.0. Potentiation 
is typically referred to in the text as a percentage of the unpotentiated response. This percentage 
is calculated as the peak of the bell shaped dose-response curve X 100. Since the unpotentiated 
response is defined as 1 .0, a 180% potentiation would, for example, represent an observed 
potentiation of 1.8 X the observed unpotentiated peak response. This peak response is typically 
less than the l m a X c a ic  due to simultaneous inhibition by the ligand that produces the bell shaped 
dose-response curve.
Simultaneous fitting of two Hill equations can prove difficult if the EC50 and IC50 values 
are close together due to the inability to collect data near the value of lmaxcaic- In these cases, 
insufficient data is present to fully define the curve and some constants must be approximated for 
the fit to converge and the appropriate EC50 and IC50 values determined. In order to overcome 
these limitations, Hill slopes for potentiation and inhibition were typically fixed at +1 and -1 
respectively. The lmaxcaic was constrained to < 6 . The constraints for the mutant P2Y127A 
expressed using the LS receptor preparation are as follows: Plateau 1 = 1 ,  lmaxcaic < 21 (due to 
dFBr having a greater lmaxcaic on P2Y127A), Plateau 2= 2.75 (the lmaX value of the highest dFBr 
concentration tested), nHi=-4 and nH2=-2 (nH values which allowed for the best curve fit of the 
data). The lmaxcaic of mutants a4W88A expressed using the LS receptor preparation were 
constrained to < 25 rather than < 6 due to dFBr having a greater lmaXcaic on a4W88A compared to 
the other examined mutations.
Some mutants displayed no potentiation on exposure to dFBr although inhibition was still 
observed. These inhibition curves were fit using non-linear curve fitting and GraphPad Prism
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Software (San Diego, CA) with standard built-in algorithms (equation 3). plC50 (-log EC50) values 
were determined by fitting concentration/response data to a log (inhibitor) verses response 
binding model:
, n, . n , (  (P lateaul-Plateaut) \  ...
I  =  Plateau2 + { il+ lo aogx-Lo9,c5o),nH))  (3)
Where I is the current elicited on application of agonist and modulator, Plateau 1 is the current 
elicited by the agonist prior to addition of the inhibitor. Plateau 2 is the current at saturating 
concentrations of inhibitor. The IC50 is the concentration of modulator that inhibits the current by 
1/2 lmax In order to permit comparison of data from different oocytes, responses for all test 
compounds were normalized to the currents obtained with 10 pM ACh for receptors expressed by 
the HS receptor preparation and 100 pM ACh for receptors expressed via the LS receptor 
preparations. The nH was constrained to -1 to allow for better comparison to results obtained for 
wild-type receptors.
The degree of change resulting from individual mutations was calculated as a ratio of the 
mutant value by the wild-type value. For values where a decrease was seen with the mutation, 
one was divided by the calculated fold change.
Statistical comparisons of pECso or pICso values used an unpaired t-test with p values 
calculated based on the null hypothesis.
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A series of amino acids were mutated to alanine to investigate the role the (32+ and 04- 
faces of the a4|32 nAChR in mediating the effects of ACh and dFBr. Residues to be mutated were 
selected based on homology with other LGIC subunits and were at equivalent positions to those 
previously identified in the binding pocket for benzodiazepines on GABAa receptors (GABAa 
a1H101, a1Y159, a1S205, a1T206, y1M130 and yF77) (Wieland et al., 1992; Amin et al., 1997; 
Buhr et al., 1997a; Buhr et al., 1997b; Buhr and Sigel, 1997; Wagner and Czajkowski, 2001). 
Figure 4.2 displays the alignments between nAChRs and GABAaR subunits involved in the 
putative dFBr binding site and the benzodiazepine binding site. Residues mutated on the (32+ 
face include W176 (GABAa aaY159), T177 and D179 on the B-loop; D217 and D218 (GABAa 
a1S205 and a1T206) on the C-loop; and D116, Y120 (GABA^alHIOI) and Y127 on the A-loop. 
Residues mutated on the a4- face include K140 (E-(3 strand) (GABAa y1M130) and W88 (D-(3 
strand) (GABAa y1 F77). Each mutant receptor was characterized using two-electrode voltage 
clamp recording. Dose-response curves were obtained for ACh stimulation in the absence of 
dFBr and for co-application of dFBr and ACh using oocytes expressing both low- (LS) and high- 
(HS) ACh sensitivity receptor populations.
4.4 Results.
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nAChRo4 F G S W T Y D K A I
nACHRp2 F R S @ 0  Y 0 R T E
GABAaRo1 f G s Y A Y T R A E
GABAARy1 F S s Y G Y P R E E
C-Loop
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nAChRp2 - 0 0 S T Y V D
GABAaRo1 S - - - - jT G E Y V V
GABAARy1
A-Loop
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Figure 4.2. DNA sequences for the binding- loops and -(3-sheets for the nAChR 
subunits a4 and (32 and GABAaR subunits a1 and y.
The residues in the a4 and (32 subunits that were mutated in the current study are emphasized ' 
back boxes. Key amino acids that are involved in the binding of benzodiazepines in the GABAa 
residues are accentuated in grey boxes.
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4.4.1. High- and Low- Sensitivity Wild-type a4^2 Receptor Preparations.
4.4.1.1. ACh Dose-Response on High- and Low- ACh Sensitivity a4[S2 Receptors.
ACh concentration-response curves were obtained for wild-type receptors using the LS 
(injection ratio 5:1 a:P) and HS (injection ratio 1:5 ccp) receptor preparations and by applying 
varying concentrations of ACh (0.1 -  3000 pM). The dose-response curves were sigmoidal in 
shape (Figure 4.3A). Receptors expressed using the LS receptor preparation had a significantly 
different ACh pEC50 value 4.5 ± 0.1 (EC50 = 34 pM) compared to receptors expressed using the 
HS receptor preparation (ACh pEC50 value of 5.2 ± 0.1 (EC50 = 5.8 pM)) (p < 0.0001) (Table 4.1 
and 4.2). The Hill slope (nH) for receptors expressed using the LS receptor preparation (nH = 1.4 ± 
0.3) were not significantly different from receptors expressed using the HS preparation (nH = 1.9 ± 
0.3) (p = 0.2893).
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Figure 4.3. ACh and dFBr dose-response curves for wild-type (WT) receptors expressed 
using the high-sensitivity (HS) and low-sensitivity (LS) receptor preparations.
Xenopus oocytes are prepared using the high and low-sensitivity receptor preparations (HS 
mRNA injected at a ratio of 1a:5|B; LS mRNA injection at a ratio of 5a:1(3). Expressing oocytes 
were exposed to increasing concentrations of ACh and dFBr. A) ACh dose-response curves for 
wild-type receptors. Individual peak amplitudes were normalized to the lmax on the same oocyte. 
B) Dose-response curves for co-application of varying concentrations of dFBr and the ACh EC75 
for wild-type receptors. C) Co-application of dFBr and ACh response traces for wild-type 
receptors expressed via the LS receptor preparation. D) Co-application of dFBr and ACh 
response profiles for wild-type receptors expressed by the HS receptor preparation. Response 
traces were recorded from a single oocyte. The solid bar above the response trace indicates the 
time the oocyte was exposed to co-application of varying concentrations of dFBr and the ACh 
EC75. The ACh and dFBr dose-response values were determined using non-linear curve fitting as 
described in the methods and are reported in Table 4.1 and 4.2. Data points represent at least 4 
replicate values obtained from a minimum of two oocytes harvested from different frogs. Error 
bars indicate ± SEM.
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Table 4.1 Summary of the calculated results determined from ACh and dFBr potentiation 
of ACh dose-response results from wild-type (WT) and mutant a4(32 receptors 
expressed using the low-sensitivity (LS) receptor preparation.
ACh Dose Response dFBr Potentiation of ACh Induced Responses
Mutation MutationLocation
pECso± 
SEM 
(ECso, pM)
nH
pEC50± 
SEM 
(EC50, pM)
plC50± 
SEM (IC50 
pM)
L a x  ± SEM
LS WT WT 4.5 ±0.1 (34) 1.4 ±0.3
6.1 ±0.4 
(0.79)
5.3 ± 0.4 
(5.0) 3.4 ± 0.4
LS |B2W176A p2, B-Loop 5.3 ±0.3 (5.1) 0.4 ±0.1***
6.6 ± 0.6 
(0.25)
5.1 ±0.6 
(7.9) 2.1 ±0.3
LS P2T177A P2, B-Loop 3.6 ±0.7 (226) 0.5 ±0.2
6.7 ±0.5 
(0.20)
4.7 ±0.5 
(20) 2.0 ± 0 .2**
LS P2D179A P2, B-Loop 4.1 ±0.3 (76) 1.2  ± 0.1
5.5 ±0.2 
(3.1) N.D. 3.7 ± 0.4
LS P2D217A P2, C-Loop 4.6 ± 0.2 (25) 1.3 ±0.2
6.6 ±0.5 
(0.25)
5.4 ± 0.6 
(4.0) 2.2 ± 0.2
LS P2D218A P2, C-Loop 4.4 ±0.1 (41) 0.8 ± 0.2
6.0 ±0.3 
(1 .0)
4.8 ±0.4 
(16) 2.7± 0.4
LS P2D116A p2, A-Loop 4.2 ±0.1 (59) 1.1 ± 0.1
6.1 ±0.3 
(0.79)
5.3 ±0.4 
(5.0) 3.0 ± 0.3
LS P2Y120A P2, A-Loop 4.0 ±0.1** (1 1 1 ) 1.3 ±0.2
8.5 ± 1.4 
(0.0032) N.D. 1.6  ± 0 .2**
LS P2Y127A P2, A-Loop 3.3 ± 1.1** (559) 0.4 ± 0.2**
5.9 ±0.6 
(1.3)
5.0 ±0.6 
(10 ) 20 ± 3**
LS O4K140A a4, E-Loop 7.0 ± 0.1*** (0.099) 0.8 ± 0 .1* N.D.
4.1 ±1.1 
(79) N.D.
LS a4W88A a4, D-Loop 4.9 ± 0.2 (14) 0.7 ± 0.3
5.5 ±0.2 
(3.2) N.D. 21.0 ±4***
Data represent mean ± SEM. Data points represent at least 4 replicate values obtained from a 
minimum of two oocytes harvested from different frogs. pEC50 is the -log of the EC50 value; plC50 
is the -log of the IC50 value; lmax observed is the maximum induced current observed nH. ** and *** 
Indicate values significantly different from wild-type receptors with p<0.01 and p<0.0001, 
respectively.
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Table 4.2 Summary of the calculated results determined from ACh and dFBr 
potentiation of ACh dose-response results from wiid-type (WT) and mutant 
a4|32 receptors expressed using the high-sensitivity (HS) receptor 
preparation.
ACh Dose Response dFBr Potentiation of ACh Induced Responses
Mutation MutationLocation
pECso± SEM 
(EC50i pM) nH
pEC50± 
SEM 
(ECso, pM)
plC50 ± 
SEM (iC50 
PM)
L a x  ± SEM
HS WT WT 5.2 ±0.1 (5.8) 1.9 ±0.3
5.7 ±0.1 
(2.0)
3.5 ± 1.9 
(316) 3.6 ±0.3
HS P2W176A P2, B-Loop 6.0 ± 0.1*** (0.91) 0.8 ±0.1 N.D.
7.9 ±0.3 
(0.013) N.D.
HS P2T177A P2, B-Loop 5.7 ±0.2 (1.9) 0.9 ±0.3
5.9 ±0.9 
(1.3)
5.4 ± 1.0 
(4.0) 2.4 ± 0.3**
HS P2D179A P2, B-Loop 6.0 ± 0.1*** (0.98) 0.7 ±0.1**
5.8 ±0.6 
(25)
3.7 ±3.0 
(200) 1.8 ± 0.2***
HS P2D217A p2, C-Loop 5.8 ± 0.1*** (1.5) 1.1 ±0.3
5.2 ± 0.4 
(6.3)
4.4 ±1.0 
(40) 3.2 ±0.1
HS P2D218A p2, C-Loop 5.5 ±0.1 (2.9) 1.2 ±0.2
5.5 ±0.3 
(3.2)
3.7 ± 1.3 
(200) 3.4 ± 0.3
HS P2D116A P2, A-Loop 5.2 ±0.1 (6.2) 0.9 ±0.2
5.8 ±0.3 
(1.6)
4.8 ±0.4 
(17) 2.6 ± 0.2**
HS P2Y120A p2, A-Loop 5.7 ±0.2 (2.2) 0.4 ± 0.1***
6.4 ± 0.7 
(0.40)
4.7 ± 1.7 
(20) 1.3 ±0.1***
HS P2Y127A P2, A-Loop 6.4 ±0.1*** (0.40) 0.5 ±0.1**
5.7 ±0.3 
(2.0)
4.1 ±0.8 
(70) 2.4 ±0.1**
HS O4K140A a4, E-Loop 7.2 ±0.1*** (0.058) 2.5 ±0.8 N.D.
5.9 ±0.3 
(1.3) N.D.
HS Q4W88A a4, D-Loop 6.2 ± 0.2** (0.57) 1.1 ±0.5
5.7 ±0.3 
(2.0)
4.3 ±0.6 
(50) 3.9 ±0.3
Data represent mean ± SEM. Data points represent at least 4 replicate values obtained from a 
minimum of two oocytes harvested from different frogs. pEC50 is the -log of the EC50 value; plC50 
is the -log of the IC50 value; lmax observed is the maximum induced current observed nH. ** and *** 
Indicate values significantly different from wild-type receptors with p<0.01 and p<0.0001, 
respectively.
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4.4.1.2. Effects of dFBr on Wild-Type Low- and High- ACh Sensitivity Receptors.
dFBr is a positive allosteric modulator (PAM) of a4|32 nAChRs (Kim et al., 2007; Weltzin 
and Schulte, 2010b). One of the goals of this study was to locate the putative dFBr binding site. 
Here we examined the effects of dFBr on the LS and HS receptor preparations using both wild- 
type and mutant receptors. dFBr did not induce activation of wild-type or mutant channels 
expressed in either the HS and LS receptor preparations without co-application of ACh.
Wild-type and mutant dose-response curves for dFBr potentiation were determined by 
co-application of dFBr at concentrations ranging from 0.001 -  100 pM dFBr and a fixed ACh 
concentration equal to the EC75for ACh (10 pM for HS and 100 pM for LS receptor preparations) 
to Xenopus laevis oocytes injected using the LS or HS injection ratios and evaluated via two- 
electrode voltage clamp. ACh (100 pM) induced responses of wild-type receptors prepared using 
the LS receptor preparation were potentiated by co-applications of 0.001 - 3 pM concentrations of 
dFBr (Figure 4.3B, Table 4.1). The pEC50 determined for dFBr on the LS receptors is 6.1 ± 0.3 
(EC50= 0.79 pM). Responses were maximally potentiated 280% by application of approximately 3 
pM dFBr co-applied with 100 pM ACh. dFBr concentrations in excess of 10 pM produced 
inhibition of dFBr potentiated ACh induced responses (Figure 4.3B, Table 4.1). The pICso value 
for dFBr inhibition was 5.3 ± 0.4 (IC50 = 5.0 pM).
In the HS preparation, co-application of varying concentrations of dFBr with 10 pM ACh 
produced a similar bell shaped dose-response curve to the LS preparation but appeared 
displaced slightly to the right (Figure 4.3B). The pEC50 value determined for the potentiation 
phase of the dose response curve was 5.7 ± 0.1 (EC5o = 2.0 pM) (Table 4.2). Co-application of 10 
pM dFBr and 10 pM ACh enhanced ACh induced currents maximally by approximately 360%. 
Concentrations of dFBr less than 30 pM potentiate ACh induced currents while those greater than 
10 pM dFBr inhibit the dFBr potentiated response (Figure 4.3B). The pICso value was estimated 
to be approximately 3.5 ±1.9 (IC5o= 316 pM) (Table 4.2).
Comparisons of the HS and LS preparations show minimal statistically significant 
differences in the dFBr dose-response results. No significant differences were observed when we 
compare pEC50, Lax observed and plC50 values for dFBr between the HS and LS receptor 
preparations (Table 4.1 and 4.2). Although visual inspection of Figure 4.3B suggested that the LS 
preparation dFBr dose-response curve was shifted to the left compared dFBr dose-response 
curve collected using the HS receptor preparation.
Typical responses to dFBr potentiation of ACh induced responses are shown in the lower 
panel in Figure 4.3. While the HS preparation appeared to produce smaller responses in this 
figure the difference is likely due to different in receptor expression levels between the two
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experiments and differences in cation conductances between the two receptor populations (Tapia 
et al., 2007). The overall effects of dFBr appeared to be similar in both cases with amplification of 
the overall response at lower concentrations followed by a sharpening of the response peak with 
an increase in the desensitizing phase at concentrations that produce the maximum potentiation 
(~ 3 pM -  10 pM) then a decrease in the sharpened peak amplitude at high dFBr concentrations. 
The presence of tail currents or hump currents in some traces (see trace e for both HS and LS 
preparations) suggested the presence of open channel block as previously determined for the 
mixed HS and LS preparations using a 1:1 a4:p2 mRNA injection ratio.
4.4.2. 02 B-Loop Mutations.
The B-loop region of the orthosteric binding site of nAChRs and other LGICs is thought to 
form a major component of the ligand binding pocket and are present on the plus face of one 
receptor subunit. In particular, a conserved W aromatic residue (P2W176, a4W149) in this region 
(see Figure 4.1) has been shown to interact with ligands in the orthosteric site (for review see 
(Lester et al., 2004)). a1Y159 is the equivalent residue in the GABAaRs allosteric benzodiazepine 
binding site that has been shown to reduce benzodiazepine modulation when mutated (Amin et 
al., 1997). The P2T177 and p2D179 are only conserved in nAChR subunits which form 
heteromeric receptors. These two residues were chosen for their potential to interact with 
functional groups on the dFBr molecule and to aid in our understanding of ligand selectivity. To 
evaluate the potential involvement of these amino acids in normal receptor function and/or the 
action of dFBr, these residues were individually mutated to alanine. The effects of these 
mutations are summarized in Table 4.1 for the LS preparation and Table 4.2 for the HS 
preparation.
4.4.2.1. Effects of/32 B-loop Mutations on ACh Induced Responses.
Figure 4.4A shows concentration-response data obtained at increasing concentrations of 
ACh concentrations (0.1 -  3000 pM) for B-loop mutant receptors using the 5:1 a4:p2 mRNA 
injection ratio (LS preparation). The pEC50 values determined for the B-loop mutations were not 
significantly different from wild-type receptors (P2T177A p = 0.0624; P2W176A p = 0.0203; 
P2D179A p=0.0144) (Figure 4.4A, Table 4.1). Thus alanine mutations of P2W176, P2T177 and 
P2D179 did not significantly alter the pEC50 for ACh stimulation of the LS a4p2 nAChR 
preparation.
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Figure 4.4. ACh and dFBr dose-response curves for P2+ face B-loop mutants and 
wild-type (WT) receptors expressed using the low- (LS) and high- (HS) sensitivity 
receptor preparation.
Xenopus oocytes were prepared using the HS and LS receptor preparations (HS mRNA injected 
at a ratio of 1a:5|3; LS mRNA injection at a ratio of 5a:ip). Expressing oocytes were exposed to 
increasing concentrations of ACh and dFBr. A and B) ACh dose-response curves for wild-type 
and p2+ face B-loop mutant receptors expressed using the LS and HS receptor preparations. 
Individual peak amplitudes were normalized to the lmax on the same oocyte. C and D) Dose- 
response curves for co-application of varying concentrations of dFBr and the EC75 ACh for wild- 
type and p2+ face B-loop mutant receptors expressed using the LS and HS receptor 
preparations. The ACh and dFBr dose-response values were determined using non-linear curve 
fitting as described in the methods and are reported in Table 4.1 and 4.2. Data points represent at 
least 4 replicate values obtained from a minimum of two oocytes harvested from different frogs. 
Error bars indicate ± SEM.
Analysis of nH values on the wild-type and mutants expressed using the LS preparation 
revealed no significant differences compared to wild-type, except in the cases of the (32W176A 
receptor (p = 0.0001) (Figure 4.4A, Table 4.1). Mutation of (32W176 to alanine produceed a
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significant decrease in nH to 0.4 (compared to 1.4 for wild-type receptors). This indicates a 
potential decrease in cooperativity between the ACh binding sites in this preparation or some 
other currently unknown effect on receptor kinetics.
The effects of B-loop mutations on ACh stimulation of HS receptors were slightly different 
from those described above for the LS preparation (Figure 4.4B and Table 4.2). p2T177A had no 
significant effect on its ACh pEC50 value. P2W176A and P2D179A receptors in the HS 
preparation produced pEC50 values that were significantly decreased compared to wild-type (p < 
0.0001). Increases in pEC50 ranged from 1.1-1.2 fold compared to wild-type receptors 
(corresponding to approximate EC50 decrease of 3.1 to 5.7 fold). The nH was significantly 
decreased only for the P2D179A mutant (0.7 for the mutant receptor, p = 0.0097) (Table 4.2). 
These results suggest that residues P2W176 and P2D179 may be involved in ACh conformational 
change of the protein.
4.4.2.2. Effects of f32 B-loop Mutations on dFBr Potentiation.
In contrast to the slight effects observed for B-loop mutations on ACh dose response 
curves, the alteration in dFBr potentiation were more profound. Co-application of dFBr at 
concentrations ranging from 0.001 -  100 pM in the presence of 100 pM ACh (Figure 4.4C, Table
4.1) produced curves with differences in dFBr efficacy (lmax) as well as potency (pEC50) on the LS 
preparation. dFBr produced similar effects to wild-type on the P2W176A and P2T177A mutant 
receptors compared to wild-type receptors with only a slight decrease in pEC50 (decreased EC50 
values of 3.2 and 4.0 fold respectively) and a significant decrease in P2T177A observed lmax (p = 
0.0050) (Table 4.1). p2D179A receptors expressed in the LS preparation did not produce bell­
shaped dose-response curves. The concentration-response data for dFBr appeard shifted to the 
right, although this decrease in the pEC50 was not statistically significant (Figure 4.4C, Table 4.1). 
Slight or perhaps no inhibitory component was observed, possibly reflecting a rightward shift in 
the inhibitory component of the curve that prevents the observation of inhibition in the 
concentration range of dFBr utilized in these experiments. The magnitude of the observed lmax for 
peak dFBr potentiation is similar to wild-type receptors (Figure 4.4C, Table 4.1).
P2W176A receptors expressed in the LS receptor preparation appeared to reduce the 
level of potentiation achieved by dFBr co-application while in the HS preparation, potentiation was 
completely eliminated (Figure 4.4D, Table 4.2). Partial inhibition of the ACh response (40-50%) 
was also observed and the plC50 of dFBr appeared to be enhanced compared to wild-type 
receptors but the values were not significantly different (p = 0.0419). As with the LS preparation, 
the P2T177A mutation produced a bell-shaped dose-response curve for dFBr but with a 
significantly reduced level of potentiation (p = 0.0062).
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The effects of the P2D179A mutation expressed in the HS preparation differed 
substantially from the LS preparation. While the LS preparation of the 02D179A mutation 
produceed an apparent rightward shift in the dose-response curve and a decrease in the 
observed potentiation, in the HS preparation this mutation produced little effect on the pEC50 and 
pIC 50 but produced a 2 fold decrease in potentiation (p <0.0001) (Figure 4.4D, Table 4.2).
These results suggest that P2T177 may be involved in the putative dFBr binding site. The 
alanine mutation of P2T177 did not alter the ACh concentration-response curve for either receptor 
preparation. Residues P2W176 and P2D179 could be involved in the dFBr binding site but due to 
the alanine mutations affecting the ACh dose-response curves, unquestionable conclusions 
cannot be made.
4.4.2.3. Response Profiles Obtained With Co-application of dFBr and ACh on B-loop Mutant 
Receptors.
The LS preparation response profiles appeared to be similar for the B-loop mutant 
receptors, P2W176A and p2T177A, compared to wild-type receptors. That is at increasing low 
concentrations of dFBr the overall response appeared augmented. At the peak dFBr potentiating 
concentrations the response peak appeared sharper and an increase in desensitization lagging 
phase was observed. Application of dFBr inhibitory concentrations, the response peak remained 
sharp and the desensitization lagging phase quickly returned to the baseline current. The 
P2D179A also followed this trend in response profiles with the exception that at low dFBr 
concentrations, the responses returned slower to the baseline current when compared to wild- 
type receptors (Figure 4.5A).
The response profiles of mutant receptors expressed using the HS preparation appeared 
to be similar to wild-type receptors in the LS and HS preparations (see appendix A). Differences 
were seen in the (32W176A receptor where only decreases in peak responses were observed 
(see appendix A). The 02T177A mutation appeared to have a prolonged return to the baseline 
compared to wild-type receptors (Figure 4.5B, traces a-c).
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Figure 4.5. Response profiles that appeared different from wild-type receptors for 
co-application of varying concentrations of dFBr and ACh for (J2+ face B-loop 
mutant receptors expressed using the low- (LS) and high- (HS) sensitivity 
receptor preparations.
Xenopus oocytes were prepared using the high- and low-sensitivity receptor preparations (HS 
mRNA injected at a ratio of 1a:5|3; LS mRNA injected at a ratio of 5a:ip). Expressing oocytes are 
exposed to increasing concentrations of ACh and dFBr. A) Co-application of dFBr and 100 pM 
ACh response traces for P2D179A receptors expressed via the LS receptor preparation. B) Co­
application of dFBr and 10 pM ACh response traces for P2T177A receptors expressed via the HS 
receptor preparation. Response traces were recorded from a single oocyte. The solid bar above 
the response trace indicates the time the oocyte was exposed to co-application of varying 
concentrations of dFBr and ACh.
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Alanine mutations were made at D217 and D218 in the C-loop of the 02 subunit. These 
amino acids are located on the + face of the receptor and thus in the putative binding domain for 
dFBr. In the GABAa receptor, a1S204 and a1T206 are equivalent to D217 and D218 of the 02 
nAChR subunit. These residues are thought to be within the GABAaR allosteric binding site for 
benzodiazepines (Amin et al., 1997; Wagner and Czajkowski, 2001). In addition to the similar 
location of these residues to the benzodiazepine binding site, 02D217 and 02D218 were 
hypothesized to be potentially important to the allosteric mechanism of dFBr due to their 
presence in the C-loop region. Since C-loop residues have been shown to be important for 
mediating agonist responses at the orthosteric site, we postulated that a similar effect of inducing 
C-loop closure might be required for dFBr action at the allosteric site (Sala et al., 2005; Weltzin 
and Schulte, 2010b).
4.4.3.1. Effects of @2 C-loop Mutation on ACh Induced Responses.
Figure 4.6A and B show concentration-response curves obtained for wild-type and 
mutant receptors using the LS and HS receptor preparations respectively. ACh was applied alone 
at varying concentrations (0.1 -  3000 pM) for the experiments shown in both A and B. Minimal 
effects were observed in the LS receptor preparation (Figure 4.6A, Table 4.1). The pEC50 and nH 
values obtained using 02D217A and 02D218A were similar to wild-type receptors (Table 4.1).
4.4.3. 02 C-loop Mutations.
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Figure 4.6. ACh and dFBr dose-response curves for (32+ face C-loop mutant and 
wild-type (WT) receptors expressed using the low- (LS) and high- (HS) sensitivity 
receptor preparations.
Xenopus oocytes were prepared using the HS and LS receptor preparations (HS mRNA injected 
at a ratio of 1a:5|3; LS mRNA injected at a ratio of 5a: 1(3). Expressing oocytes were exposed to 
increasing concentrations of ACh and dFBr. A and B) ACh dose-response curves for wild-type 
and p2+ face C-loop mutant receptors expressed using the LS and HS receptor preparations. 
Individual peak amplitudes were normalized to the lmax on the same oocyte. C and D) Dose- 
response curves for co-application of varying concentrations of dFBr and 100 pM ACh for wild- 
type and (32+ face C-loop mutant receptors expressed using the LS and HS receptor 
preparations. The ACh and dFBr dose-response values were determined using non-linear curve 
fitting as described in the methods and are reported in Table 4.1 and 3.2. Data points represent at 
least 4 replicate values obtained from a minimum of two oocytes harvested from different frogs. 
Error bars indicate ± SEM.
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(32D218A receptors expressed in the HS receptor preparation also produced no change 
in pEC50 or nH values for ACh stimulation (Figure 4.6B, Table 4.2). A slight, but statistically 
significant shift in pEC50 (1.1 fold) was observed for the (32D217A mutant (p < 0.0001) with no 
concurrent decrease in nH (Figure 4.6B, Table 4.2).
4.4.3.2. Effects of [32 C-loop Mutations on dFBr Potentiation.
Mutation of (32D217 to alanine had no significant effect on pEC50, plC50 or lmax values for 
dFBr potentiation and inhibition in either the LS or HS receptor preparations (LS: Figure 4.6C, 
Table 4.1; HS: Figure 4.6D, Table 4.2). In the LS preparation, the P2D217A dFBr dose- 
response curve appeared to have a reduced lmax and be shifted to the left but differences were 
not significantly different from wild-type receptors.
The P2D218A mutation produced no effect on the dFBr dose-response curve in either the 
LS or HS receptor preparations compared to wild-type receptors (Figure 4.6C and D). No 
significant alterations to pEC50, plC50 or lmax values were observed (Table 4.1 and 4.2).
The lack of any substantial effect of the p2D217A and P2D218A mutations of dFBr 
effects was surprising due to its presence in a key region of the C-loop and its equivalent position 
in the GABAa benzodiazepine binding pocket (Amin et al., 1997; Wagner and Czajkowski, 2001). 
These data do not strongly support a role of the C-loop in dFBr interaction although other 
residues within the C-loop may be involved.
4.4.3.3. ACh Response Profiles of [32 C-loop Mutations.
P2D217A and P2D218A response profiles appeared similar to wild-type receptors 
expressed using both the LS and HS receptor preparations (for traces see appendix A).
4.4.4. p2 A-loop Mutations.
P2 subunit amino acids at position D116, Y120 and Y127A in the A-loop region were 
mutated to alanine and evaluated for their effects on stimulation by ACh and/or the potentiating 
effects of dFBr (Figure 4.7). P2Y120 was chosen since it is equivalent to aH101 located in the 
GABAa benzodiazepine binding site (Wieland et al., 1992). The Aspartate at position 116 was 
chosen since it is highly conserved in both GABA and nAChRs (Figure 4.1 and 4.2). Similarly, at 
an aromatic amino acid is conserved at position 127 in both GABA and nAChRs (Figure 4.1 and
4.2).
4.4.4.1. Effects of [32 A-loop Mutation on ACh Induced Responses.
Figure 4.7A and B show concentration-response data obtained for wild-type and mutant 
receptors using the LS and HS receptor preparations respectively. Minimal effects were observed
161
on the ACh dose-response in the LS preparation (Figure 4.7A, Table 4.1). The pEC50 value 
obtained using P2D116A on LS or HS receptors were not significantly different then for wild-type. 
For the P2Y120A and P2Y127A LS mutants, a significant change in pECso (p=0.0021 and p= 
00026 respectively) of 1.1 and 1.4 fold wass observed. (Figure 4.7A, Table 4.1). A similar, 
significant shift 1.2 fold was observed for P2Y127A on the HS preparation (p < 0.0001) while no 
significant change was observed for P2Y120A. No significant change in nH was observed for 
P2D116A or P2Y120A in the LS preparation, although the nH of 0.4 ± 0.2 for the P2Y127A mutant 
was significantly different then 1.4 ± 0.3 for wild-type receptors (Table 4.1). In the HS preparation, 
nH decreased to 0.4 ± 0.1 for P2Y120A and 0.5 ± 0.1 for P2Y127A, significant decreased from the 
1.9 ±0.3 observed in wild-type receptors (Table 4.2).
Figure 4.7. ACh and dFBr dose-response curves for p2+ face A-loop mutant and wild- 
type (WT) receptors expressed using the iow- (LS) and high- (HS) sensitivity receptor 
preparations.
Xenopus oocytes were prepared using the high and LS receptor preparations (HS mRNA injected 
at a ratio of 1a:5P; LS mRNA injected at a ratio of 5a: 1P). Expressing oocytes were exposed to 
increasing concentrations of ACh and dFBr. A) ACh dose-response curves for wild-type and P2+ 
face A-loop mutant receptors expressed using the LS receptor preparation. Individual peak 
amplitudes were normalized to the lmax on the same oocyte. B) ACh dose-response curves for 
wild-type and P2+ face A-loop mutant receptors expressed using the HS receptor preparation. 
Individual peak amplitudes were normalized to the imax on the same oocyte. C) Dose-response 
curves for co-application of varying concentrations of dFBr and 100 pM ACh for wild-type and 
(32+ face A-loop mutant receptors expressed using the LS receptor preparation. Insert: A graph 
with the same y-axis as in figure D for easy comparison. D) Dose-response curves for co­
application of varying concentrations of dFBr and 10 pM ACh for wild-type and |32+ face A-loop 
mutant receptors expressed using the HS receptor preparation. The ACh dose-response values 
were determined using non-linear curve fitting as described in the methods and are reported in 
Table 1 and 2. The dFBr dose-response values were determined using non-linear curve fitting as 
described in the methods and are reported in Table 4.1 and 4.2. Data points represent at least 4 
replicate values obtained from a minimum of two oocytes harvested from different frogs. Error 
bars indicate ± SEM.
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4.4.4.2. Effects of (32 A-loop Mutations on dFBr Potentiation,
The (B2D116A mutation expressed in the LS receptor preparation produced no change in 
pEC50, plC50 or lmax values for dFBr potentiation and inhibition compared to wild-type receptors, 
although a slight non-significant decrease in the HS lmax was observed (Figure 4.7C, Table 4.1). 
Similar to the LS preparation, co-application of dFBr and 10 pM ACh on (32D116A in a HS 
preparation had no significant effect on dFBr’s pEC50 or plC50 values although the observed lmax 
was significantly reduced (p = 0.0087) from 3.6 ± 0.3 to 2.6 + 0.2 (Figure 4.7D, Table 4.2).
The (B2Y120A mutation expressed in the LS preparation only mildly enhanced ACh 
induced currents (lmax = 1.6 ± 0.2) and no inhibition by dFBr was observed (Figure 4.7C). Co­
exposure to 0.1-1 pM dFBr and 100 pM ACh induced the maximum amount of potentiation. The 
pEC50 for dFBr potentiation of (32Y120A in the LS preparation was not significantly different from 
wild-type receptors although the observed lmax was significantly reduced (p = 0.0020) compared 
to 3.4 ± 0.4 obtained on wild-type receptors in this preparation (Table 4.1). In the HS receptor 
preparation, a bell-shaped dose-response curve showing both potentiation and inhibition was 
observed on mutant (B2Y120A (Figure 4.7D). Responses were minimally potentiated by dFBr with 
the maximum potentiation (lmax = 1.3 ± 0.1) observed at co-application of 3 pM dFBr and 10 pM 
ACh. dFBr concentrations in excess of 3 pM weakly inhibits ACh potentiated currents (Figure 
4.7D). No significant shifts were seen in dFBr pEC50 and plC50 values were observed in the HS 
preparation compared to those obtained on wild-type receptors, although the observed lmax was 
significantly reduced (p < 0.0001) compared to wild-type receptors (3.6 ± 0.3) (Table 4.2).
(32Y127A receptors expressed in the LS receptor preparation also produced a bell­
shaped dose-response curve; however, both the shape and magnitude of the curve was 
dramatically altered for this receptor (Figure 4.7C). (32Y127A mutant receptors were significantly 
and maximally potentiated by an enormous 2000% by 10 pM dFBr co-applied with 100 pM ACh 
( l m a x  = 20.0 ± 3, p = 0.0018) (Table 4.1). Similar to wild-type, receptors were inhibited at dFBr 
concentrations > 3 pM (Figure 4.7C). Visual inspection of Figure 4.7C showed an apparently 
large increase in the slope of the dFBr potentiation phase compared to wild-type receptors. The 
rapid change in dFBr potentiated ACh currents made accurate determination of pECso and plC50 
values difficult, although the dFBr pECso and plC50 values seemed comparable to wild-type 
receptors (Table 4.1). In the HS preparation, the (32Y127A mutant produced a bell-shaped dFBr 
dose-response curve that was similar to wild-type receptors with no significant changes in pEC50 
or pICso values (Figure 4.7D, Table 4.2). Maximum potentiation of 240% was observed with co­
application of 10 pM dFBr and 10 mM ACh (lmax=2.4 ± 0.1), a significant reduction in lmax (p = 
0.0087) compared to 3.6 ± 0.3 for wild-type receptors in the HS preparation (Table 4.2).
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These findings suggest that the A-loop is important for dFBr interactions with a4p2 
nAChR expressed in either the LS or HS preparations. (32D116A is the only residue not to affect 
the ACh dose-response curve, unlike P2Y120A and P2Y127A receptors in the LS and HS 
preparations. All of the examined A-loop mutations alter the dFBr concentration-response curve 
in the LS preparation, while only mutations p2Y120A and P2Y127A affect the dFBr dose- 
response curve in the HS preparation.
4.4.4.3. Response Profiles Obtained with Co-application of dFBr and ACh on A-loop Mutant 
Receptors.
The response traces for the A-loop mutations in both the LS and HS preparation 
appeared to be similar to wild-type receptors (see appendix A for traces).
4.4.5. a4 D- and E- p-Sheet Mutations.
The minus face of the putative allosteric binding domain for dFBr was hypothesized to be 
composed of the a4 D- and E- p-sheets based on homology to the orthosteric nAChR binding site 
and the benzodiazepine binding site of GABAa receptors. Two amino acids, in equivalent 
locations to the GABAa benzodiazepine binding site residues yM130 (E-loop) and yF77 (D-loop) 
were chosen for alanine mutation on the a4 subunit (Buhr et al., 1997a; Buhr and Sigel, 1997). 
These correspond to the a4 subunit amino acids K140 and W88 respectively.
4.4.5.1. Effects of a4 D- and E- fi-Sheet Mutations on ACh Induced Responses.
Figure 4.8A and B shows ACh dose-response data obtained for wild-type and mutant 
receptors expressed using the LS and HS receptor preparations. For a4W88A receptors in the 
LS preparation, pEC50 and nH values are similar to wild-type receptors (Table 4.1). In contrast, for 
the HS preparation the curve is shifted significantly to the left and the pEC50 is increased 
significantly from 5.2 ± 0.2 (wild-type) to 6.2 ± 0.2 (P2W88A) (1.4 fold shift) (p = 0.0012) (Table
4.2). Similar to LS mutant receptors, no effect in nH is observed on the HS preparation.
For the a4K140A mutation, the dose-response curve shifts to the left in both the LS and 
HS preparations (Figure 4.8B). For the LS preparation the pEC50 is increased significantly from
4.5 ±0.1 (wild-type) to 7.0 ±0.1 (a4K140A) (p<0.0001) compared to LS wild-type receptors 
(Table 4.1). a4K140A expressed via the HS preparation, the pEC50 is also significantly increased 
from 5.2 ± 0.1 (wild-type) to 7.2 ± 0.1 (a4K140A) compared to HS wild-type receptors (p < 0.001) 
(Table 4.2). The nH values are similar to wild-type receptors in both the LS and HS preparations 
(Table 4.1 and 4.2).
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4.4.5.2. Effects of a4 D- and E- /3-Sheet Mutations on dFBr Potentiation.
Mutation of a4K140 to an alanine produces receptors insensitive to potentiation by dFBr 
in both the LS and HS preparations. In the preparations, inhibition was observed at high dFBr 
concentrations (Figure 4.8C and D). The plC50 value for dFBr inhibition was not significantly 
different from LS wild-type receptors.
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Figure 4.8. ACh and dFBr dose-response curves for a4- face mutant and wild-type (WT) 
receptors expressed using the low- (LS) and high- (HS) sensitive receptor preparations.
Xenopus oocytes were prepared using the high and low-sensitivity receptor preparations (HS 
mRNA injected at a ratio of 1a:5p; LS mRNA injected at a ratio of 5a: 1P). Expressing oocytes 
were exposed to increasing concentrations of ACh and dFBr. A and B) ACh dose-response 
curves for wild-type and a4- face mutant receptors expressed using the LS and HS receptor 
preparations. Individual peak amplitudes were normalized to the lmax on the same oocyte. C and 
D) Dose-response curves for co-application of varying concentrations of dFBr and the EC75 ACh 
for wild-type and a4- face mutant receptors expressed using the LS and HS receptor 
preparations. Insert: A graph with the same y-axis as in figure D for easy comparison. The ACh 
and dFBr dose-response values were determined using non-linear curve fitting as described in 
the methods and are reported in Table 4.1 and 4.2. Data points represent at least 4 replicate 
values obtained from a minimum of two oocytes harvested from different frogs. Error bars indicate 
± SEM.
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Mutation of a4W88 to an alanine amplified lmax in the presence of dFBr from 3.4 ± 0.4 
(wild-type) to 21 ±4  (a4W88A) (p < 0.0001) in the LS receptor preparation, although the pECsofor 
dFBr potentiation was not significantly different from wild-type receptors (Figure 4.8C, Table 4.1). 
Maximum dFBr potentiation of 2100% was observed at dFBr concentration > 30 pM, similar to the 
|B2Y127A A-loop mutation in the LS preparation. In the LS preparation, no inhibition was 
observed for a4W88A in the concentration range of dFBr tested. In the HS preparation the 
a4W88A mutant had little effect on dFBr dose-responses curves when compared to those 
obtained using wild-type receptors (Figure 4.8D). No significant shifts in pEC50, plC50 or lmax observed 
values were seen (Table 4.2).
ACh concentration-response results for the mutant a4K140A was different from wild-type 
receptors in both the LS and HS preparations, while the a4W88A results were only affected in the 
HS preparation. These findings suggested that these residues may be involved in ACh induced 
conformational change and may depend on the a4p2 receptor preparation. It is difficult to 
determine if these residues are also involved in dFBr interactions with the receptor. Because 
a4W88A in the LS preparation did not affect ACh results but did eliminate the bell-shaped dose- 
response of dFBr, we suggest that this residue is possibly located in the dFBr binding site.
4.4.5.3. Response Profiles Obtained With Co-application of dFBr and ACh on a4 Mutant
Receptors.
The dFBr concentration-response traces for a4K140A in both the LS and HS receptor 
preparation appeared similar to wild-type receptors with the exception to increases in the peak 
response (see appendix A for traces). The a4W88A expressed in the HS preparation response 
profiles appeared similar to wild-type receptors (see appendix A for traces). In the LS preparation, 
a4W88A traces appeared to look more like a7 nAChR traces (Figure 4.9). At low, increasing dFBr 
concentrations co-applied with 100 pM ACh the response peak sharpens and there was a 
decrease in the desensitization. At dFBr potentiating concentrations, the peak response was 
sharper and the desensitization lagging phase was decreased but the current does not return to 
the baseline. At inhibiting concentrations, the peak response continued to sharpen and the 
lagging phase decreased sharply and returned to the baseline current (Figure 4.9).
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LS aW88A
Figure 4.9. Response profiles for co-appiication of varying concentrations of dFBr 
and ACh for a4- face mutant W88A expressed using the low- (LS) sensitive 
receptor preparation.
Xenopus oocytes were prepared using the low-sensitivity receptor preparations (LS mRNA 
injected at a ratio of 5a: 1P). Expressing oocytes were exposed to increasing concentrations of 
dFBr and co-application of 100 pM ACh. Response traces were recorded from a single oocyte. 
The solid bar above the response trace indicates the time the oocyte was exposed to co­
application of varying concentrations of dFBr and ACh.
4.5 Discussion.
The primary goal of this study is to test the hypothesis that the plus face of the (32 subunit 
and the minus face of the a4 subunit form the binding domain for dFBr and/or mediate its 
potentiating effects. To test this hypothesis, we conducted a site directed mutagenesis study of 
amino acids located in this domain. Residues previously shown to be conserved or important to 
ligand binding in LGIC receptors were chosen for mutation. Amino acids in loops A, B and C on 
the P2 subunit (+face) and D and E on the a4 subunit (- face) were mutated to alanine. All of the 
mutants tested appeared to express well in Xenopus oocytes although some seem to produce 
smaller macroscopic currents, possibly due to lower expression levels. Receptors were 
expressed in both LS and HS preparations and ACh EC50 values were either unaltered or only 
slightly affected in most cases suggesting the receptor stoichiometry is likely unchanged as a 
result of the mutation.
P2T177A, P2D179A, P2D217A, p2D218A, p2D116Aand a4W88A receptors expressed in 
the LS preparation produces minimal effects on ACh responses compared to wild-type receptors. 
P2T177A, P2D218A, P2D116A and P2Y120 mutant receptors expressed in the HS receptor 
preparation also produced only minimal effects on ACh dose-response curves. Small changes in 
ACh pECso’s due to mutations were likely to occur within in any region of the protein, it is the
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degree of change that is important. In the LS preparations P2T177A, p2D179A, P2Y120A, 
P2Y127A, a4K140A and a4W88A receptors produced large effects on potentiation by dFBr 
including decreases and increases in efficacy of potentiation and shifts in both EC50 and IC50 
values In the HS preparation, P2W176A, p2T177A, P2D179A, p2D116A, p2Y120A, P2Y127A, 
a4K140A and a4W88A receptors produced large changes in the dFBr concentration-response 
data. These data suggest involvement of these amino acids in either the binding of dFBr or in 
mediating dFBr’s potentiating effects. The elimination of dFBr potentiation in mutants such as 
a4K140A or P2Y120A suggests that these amino acids may be directly involved.
We postulate that the dFBr binding site is located on the + face of the P2 subunit and 
involves p2T177 in a4p2 receptors expressed in either the LS or HS receptor preparation. In the 
LS preparation, P2W176A, P2T177A, P2D179A and a4W88A significantly altered the potentiating 
effects of dFBr but only minimally altered the ACh dose-response curves. In the HS receptor 
preparation P2T177A, P2D116A and P2Y120A receptors showed significant effects on dFBr 
potentiation despite the minimal effects on ACh stimulation.
4.5.1 Stoichiometries of Receptors in LS and HS 04(32 nAChR Preparations.
Injection of different concentrations of a4:p2 mRNA or DNA has been shown to cause the 
expression of two different receptor populations (Nelson et al., 2003; Zhou et al., 2003; Briggs et 
al., 2006; Moroni et al., 2006; Zwart et al., 2006; Tapia et al., 2007). Previous studies have 
suggested that the HS receptor preparation predominantly forms receptors with two a4 and three 
P2 subunits in the pentameric arrangement apapp ((a4)2(P2)3) (Nelson et al., 2003; Zhou et al., 
2003; Briggs et al., 2006; Moroni et al., 2006; Zwart et al., 2006; Tapia et al., 2007). This 
stoichiometry would produces receptors in the HS preparation containing two a+/p- clefts, two 
P+/a- clefts and one p+/p- cleft (see Figure 1.4 in introduction). Several lines of evidence suggest 
that receptors formed in the LS receptor preparation are predominantly composed of three a4 
and two P2 subunits in the arrangement apapa ((a4)3(P2)2) (Nelson et al., 2003; Zhou et al., 
2003; Briggs et al., 2006; Moroni et al., 2006; Zwart et al., 2006; Tapia et al., 2007). If this 
stoichiometry is correct, the receptors in the LS preparation would contain two a+/p- clefts, two 
P+/a- clefts and one a+/a- cleft. It is likely that other arrangements are subunits are also 
expressing in both the HS and LS preparation although possibly to a lesser extent.
The presumed HS and LS stoichiometries have not yet been conclusively demonstrated. 
Studies have shown that receptors expressed using the LS receptor preparation have an ACh 
EC50 of -60-90 pM and HS receptor preparations have an ACh EC50 of -1.8-4 pM (Zwart and 
Vijverberg, 1998; Moroni et al., 2008). These values are similar to what we observed for the HS 
and LS preparations, indicating that our receptor expression systems likely form comparable
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receptors to those used in previous studies (Nelson et al., 2003; Zhou et al., 2003; Briggs et al., 
2006; Moroni et al., 2006; Zwart et al., 2006; Tapia et al., 2007).
In general, mutant receptors expressed using the HS receptor preparation produced 
greater changes in ACh dose-response data than mutant receptors expressed using the LS 
preparation. One explanation for this phenomenon may lie in the possible different stoichiometric 
arrangements of subunits in the two different preparations. As described above, the HS 
preparation may contain receptors containing two a4 and three 02 subunits. Thus receptors 
would contain three rather than two mutant subunits and these mutations would be present at 
three of the five subunit interfaces (one 02+/02- subunit interface and two 02+/a4- subunit 
interfaces). In the LS preparation 02 mutations would only be present at two of the interfaces.
Differences in mutant and wild-type ACh dose-response data, particularly in the HS 
receptors might be explained by alteration in receptor gating. Previous studies using muscle 
AChRs have demonstrated that single point mutations can reduce receptor open state stabilities 
(Akk, 2002; Purohit and Auerbach, 2010). Purohit and Auerbach (2010) show that mutation of 
aY93 and aW149 in mouse muscle AChR increased spontaneous and monoligand open events, 
indicating a change in receptor gating. Mutation of 6W57 has also been shown to alter channel 
gating by single channel analysis (Akk, 2002). The homologous residues to Torpedo aY93, 
aW149 and 5W57 are 02Y12O, 02W176 and a4W88 respectively. Effects similar to those 
observed in Torpedo receptors may be responsible for the effects we observed on mutant a402 
nAChRs.
Unwin has previously hypothesized that the localized twisting of the Torpedo a5 subunit in 
response to ACh application must also affect the neighboring subunits (Unwin, 1995). Current 
crystallography structures of the acetylcholine binding protein have shown various structural 
arrangements of the C-loop in binding clefts without ligand (Brejc et al., 2001; Celie et al., 2005). 
A study by Teissere and Czajkowski (2001) provides further support that non-orthosteric clefts 
are structurally altered by agonist binding to their receptors. Teissere and Czajkowski (2001) 
have shown that mutating yY72C, yD75C and yF78C located within the benzodiazepine binding 
site in GABAa receptors caused a shift in the GABA EC50 values less than four fold. SCAM 
studies have additionally shown that a cysteine substituted for yA79 in the GABA receptor is more 
accessibility to MTSEA-biotin modification during GABA binding and channel gating (Teissere 
and Czajkowski, 2001). Authors suggest that their data confirms that structural rearrangements 
occur within the benzodiazepine binding site in response to GABA binding in its orthosteric site. 
These results are similar to our current findings that mutations in interfaces not involved in 
binding ACh can alter ACh stimulation of the receptor. If dFBr acts similar to the benzodiazepine
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drug class, then dFBr may be exerting a similar modifying effect on the normal processes of 
receptor gating mediated through the non-orthosteric interfaces. Alternatively, a possibility that we 
cannot rule out is that the mutations made in on allosteric subunit faces could cause structural re­
arrangements in the orthosteric binding site.
In summary, data obtained in our mutagenesis studies suggest a role of non-orthosteric 
subunit interfaces in ACh receptor gating and desensitization. This is the first data supporting a 
role of this region of the nAChR in mediating responses to ACh.
4.5.2 The (32+ and a4- Subunits Contain the dFBr Allosteric Binding Site.
Wild-type receptors expressed in the LS and HS receptor preparations responded 
similarly to dFBr. In the LS receptor preparation, P2W176A, P2T177A, P2D179A (B-loop) and 
a4W88A (D-P-sheet) significantly affected the ability of dFBr to potentiate ACh responses but had 
only minimally modified the ACh dose-response relationships. In the HS receptor preparation 
P2T177A (B-loop), P2D116A (A-loop) and P2Y120A (A-loop) significantly altered the dFBr 
potentiation but with only minimally effects on the ACh dose-response. All of these mutations are 
at positions where homologous amino acids in the GABAaR benzodiazepine binding site have 
been shown to participate in the interaction of benzodiazepines (Duncalfe et al., 1996; Amin et 
al., 1997; Buhr et al., 1997a; Buhr et al., 1997b; Wingrove et al., 1997; Wagner and Czajkowski, 
2001). These data are consistent with an effect of dFBr on the nAChR similar to the action of 
benzodiazepines on the GABAa receptor.
4.5.3 Summary.
Our data supports a role for the non-orthosteric cleft in ACh activation of the a4p2 
receptor. In particular, the p2+/a- cleft appears to play a role in normal receptor function in 
response to ACh. This region of the receptor, particularly the (32 subunit, also appears to be 
involved in mediating the effects of dFBr as a PAM. We hypothesize that dFBr may exert its 
effects by altering the normal conformational changes in the receptor that involve the non- 
orthosteric clefts. Amino acids expressed in the LS preparation include P2W176A, p2T177A, 
P2D179A and a4W88A, while in the HS preparation residues P2T177A, P2D116A, P2D116A and 
P2Y120A appear to be involved in dFBr actions. Results from this study enhance our 
understanding of non-orthosteric clefts of a4p2 nAChRs response mechanisms to the orthosteric 
ligand ACh. In addition, residues involved in dFBr actions have been resolved, paving the way for 
the design of therapeutic ligands acting at this novel site.
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CHAPTER 5: Allosteric Modulation of High- and Low- Sensitivity alpha4beta2 Nicotinic 
Acetylcholine Receptors by HEPES.
5.1 Abstract.
A number of new positive allosteric modulators (PAMs) have been reported that 
enhance responses of neuronal alpha7 and alpha4beta2 nicotinic acetylcholine receptor 
(nAChR) subtypes to orthosteric ligands. PAMs represent promising new leads for the 
development of therapeutic agents for disorders involving alterations in nicotinic 
neurotransmission such as Autism, Alzheimer’s and Parkinson’s disease. During our recent 
studies of alpha4beta2 PAMs, we identified a novel effect of 4-(2-hydroxyethyl)-1- 
piperazineethanesulfonic acid (HEPES). The effects of HEPES were evaluated in phosphate 
buffered recording solutions using two-electrode voltage clamp techniques and alpha4beta2 
and alpha7 nAChR subtypes expressed in Xenopus laevis oocytes. Acetylcholine induced 
responses of high-sensitivity alpha4beta2 receptors were potentiated 190% by co-exposure to 
HEPES. Responses were inhibited at higher concentrations (bell-shaped dose-response 
curve). Coincidentally, at concentrations of HEPES typically used in oocyte recording (5-10 
mM), the potentiating effects of HEPES are matched by its inhibitory effects thus producing no 
net effect. Mutagenesis results suggest HEPES potentiates the high-sensitivity stoichiometry of 
the alpha4beta2 receptors through action at the beta+/beta- interface and is dependent on 
residue beta2D218. On low-sensitivity alpha4beta2 receptors, HEPES produced only inhibition 
of ACh induced responses. HEPES was not observed to potentiate or inhibit acetylcholine 
induced responses on alpha7 nAChRs.
Our data may alter the interpretation of previous PAM studies due to the common use 
of HEPES as a buffering agent in electrophysiological recording buffer. We performed 
experiments using previously published alpha4beta2 potentiating agents to document these 
effects.
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Nicotinic acetylcholine receptors (nAChR), GABAa, 5HT3a and glycine receptors are 
members of the Cys-loop super family of ligand gated ion channels. Alterations in expression of 
nAChRs have been implicated in neurological disorders including Alzheimer’s disease (Court et 
al., 2001; Nordberg, 2001), Parkinson’s disease (Aubert et al., 1992), Autism (Martin-Ruiz et al., 
2004; Lippiello, 2006), Schizophrenia (Adams and Stevens, 2007) and nicotine addiction 
(Picciotto et al., 2001). In addition, mutations in the a4 (CHRNA4) and p2 (CHRNB2) subunit 
genes cause autosomal nocturnal frontal lobe epilepsy (Weiland et al., 2000).
Studies have provided suggestive evidence that both the high- (HS) and low- (LS) ACh 
sensitivity a4p2 nAChR stoichiometries are expressed in the mammalian brain (Marks et al., 
2000; Butt et al., 2002; Gotti et al., 2008) and can be altered by chronic exposure to nicotine 
(Moretti et al., 2010). In the brain, most <34(32 nAChRs act presynaptically or preterminally to 
modulate neurotransmitter release (Wonnacott, 1997).The composition of the human a4p2 
stoichiometries has not been elucidated in neurons.
In heterologous expression systems, both HS and LS receptors have been observed and 
these are attributed to a predominance of either the (a4)2(P2)3* or (a4)3(p2)2* stoichiometries 
even though it is acknowledged that other stoichiometries may also be present. The expression of 
different a4p2 stoichiometries in Xenopus laevis oocytes can be influenced by injecting higher 
concentrations of mRNA for one subunit over the other (Zwart and Vijverberg, 1998; Moroni and 
Bermudez, 2006; Moroni et al., 2006a; Tapia et al., 2007). These stoichiometries differ in their 
functional pharmacology, desensitization kinetics, unitary conductance and calcium permeability. 
The presumed HS stoichiometry has a high acetylcholine (ACh) sensitive (Nelson et al., 2003). 
The LS stoichiometry possess a lower ACh sensitive and reduced sensitivity to up-regulation by 
agonists, desensitizes more rapidly and has a higher Ca2+ permeability than the HS receptors 
(Nelson et al., 2003; Tapia et al., 2007).
This study investigates allosteric modulation of HS and LS a4p2 nAChRs and a7 
nAChRs by 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES). HEPES is a popular 
buffering agent originally developed 1966 by Normon Good and colleagues as one of a series of 
related buffers with pKa values around physiological pH (Good et al., 1966). Collectively known 
as “Good’s buffers”, these compounds were thought to be physiologically inert. Over the years 
there has been accumulating evidence that HEPES is a fairly reactive molecule which interacts 
with in vitro experimentation. HEPES has been shown to stimulate the production of ATP, 
decrease the uptake of P-glycoprotein, effect cell membrane and block both chloride ion channels
5.2 Introduction.
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and mammalian 5-hydroxytryptamine transporters (Li et al., 2002). These findings suggest that 
HEPES may not be a benign molecule.
Our results indicate a specific interaction of HEPES with the HS a4|32 nAChR. HEPES 
dose-response curves on HS receptors activated by acetylcholine (ACh) are triphasic with a 
potentiation phase followed by two distinct inhibitory phases. LS a4(32 receptors are not 
potentiated but show a single inhibitory phase at high HEPES concentrations equivalent to the 
second inhibitory phase observed on high-sensitivity receptors. Mutagenesis of the p2D218 to an 
alanine in the C-loop region of the + face of the (32 subunit abolishes the potentiation phase and 
the first inhibitory phase on HS receptors but leaves the third, low-sensitivity inhibitory phase 
intact. This mutation does not alter inhibition by HEPES on the LS subtype. The apparent 
selectivity for the HS receptor combined with mutagenesis data indicates the involvement of the 
P2+ face and suggests that at the p+/p- cleft contains the HEPES allosteric potentiation binding 
site.
The ability of HEPES to modulate a4p2 nAChRs may alter the interpretation of previous 
studies of a4p2 modulators due to the wide use of HEPES in electrophysiological recording 
buffers. We have included a re-analysis of two such modulators (desformylflustrabromine (dFBr) 
and Zn2+) in this study to demonstrate how the presence of HEPES in the recording buffer may 
hinder interpretation of experimental data.
5.3 Materials and Methods.
5.3.1 Receptors and mRNA.
The cDNA sequences for human a4 (NCBI Reference Sequence: NM_000744.5), p2 
(NCBI Reference Sequence: NM_000748.2) and a7 (NCBI Reference Sequence: NM_000746.3) 
nAChR subunits were used to synthesize a full length cDNA for each subunit. cDNA synthesis 
was conducted by GeneArt Inc. (Burlingame, CA). The p2 cDNA was inserted into the 
pcDNA3.1/Zeo(+) mammalian expression vector with restriction enzymes Not I and Xho I and the 
a4 cDNA was inserted into the pcDNA3.1/hygromyocin mammalian expression vector with 
restriction enzymes Hind III and BamHI (vectors procured from Invitrogen, Carlsbad, CA; 
restriction enzymes purchased from New England Biolabs). The constructs were transformed into 
AG1 super-competent cells (Stratagene) for production of cDNA. The cDNA for a7 nAChR 
subunit was inserted with restriction enzymes Sal I and Xba into the pBudCE4.1 expression 
vector (Invitrogen). Synthetic cRNA transcripts for a4, (32 and a7 subunits were prepared using 
the T7 mMESSAGE mMACHINE™ High Yield Capped RNA Transcription Kit (Ambion, Austin,
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TX). All constructs were fully sequenced and confirmed to be identical to the published 
sequences for each subunit.
The (32D218A mutation was created using the QuickChange® mutagenesis kit as 
described previously (Agilent Technologies, Inc. Santa Clara, CA) (Venkataraman et al., 2002; 
Moroni et al., 2008). The resulting DNA was used to transform AG1 super-competent cells and 
individual colonies were screened to identify those producing mutant [32 cDNA. To facilitate 
screening of mutant receptors, a silent Sac II restriction site was engineered into the mutant 
cDNA. The mutation was confirmed by commercial DNA sequencing (Sequetech, Mountain 
View, CA).
5.3.2 Test Compounds.
4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES), Acetylcholine (ACh), Tris 
(hydroxymethyl)-aminomethane hydrochloride, Tris (hydroxymethly) aminomethane, potassium 
dihydrogen phosphate, potassium phosphate dibasic, ZnCI and other salts and buffering agents 
were obtained from Sigma-Aldrich, Inc (MO). Desformylflustrabromine-HCI (dFBr) was 
synthesized by Dr. Richard Glennon (Virginia Commonwealth University) according to a 
previously published procedure (Kim et al., 2007).
5.3.3 Xenopus laevis Oocytes and Receptor Expression.
Xenopus laevis frogs and frog food were purchased from Nacso (Fort Atkinson, Wl). 
Ovarian lobes were surgically removed from Finquel anesthetized Xenopus laevis frogs and 
washed twice in Ca2+-free Barth’s buffer (82.5 mM NaCI; 2.5 mM KCI; 1 mM MgCI2; 5 mM 
HEPES, pH 7.4) then gently shaken with 1.5 mg/mL collagenase (Sigma type II, Sigma-Aldrich 
Inc., MO) for 20min at 20-25°C. Stage V and VI oocytes were selected for microinjection. No 
more than four surgeries were conducted on each frog. A recovery period greater than six weeks 
was allowed in between surgeries (Xenopus protocols conform to those approved by the 
University of AK Fairbanks Intuitional Animal Care and Use Committee; approval number 08-71).
For expression of high- (HS) and low- (LS) sensitivity subtypes, oocytes were injected 
with 50 nL cRNA. Injected oocytes were incubated at 19°C for 24-72h prior to their use in voltage 
clamp experiments. For expression of primarily HS receptors 50 nL of a mixture containing 250 
ng/pL of a4 cRNA and 50 ng/pL of (32 cRNA was injected (5:1 ratio of (a4 to P2). Expression of 
LS receptors was achieved by injecting 50 nL of a mixture of 50 ng/pL a4 cRNA and 250 ng/pL 
P2 cRNA (1:5 ratio of a4 to P2). Expression of a7 nACh was achieved by injecting 50 nL of 250 
ng/pL of a7 cRNA. The EC50 values obtained for ACh induced currents on the HS and LS 
subtypes obtained from these injection ratios were verified by electrophysiology assays as
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described below and found to compare well with published values for the (a4)2(P2)3 (HS) and 
(a4)3(p2)2 (LS) receptors (Zwart and Vijverberg, 1998; Moroni et al., 2006a). EC50 values and 
response profiles indicated the expression of predominantly the HS or LS receptor subtypes 
although it is likely that both are present in each experiment (see results section).
5.3.4 Two-Electrode Voltage Clamp.
Recordings were performed using an automated two-electrode voltage-clamp system 
incorporating an OC-725C oocyte clamp amplifier (Warner Instruments, Hamden, CT) coupled to 
a computerized data acquisition (Datapac 2000, RUN technologies, Mission Viejo, CA) and 
autoinjection system (Gilson, Middleton, Wl). Recording and current electrodes with resistance 1­
4 MQ were filled with 3 M KCI. Details of the chambers and methodology employed for 
electrophysiological recordings have been described earlier (Joshi et al., 2004). Oocytes were 
held in a vertical flow chamber of 200 pL volume, clamped at a holding potential of -60 mV and 
perfused with various ND-96 recording buffers. Three different ND-96 recording buffers were 
used in these experiments: HEPES-ND96 (96 mM NaCI, 2 mM KCI,1.8 mM CaCI2, 1 mM MgCI2, 
5 mM HEPES); Tris ND-96 (96 mM NaCI, 2 mM KCI,1.8 mM CaCI2, 1 mM MgCI2, 5 mM Tris- 
HCL); phosphate ND-96 (96 mM NaCI, 2 mM KCI, 1.8 mM CaCI2, 1 mM MgCI2, 2 mM 
phosphate). The pH for all three buffers was 7.4. Osmolarity differences between the three 
recording buffers were minimal based on calculated osmolarities (HEPES buffer: 214.4 mOsm, 
Phosphate Buffer: 212.4 mOsm, Tris buffer: 219.4 mOsm). While it is clear that osmolarity 
differences can affect ion channel function, all running buffers, wash solutions and test solutions 
containing agonists or modulators (including HEPES) were made from common stock solutions to 
minimize any effects on osmolality. In addition, oocytes were equilibrated in the appropriate buffer 
for at least seven minutes prior to exposure to agonists. To assure that observed effects were not 
a result of slight pH changes on addition of test compounds, the pH of every buffer and test 
solution was verified using a calibrated pH meter. Addition of HEPES to phosphate and Tris 
buffers did not alter the pH for HEPES concentrations less than 100 mM thus pH changes were 
not observed for most solutions. In the case of solutions containing 100 mM and 300 mM HEPES 
or Tris, pH decreased slightly to 7.3. The pH of these solutions were corrected to pH 7.4 using 
NaOH (typically >200 ml_/100 mL of test solution of 1M NaOH). Oocytes were perfused with the 
different recording buffers at a rate of 20 mL/ min. Test compounds were dissolved in buffer and 
injected into the chamber at 20 mL/min using a Gilson auto-sampler injection system (Joshi et al., 
2004).
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5.3.5 Electrophysiology Dose-Response Experiments.
Dose-response curves for the endogenous nAChR agonist AcetylcholineCI, (ACh) 
(Sigma-Aldrich) were determined for both HS and LS receptors at concentrations ranging from 
0.1 pM- 3 mM in all three buffer systems. The ACh dose-response curves on a l  nAChR were 
conducted at concentration ranges from 0.1 pM - 1 mM in HEPES buffer and 0.001 pM - 1 mM 
ACh in the phosphate buffer. Dose-response curves for HEPES and Tris-HCI were determined by 
co-application with either 10 pM ACh (EC75) for HS receptors, 100 pM ACh (EC75) for LS 
receptors with HEPES or Tris-HCI at concentrations ranging from 0.01 pM -  300 mM. The a l  
nAChR dose-responses curves for HEPES were determined by co-application with 1 mM ACh for 
nAChR at HEPES concentrations ranging from 0.01 pM -  300 mM. HEPES and Tris dose- 
response curves were performed with phosphate ND-96 as the recording buffer. The effects of 
dFBr on Tris inhibition was determined by co-exposure of varying concentrations of ligand co­
applied with 1 pM dFBr.
Verification of HEPES as an allosteric modular was achieved by conducting ACh 
does/response curves co-applied with 100 pM HEPES. Zn2+ was confirmed as a modulator by 
co-applying a range of Zn2+ concentrations (0.001 pM -  1 mM) with either 10 pM ACh (high- 
sensitivity receptors) or 100 pM (low-sensitivity receptors). Changes in dFBr efficacy was 
evaluated by dose-response curves of increasing dFBr concentrations ranging from 0.001 pM -  
100 pM dFBr co-applied with 10 pM ACh for high receptors or 100 pM ACh for low-sensitivity 
receptors. To verify that the phosphate ND-96 buffer did not alter receptor lmax, a series of buffers 
with different phosphate concentrations (0.5 mM, 1 mM and 2 mM phosphate) were tested at the 
ACh lmax concentrations (300 pM ACh for high-sensitivity receptors and 1 mM ACh for low- 
sensitivity).
In order to compare responses from different oocytes, individual responses to drug 
application were normalized to control responses elicited using 10 pM ACh for HS receptors or 
100 pM ACh for low-sensitivity receptors. Data were collected from at least four replicate 
experiments using oocytes obtained from at least two different frogs.
5.3.6 Data Analysis and Statistics.
Dose-response curves were fit using non-linear curve fitting and GraphPad Prism 
Software (San Diego, CA) with standard built-in algorithms. pEC50 (-log EC50) and EC50 values 
were determined by fitting concentration/response data to a single site binding model:
r b + (T -  b)T  „  ^  m a x  /  ^  ^
\ -f \ 0 ( L°gEC50 - IL ] ) * ”#
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Where I is the current elicited on application of agonist, b is the baseline current in the absence of 
ligand, L is the ligand concentration and nH is the Hill slope. The EC50 value is the concentration 
of agonist producing currents equal to one half the maximal current (lmax)- lmax values for ACh 
were evaluated to compare the changes in apparent efficacy as a result of co-application by 
HEPES, Tris, dFBr or Zn2+.
Dose-response curves were fit using a non-linear curve fitting algorithm and GraphPad 
Prism Software (San Diego, CA). PAMs often produce bell-shaped dose-response curves with 
both potentiating and inhibiting phases. HEPES, dFBr and Zn2+ displayed this typical dose- 
response profile. pEC50 (-log EC50) and plC50 (-log IC50) values were determined in these cases 
by simultaneously fitting both the potentiation and inhibition phases using equation 2. Similar 
equations have been used previously to examine bell-shaped PAM data (Harvey et al., 1999; 
Hsiao et al., 2001; Hsiao et al., 2006; Kim et al., 2007; Weltzin and Schulte, 2010).
j    j  . (  (P la tea u l-Im oxca ic )  \  , / (P la teg u 2 - I maxcaic)  \
-  m a x c a lc  V1+ 10(a o sE C 50-Loa x).n//1) /  \ 1+ 10(aogX-LogIC50>nH2) )  '  '
I is the current elicited on application of agonist, lmaxcaic is the calculated maximum induced
current of both the potentiation and inhibition curves. Plateau 1 is the initial current prior to 
addition of the modulator and Plateau 2 is the plateau after the inhibition of the agonist response 
at high concentrations of the modulator. The EC50 value is the concentration of modulator 
producing currents equal to one half the calculated maximum current ( lm a x c a i c )  during co­
application with agonist. The IC50 is the concentration of modulator required to inhibit the 
response to 1/2 Laxcaic ■
Equation 2 describes the sum of two Hill equations and is considered an appropriate 
model for two interacting binding sites (Kim et al., 2007; Weltzin and Schulte, 2010; Pandya and 
Yakel, 2011). This is in contrast to use of the product of Hill Equations described by Kasai et al. 
which is more appropriate for two independent binding sites (Kasai, 1998). Since the 
simultaneous action of ACh and the potentiator alter the protein conformation (channel opening) 
to expose a site for binding of the inhibitor (open channel block), the two processes are not 
independent and a summation model seems more appropriate.
Simultaneous fitting of two Hill equations can prove difficult if the EC5o and IC50 values
are close together due to the inability to collect data near the value of lm a x c a ic -  In these cases,
insufficient data is present to fully define the curve and some constants must be approximated for 
the fit to converge and the appropriate EC50 and IC50 values determined. In order to overcome 
these limitations, Hill slopes for potentiation and inhibition were typically fixed at +1 and -1 
respectively unless otherwise indicated.
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Despite our hypothesis of interdependence of the potentiating and inhibiting binding site, 
it is possible that a distinct mechanism of inhibition is present and the two binding sites may, in 
fact, be independent. Separate potentiating and inhibiting sites not allosterically linked as 
postulated by Moroni et al. (2008) for Zn2+ would be best fit by a multiplicative model. We thus 
compared curve fits using the summation model to the multiplicative model. Comparison of the 
two models showed that the fits were significantly (p = 0.0192; F=5.679). The summation model 
better fit the data and hence we used this model, consistent with our hypothesis of dependent 
sites, to calculate the data provided in the results section (see Results section for statistical 
analysis of these curve fits).
Inhibition curves were fit using non-linear curve fitting and GraphPad Prism Software 
(San Diego, CA) with standard built-in algorithms. plC50 (-log EC50) values were determined by 
fitting concentration/response data to a log(inhibitor) verses response binding model:
I - Plateau2 +  (3)V f l + l O ' - & a —L o g 1 L 5 0 ) \  /
Where I is the current elicited on application of agonist and modulator, Plateau 1 is the current 
elicited by the agonist prior to addition of the inhibitor. Plateau 2 is the current at saturating 
concentrations of inhibitor. The IC50 is the concentration of modulator that inhibits the current by 
1/2 lmax In order to permit comparison of data from different oocytes, responses for all test 
compounds were normalized to the currents obtained with 10 pM ACh for HS receptors and 100 
pM ACh for LS receptors.
Statistical comparisons of pECso or pICso values used an unpaired t-test with p values 
calculated based on the null hypothesis. One way ANOVA was used to compare lmax values in 
different ND-96 recording buffers for both high and low-sensitivity receptors.
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5.4.1 HEPES is an Allosteric Modulator of the High-sensitivity a4(32 nAChR.
To explore the effects of HEPES on HS and LS preparations of a4p2 receptors, 
increasing concentrations of HEPES (0.01 pM- 300 mM) were co-applied with ACh at a 
concentration equal to the ACh EC75 (10 pM for HS receptors or 100 pM for LS receptors) in a 
phosphate buffered ND-96 recording solution (pH 7.4) on oocytes expressing predominantly HS 
or LS a4(32 stoichiometries. Test solutions were monitored for any changes in pH. No changes in 
pH were observed at HEPES concentrations <100 mM. For concentrations S: 100 mM a slight 
decrease to pH 7.3 was observed and the solution adjusted to pH 7.2 using NaOH as described 
in the methods. With co-application of < 300 pM HEPES (potentiating concentrations) and 10 pM 
ACh on HS receptors, the response profile showed a slight sharpening of the response peak, 
larger overall responses and a faster return to the baseline (Figure 5.1 A -  responses b-d). 
Application of > 300 pM HEPES and 10 pM ACh further sharpened the response peak but also 
decreased the overall amplitude of the response (Figure 5.1A -  responses b-d). In addition a 
possible tail current is evident at HEPES concentrations >100 pM (Figure 5.1A, trace f), 
suggesting a possible open-channel block by HEPES. On LS receptors, increasing 
concentrations of HEPES co-applied with 100 pM ACh inhibited responses with a decrease in the 
overall amplitude of the response and a decrease in sharpness of the peak (Figure 5.1 B -  
responses b-e). No significant potentiation was evident when HEPES was co-applied with ACh on 
LS receptors.
5.4 Results.
Figure 5.1 HEPES dose-response curves on high- and iow- sensitivity receptors.
HEPES and the appropriate concentration of ACh were co-applied to Xenopus oocytes 
expressing HS (mRNA injected at a ratio of 1a:5|3) or LS receptors (mRNA injected at a ratio of 
5a: 1(3). Responses were obtained from Xenopus oocytes under voltage clamp conditions (Vm = - 
60 mV). The peak currents were measured and responses normalized to currents elicited by ACh 
applied alone to the same oocyte. Each data point represents the combined data from at least 
four different experiments from a minimum of two different oocytes harvested from different frogs. 
Error bars indicate ± SEM. pEC50, pICso, lmax and Hill slope (nH) were calculated using non-linear 
curve fitting algorithms. Response traces were recorded from a single oocyte expressing HS and 
LS receptors. The solid bar above the response trace indicates the time the oocyte was exposed 
to HEPES and ACh (3s). The response trace scale bars is 1 pA on the y-axis and 3s on the x- 
axis. A) Top: Co-application of HEPES and 10 pM ACh concentration response curves on HS 
and HSB2D218A receptors. Bottom: Response traces for co-application of varying concentrations 
of HEPES and 10 pM ACh on HS (left) and HSB2D218A (right) receptors. B) Top: Co-application 
of HEPES and 100 pM ACh concentration response curves on LS and LSB2D218A receptors. 
Bottom: Response profiles for co-application of HEPES and 100 pM ACh concentration response 
curves on LS (left) and LSB2D218A (right) receptors. C) Left: Co-application of 100 pM HEPES 
and 10 pM ACh on HS receptors. Right: Response traces for co-application of 100 pM HEPES 
and 10 pM ACh on HS receptors.
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Bell-shaped dose-response curves were obtained when peak amplitudes from response 
traces were plotted against HEPES concentration (0.01 pM- 300 mM HEPES co-applied with 10 
pM ACh on high-sensitivity receptors) (Figure 5.1A). Concentrations of HEPES < 300 pM 
potentiated ACh induced currents by 180% (the calculated lmax was 2.7 ± 3.1). The pEC50 value 
for HEPES potentiation was 5.2 ± 0.9 (EC50 = 7.1 pM). HEPES concentrations > 300 pM 
produced a biphasic inhibition of the ACh induced responses. The first inhibitory phase appeared 
to inhibit only the HEPES potentiated portion of the response and plateaued at 1.0 (the 
normalized, unpotentiated response amplitude using 10 pM ACh). A second phase inhibited the 
response amplitude below 1.0. The pICso value for the first inhibitory phase was 3.4 ± 0.4 (IC50 = 
430 pM) (Figure 5.1A) while the pICso of the second inhibitory phase was estimated to be 0.4 ± 
0.8 (IC50 ~ 420 mM). The second inhibitory component of HEPES inhibition on HS receptors was 
fit using equation 3 and the curve is indicated by a black, dashed line in Figure 5.1 A to distinguish 
it from the separate bell-shaped curve used to fit dose-response data for HEPES concentrations 
less than 3 mM. On LS receptors, HEPES produced only a single phase inhibitory response with 
a plC50 = 1.0 ± 0.2 (IC50 = 90 mM) (Figure 5.1 B). This is similar to data from previous studies 
which determined the HEPES dissociation rate to be 100 mM on the AChBP, a structural 
homolog of nAChRs (Brejc et al., 2001). Coincidentally, minimal net effects of HEPES are seen at 
concentrations between 5 - 1 0  mM (typical concentration in HEPES recording buffers). This may 
be one reason why the functional effects of HEPES potentiation have gone unobserved for so 
many years. Comparison of data from oocytes expressing predominantly LS and HS receptors 
suggest that HEPES selectively potentiates the HS population compared to the LS stoichiometry. 
The application of HEPES alone to a4|B2 nAChR expressing oocytes produced no induced 
current (data not shown).
HEPES positive modulation was further investigated by applying the maximum 
potentiating concentration of HEPES (100 pM) over a range of ACh concentrations (0.1 pM -  1 
mM) to the HS preparation. The response profiles displayed overall larger responses and sharper 
response peaks compared to those obtained by exposure to ACh alone (Figure 5.1C). Results 
show no significant change in pEC50 values for stimulation by ACh in the presence of 100 pM 
HEPES (p = 0.1687). In the absence of HEPES, the pEC50 for ACh stimulation was 5.4 ± 0.1 
(EC50 = 3.7 pM). In the presence of 100 pM HEPES the pEC50 was 5.1 ± 0.3 (EC50 = 8.6 pM). 
Application of 100 pM HEPES produced a 285% potentiation of the ACh induced lmax currents 
(Figure 5.1 C). The Hill slope for ACh stimulation appeared to decrease with application of 100 pM 
HEPES (from 0.97± 0.11 to 0.49 ± 0.25), but differences were not significant (p=0.1773).
Based on the observation that HEPES selectively potentiates receptors in the HS 
preparation (presumably due to high expression levels of the HS stoichiometry), it appears that
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allosteric modulation by HEPES may be HS specific. Comparison of the HS and LS a4p2 
nAChRs reveals that the high-sensitivity subtype ((a4)2(P2)3) may contain a p+/p- interface which 
is not present in the low-sensitivity subtype ((a4)3(p2)2). In contrast, the LS receptors contains an 
a+/a- interface which may not be present in the HS receptor. Both receptor stoichiometries 
contain p+/a- interfaces. Since potentiation by HEPES was only seen in oocytes expressing HS 
receptors, we hypothesized that the P+/p- interface likely contains the binding site involved in 
HEPES potentiation. As determined from bell-shaped dose-response curves, the EC50 for HEPES 
potentiation at this site is approximately 7.1 pM (see section above results). By comparing the 
sequence of AChBP and the P2 subunit, we hypothesized that HEPES potentiation of ACh 
responses could involve unique residues found in an allosteric binding cleft in a region 
comparable to the orthosteric binding site for ACh. Two cysteine residues located in the C-loop 
of the orthosteric site (C187 and C188, AChBP numbering) of the AChBP and a nAChR subunits 
are involved in ligand binding. We hypothesized that the C-loop on the principal face of the p2 
subunit might form an allosteric binding domain for HEPES. In particular, one of the two vicinal 
aspartates found in the C-loop (D218) on the principal face of the P2 subunit (P2+) may contribute 
to HEPES- interactions (P2 numbering; D188 in the AChBP sequence. Amino acids are 
numbered from the initial methionine of the unprocessed subunit. To find the amino acid position 
in the mature form subtract 30 resides from the number for a4 and 25 residues for P2 (Moroni et 
al., 2008). The D218 residue described here is in the identical position to that hypothesized by 
Moroni to form part of the Zn2+ inhibitory binding site (Moroni et al., 2008).
To examine the possibility that the p+ face may be involved in HEPES binding, a alanine 
mutation of P2D218 was constructed and injected into oocytes with a 1:5 or 5:1 ratio of a4: 
P2D218A mRNA (Figure 5.1 A and B, right panels). For the HS preparation, P2D218A responses 
obtained by application of ACh alone showed similar response kinetics compared to wild-type 
receptors but the induced current in mutated receptors was much smaller than wild-type 
receptors. This observation may suggest that some alteration in receptor function, conductance 
and/or expression may be occurring with p2D218A receptors (Figure 5.1A, bottom. Right and left 
set of responses, trace a). Dose-response curves for ACh stimulation of oocytes expressing HS 
(32D218A receptors produced an EC50 value of 2.1 pM (Figure 5.2C and Table 5.1). This was 
similar to that obtained for wild-type (3.7 pM) receptors with the identical injection ratio (1:5). The 
Hill slopes were also similar for HS wild-type receptors (1.0 ± 0.2) and HS (32D218A receptors 
(0.9 ± 0.3). These results indicate that the 1:5 injection ratio p2D218A receptors are likely 
assembling similar to the HS wild-type receptors and are predominantly HS receptors with a 
presumed stoichiometry of (a4)2(p2D218A)3.
188
For oocytes injected with a 5:1 ratio of a4:(B2D218A, ACh alone response amplitudes 
appeared to decrease with a loss of the sharp response peak and altered desentization (Figure 
5.1B, bottom, right and left set of response traces, trace a). Results of the (B2D218A LS dose- 
response curves for ACh stimulation produced an EC50 value of 58 pM, similar to those obtained 
for wild-type receptors with the 5:1 injection ratio (32 pM) (Figure 5.2D and Table 5.1). The Hill 
slopes were also similar for the LS wild-type (1.2 ± 0.2) and [32D218A receptors (0.8 ± 0.2) 
(Figure 5.2 and Table 5.1). These results suggests that the 5:1 injection ratio [32D218A receptors 
assembled similar to wild-type receptors with the presumed (a4)3(p2D218A)2 LS stoichiometry. 
Modified response kinetics suggests the P2D218A mutation alters receptor function, conductance 
and/or expression.
We evaluated the effects of HEPES on HS and LS P2D218A nAChRs preparations. 
Oocytes injected with either a 1:5 or 5:1 ratio of a4: P2D218A mRNA were exposed to increasing 
concentrations of HEPES (0.001 pM-300 mM) and ACh (10 pM the 1:5 ratio or 100 pM for the 5:1 
ratio) in phosphate buffered ND-96 recording solution. In contrast to wild-type receptors, the 
P2D218A mutant abolished HEPES potentiation in the HS preparation (Figure 5.1A, dose- 
response curve). Inhibition by HEPES at high concentrations (> 3 mM) was evident in both HS 
and LS preparations of (32D218A receptors and was similar to that observed for wild-type 
receptors. For HS p2D218A receptors, HEPES inhibited ACh responses with a calculated plC50 
= 0.23 ± 0.7 (IC50 = 590 mM). For LS P2D218A receptors the plC50 for inhibition of ACh 
responses was 0.78 ± 0.23 (IC50 = 170 mM). These data are not statistically different from the 
inhibition observed on wild-type receptors at high concentrations of HEPES (p = 0.9144 for HS 
and p = 0.4304 for LS receptors).
The differences in response profiles on both the HS and LS P2D218A receptors 
compared to wild-type receptors suggest that the P2D218 residue may play a role in receptor 
function. However, the eradication of HEPES potentiation by this mutation suggests that the 
binding site for HEPES potentiation involves D218 on the p2+ face.
5.4.2 Minimal Changes Were Observed in ACh Dose-Response Curves When HEPES and
Phosphate ND-96 Recording Buffers.
To ensure that the effects seen with HEPES buffer were not attributable to the presence 
of phosphate in the phosphate buffered ND-96, ACh dose-response curves were compared on 
high and low-sensitivity receptors in both HEPES and phosphate containing buffers (Figure 5.2). 
Responses to ACh on the high-sensitivity oocyte preparation appeared similar in both phosphate 
and HEPES buffer. Different amplitudes can be observed in the responses shown in Figure 5.2 (A
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and C) but these can be attributed to different expression levels in the different oocytes tested. 
For LS preparations, slight variations in response characteristics were observed mostly with 
respect to the sharpness of the peak response at higher ACh concentrations (Figure 5.2, B and 
D).
Figure 5.2 ACh dose-response curves in HEPES and phosphate ND-96 recording 
buffer.
Xenopus oocytes expressing high-sensitivity a4|B2 nAChR (HS) (mRNA injected at a ratio of 
1a:5(3) or low-sensitivity receptors (LS) (mRNA injected at a ratio of 5a: 1 (B) were exposed to 
increasing concentrations of ACh in HEPES (A and B) or Phosphate (C and D) recording buffer. 
Individual peak amplitudes were normalized to the lmax on the same oocyte. Response traces 
were recorded from a single oocyte expressing HS and LS receptors. The solid bar above the 
response trace indicates the time the oocyte was exposed to varying concentrations of ACh. 
pEC50 and nH values (see table 5.1) were determined using non-linear curve fitting as described 
in the methods. Data points represent at least 4 replicate values obtained from a minimum of two 
oocytes harvested from different frogs. Error bars indicate ± SEM.
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Table 5.1. Summary of the calculated results determined from ACh dose-response 
curves in HEPES and phosphate ND-96 recording buffer.
Receptor Buffer
pECso ± SEM 
(EC50 pM)
nH ± SEM
HS HEPES
5.7 ±0.1 
(2 .2 )
0.9 ±0.2
HSP2D218A HEPES
5.5 ±0.1 
(3.5)
1.1 ±0.3
LS HEPES
4.3 ±0.1 
(54)
1.2  ± 0.1
LSp2D218A HEPES
3.83 ± 0.04 
(150)
1.0  ± 0.1
HS Phosphate
5.4 ± 0.1 
(3.7)
1.0 ± 0.2
HSp2D218A Phosphate
5.7 ±0.2 
(2 .1 )
0.9 ±0.3
LS Phosphate
4.5 ± 0.1 
(32)
1.2  ± 0.2
LSP2D218A Phosphate
4.2 ± 0.2 
(58)
0.8 ± 0.2
ACh dose-response curves determined from peak currents showed no effect of buffer 
composition on ACh pECso (p = 0.2365) and Hill slope (p = 0.7478) for HS receptors (Figure 5.2A 
and C, and Table 5.1). A slight, but significant change in pEC50 for ACh stimulation was observed 
for LS receptors (p = 0.0277) although there was no significant change in Hill slopes (p = 0.9162) 
(Figure 5.2B and D, and Table 5.1). Mutation of 32D218 to alanine had no effect on ACh pEC50 
values for HS receptors in either phosphate or HEPES buffers (Figure 5.2 A and C, and Table
5.1) (p = 0.3891). For LS receptors, the pECso values for ACh stimulation were significantly 
different in both phosphate and HEPES buffer (p = 0.0246) (Figure 5.2 B and D, and Table 5.1). 
The Hill slopes for ACh stimulation of the 32D218A HS and LS receptors in either the HEPES or 
phosphate buffers were not significantly different (HS receptors p = 0.6733; LS receptors p = 
0.3760) (Figure 5.2 and Table 5.1).
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As seen in Figure 5.2, the phosphate buffered ND-96 had minimal or no effect on ACh 
EC50 values for either receptor preparation. To further evaluate possible effects of the phosphate 
buffer, lmax values obtained at saturating concentrations of ACh in different concentrations of 
phosphate buffer were determined. Varying concentrations of phosphate buffer ranging from 0.5 
mM to 2 mM were used to prepare phosphate ND-96 recording solutions. The pH for each 
recording buffer was 7.4. The lmax currents induced by ACh for each stoichiometry (300 pM and 1 
mM for HS and LS receptors respectively) were measured for each phosphate buffer. Each 
phosphate concentration course was run on the same oocyte. Alterations in the ACh induced 
current in different buffers containing different concentrations of phosphate would indicate 
interactions of phosphate with the receptors and/or ligands. We saw no change in the ACh 
induced lmax current for any concentration of phosphate buffer between the HS (ANOVA p = 
0.6751) and LS (ANOVA p = 0.8921) a4(32 receptors (results not shown). No induced responses 
were seen with application of different phosphate solutions when applied alone (without agonist). 
These data show no apparent effect of the phosphate buffer on a4p2 receptors making it a good 
choice for evaluation of a4p2 receptor function.
5.4.3 Tris Buffer
As a result of our discovery that HEPES modulates a4(32 nAChR function, we also 
considered whether or not the commonly used Tris buffer had any effect on a4p2 receptors. Like 
HEPES, Tris is a polar molecule that is a member of the family of Good’s buffers and is used as a 
physiological buffering agent. We examined the effect of Tris on ACh induced responses on HS 
and LS subtypes of the a4p2 nAChR. Increasing concentrations of Tris (0.01 pM - 300 mM) were 
co-applied with either 10 pM or 100 pM ACh to HS and LS oocytes preparations using a 
phosphate ND-96 recording buffer. We found that Tris inhibits both HS (pICso = 2.0 ± 0.1; IC50 = 
10 mM]) and LS a4p2 nAChRs (plC50 = 2.2 ± 0.1; IC50 = 6.8 mM) (Figure 5.3). The plC50 values 
were not significantly different from each other (p = 0.2590).
To examine possible effects of Tris buffer on a high efficacious PAM, we used the a4p2 
selective compound desformylflustrabromine (dFBr) (Sala et al., 2005; Kim et al., 2007). dFBr 
was co-applied with ACh and Tris in phosphate buffered ND-96 recording solution. Potentiation of 
Tris and ACh induced responses by 1 pM dFBr did not significantly change the Tris pICso of high- 
sensitivity receptors (plC50 = 2.2 ± 0.1; IC50 = 6.8 mM) (p = 0.3422) (Figure 5.3A). For LS 
receptors, pICso values with and without 1 pM dFBr (plC50 = 1.3 ± 0.2; IC50 = 47 mM) were 
significantly different from each other (Figure 5.3B). dFBr produced potentiation of -360% when 
co-applied with 10 pM ACh and Tris (Tris concentrations < 300 pM) on HS receptors (Figure 
5.3A). On the HS receptors, co-application of 1 pM dFBr, Tris (Tris concentrations < 1000 pM)
193
and ACh produced responses potentiated by 280% compared to Tris and ACh alone (Figure 
5.3B). dFBr potentiation was reduced by -50% at Tris concentrations > 1 mM on HS receptors 
and > 30 mM on LS nAChRs. Application of Tris alone did not induce currents. Given that Tris 
did inhibit ACh induced currents on HS receptors at concentrations greater than 1 mM and 
inhibited dFBr potentiation by -50% at Tris concentrations >1 mM, we found Tris to be an 
inadequate buffer agent.
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Figure 5.3 Tris concentration response curves for co-application of ACh and 1 pM 
dFBr on high- (HS) and low- (LS) sensitivity a4p2 receptors.
Xenopus oocytes expressing HS (mRNA injected at a ratio of 1a:5P) or LS (mRNA injected at a 
ratio of 5a:1p) receptors were exposed to increasing concentrations of Tris and ACh (at 
concentrations equal to the EC75). Responses were potentiated with 1 pM of the high efficacious 
allosteric modulator desformylflustrabromine (dFBr). Individual peak amplitudes were normalized 
to those elicited by the identical concentration of ACh alone on the same oocyte. pEC50, plC50 
and nH values were determined using non-linear curve fitting as described in the methods. Data 
points represent at least 4 replicate values obtained from a minimum of two oocytes harvested 
from different frogs. Error bars indicate ± SEM.
5.4.4 The a7 nAChR is Unaffected by HEPES.
The a7 nAChR is one of the most common nAChRs found in the central nervous system. 
The expression of a7 nAChRs are altered in many neurological disorders including Alzheimer’s 
disease and Schizophrenia (Levin and Rezvani, 2007). The effects we observed on a4p2 
stoichiometries led us to investigate possible interactions of HEPES’s with the a7 nAChR 
subtype. ACh dose-response curves were determined from peak currents obtained from oocytes 
expressing a l  receptors in either HEPES or phosphate ND-96 recording buffers (Figure 5.4A). 
For ACh stimulation, pECso values were identical in both HEPES and phosphate buffers (HEPES:
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pEC5o = 3.8 ± 0.1; EC50 = 146 pM. Phosphate buffer: pEC50 = 3.8 ± 0.1; EC50 = 177 pM) (p = 
0.5893). The Hill slopes were 1.1 ± 0.2 and 0.79 ± 0.13 for the HEPES and phosphate recording 
buffers respectively (p = 0.2061).
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Figure 5.4 a7 ACh dose-response curves obtained using HEPES or phosphate ND- 
96 recording buffers.
Xenopus oocytes expressing a7 receptors were exposed to increasing concentrations of ACh in 
HEPES or phosphate recording buffer (A). Individual peak amplitudes were normalized to the lmax 
on the same oocyte. pEC^ and nH values were determined using non-linear curve fitting as 
described in the methods. B) Increasing concentrations of HEPES co-applied with 1 mM ACh on 
a7 receptors. Responses were normalized to 1 mM ACh in both the HEPES and phosphate 
buffer. Data points represent at least 4 replicate values obtained from a minimum of two oocytes 
harvested from different frogs. Error bars indicate ± SEM.
To investigate the effects of HEPES on the a7 nAChR, we co-applied varying 
concentrations of HEPES (0.01 pM- 300 mM) with 1 mM ACh (ACh EC75) to oocytes expressing 
a7 receptors. Unlike a4(32 stoichiometries, HEPES showed no effect on a7 receptors. Figure 
5.4B shows no potentiation or inhibition of responses induced by 1 mM ACh for HEPES 
concentrations up to 300 mM. This is further evidence of the selectivity of HEPES potentiation to 
HS ci4p2 receptors.
5.4.5 HEPES Effects Other PAM Interactions with a4|32 nAChR.
In light of our study showing that HEPES modulates a4|32 nAChR, we hypothesized that 
HEPES may have altered the results of previous studies using other modulators. We investigated 
the possible differences in observed effects of the previously tested a4(32 PAMs 
desformylflustrabromine and Zn2+using both HEPES and phosphate ND-96 recording buffers.
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5.4.5.1 Desformylflustrabromine Modulation of High- and Low-sensitivity a4/32 Receptors in 
HEPES ND-96 Recording Buffer.
Desformylflustrabromine (dFBr) is novel PAM that potentiates ACh induced currents of 
a4p2 nAChR by 265% at concentrations < 10 pM and inhibits at concentrations > 10 pM (Sala et 
al., 2005; Kim et al., 2007; Weltzin and Schulte, 2010a). This compound appears to potentiate 
a4(B2 nAChRs by shifting the equilibrium between open and desensitized conformations (Weltzin 
and Schulte, 2010a). Inhibition caused by application of high concentrations of dFBr has been 
shown to be the result of open channel block (Weltzin and Schulte, 2010a). These experiments 
were conducted using a 5 mM HEPES- ND-96 recording buffer. Given the current findings it is 
possible that the results found with dFBr have been altered by the presences of HEPES.
Differences in dFBr potentiation of ACh induced responses on HS and LS a4p2 nAChR 
in a HEPES and phosphate buffered ND-96 recording solution were investigated. A range of dFBr 
concentrations (0.001 pM - 100 pM) were co-applied with either 10 pM or 100 pM ACh on 
oocytes expressing HS and LS a4p2 nAChRs respectively. Both receptor types were potentiated 
by dFBr. Results showed that in HEPES ND-96 recording buffer, the pEC50 values for dFBr on 
the two receptor types were not significantly different (p = 0.4040) (Figure 5.5 A and Table 5.2).
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Figure 5.5 dFBr concentration responses curves for high- (HS) and low- (LS) 
sensitivity a4p2 nAChR obtained using HEPES or phosphate ND-96 buffers.
Responses were obtained from Xenopus oocytes under voltage clamp conditions (Vm = -60 mV). 
Xenopus oocytes expressed either HS (mRNA injected at a ratio of 1a:5p) or LS (mRNA injected 
at a ratio of 5a:ip) receptors. A) Dose-response curves obtained from co-application of dFBr and 
ACh (concentration equal to the ACh EC75) on HS and LS a4|32 nAChR in HEPES buffer. B) 
Dose-response curves obtained from co-application of dFBr and ACh (concentration equal to the 
ACh EC75) on HS and LS a4(32 nAChR in phosphate recording buffer. Individual peak amplitudes 
were normalized to the response obtained using an identical concentration of ACh alone (equal to 
the ACh EC75). pEC50, plC50 and nH values (see Table 5.2) were determined using non-linear 
curve fitting as described in the methods. Data points represent at least 4 replicate values 
obtained from a minimum of two oocytes harvested from different frogs. Error bars indicate ±
Log [dFBr] (M) in HEPES Buffer Log [dFBr] (M) in Phosphate Buffer
SEM.
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Table 5.2. Summary of calculated results from dFBr concentration responses curves 
for high- (HS) and iow- (LS) sensitivity a4(32 nAChR obtained using HEPES 
or phosphate ND-96 buffers.
Receptor Buffer
pEC50 
(EC50 pM)
lmax
pICso 
(IC50 pM)
HS HEPES
5.6 ±0.5 
(2.5)
370%
4.3 ±0.8 
(50)
LS HEPES
6.2 ± 0.4 
(0.63)
260%
4.0 ±1.3 
(100)
HS Phosphate
5.5 ±0.3 
(3.2)
360%
4.1 ±0.1 
(79)
LS Phosphate
5.9 ±1.1 
(1.3)
370%
5.2 ± 0.6 
(6.3)
The amount of potentiation produced by dFBr on the ACh induced currents using a 
HEPES ND-96 recording buffer was greater on the HS receptors compared to the LS 
stoichiometry. The LS receptors were potentiated 260% while the HS receptors were potentiated 
by 370%. This finding suggest that either; 1) dFBr has a higher efficacy on the HS receptor; 2) 
The potentiating effects of HEPES and dFBr produce an additive effect on the HS stoichiometry; 
or 3) competition between HEPES and dFBr is causing a reduction in the apparent efficacy on the 
LS stoichiometry.
dFBr Modulation of High- and Low-sensitivity a4/32 Receptors in Phosphate ND-96 Recording 
Buffer.
To evaluate possible differences of dFBr-receptor interactions without the conflicting 
actions of HEPES, dFBr dose-response curves were performed in a phosphate buffered ND-96 
recording solution. Varying concentrations of dFBr (0.001 pM - 100 pM) were co-applied with 
either 10 pM or 100 pM ACh on oocytes expressing HS or LS receptors. Results showed that the 
amount of dFBr potentiation of ACh induced responses using phosphate buffer was similar for HS 
(360%) and LS (370%) receptors (Figure 5.5B and Table 5.2). The pEC50 values for dFBr 
potentiation were also not significantly different between HS and LS receptors tested in 
phosphate buffered ND-96 (Figure 5.5B and Table 5.2) (p = 0.6362). The pECso values for dFBr
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potentiation of HS (p = 0.7459) and LS (p = 0.8377) nAChRs were also not significantly different 
from those determined in HEPES ND-96 recording buffer although the degree of potentiation of 
HS receptors by dFBr was decreased in HEPES relative to phosphate buffer (Figure 5.5 and 
Table 5.2).
No significant difference in plC50 values were observed for inhibition of ACh induced 
currents by application of high (>10 pM) dFBr concentrations using either HEPES or phosphate 
buffer on HS or LS receptors (HS, p = 0.7683); LS, p = 0.4040) (Figure 5.5 A and B and Table
5.2). In addition no change was observed in dFBr plC50 values for HS or LS receptors in HEPES 
buffer (p = 0.8485). An increase in the pICso value on the LS receptors was seen compared to the 
HS receptor in phosphate buffered ND-96 (p = 0.0435) (Figure 5.5B and Table 5.2).
5.4.5.2 Zn2+ Modulation of Low and High-sensitivity a4(i2 Receptors in HEPES ND-96 Recording 
Buffer.
Zn2+ has been reported to be a selective LS receptor PAM and an allosteric inhibitor of 
HS receptors (Hsiao et al., 2001; Hsiao et al., 2006; Moroni et al., 2008). Based on data showing 
decreased inhibition of HS(32D218A receptors by Zn2+and enhanced potentiation of LS(32D218A 
receptors, Moroni et al., (2008) have suggested that Zn2+ inhibits a4p2 receptors by binding to an 
allosteric inhibitory site at the p+/a- interface. Thus P2D218 is apparently involved with binding of 
Zn2+. Mutation of a a4H195, located on the -  face of the a subunit, abolished potentiation of the 
LS receptor by Zn2+. In combination with the apparent selective potentiation of the LS receptor, 
this suggested that the potentiation site was located at the a+/a- interface on the LS 
stoichiometry. These experiments and others have used a 10 mM HEPES ND-96 recording 
solution to study the modulation of nAChRs by Zn2+ (Hsiao et al., 2001; Hsiao et al., 2006; Moroni 
et al., 2008). As for dfBr above, we re-evaluated Zn2+ modulation in non HEPES containing 
buffers to determine if HEPES might have altered the results of these studies.
In a HEPES ND-96 recording buffer, dose-response curves resulting from co-application 
of Zn2+ (0.001 pM-1 mM) and 10 pM ACh on HS nAChRs produced inhibition of ACh induced 
currents (Figure 5.6A and Table 5.3). Mutation of p2D218Aof this receptor produced a significant
1.3 fold decrease in the plC50 value for Zn2+ inhibition (Figure 5.6A and Table 5.3) (p = 0.0362). 
These results are consistent with previous results of Moroni et al. (2008) and appear to suggest 
that residue P2D218A is involved in Zn2+ inhibition on the HS a4p2 receptor.
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Figure 5.6 Zn2+ concentration responses curve obtained by co-appiication of Zn2+ and ACh 
on high- (HS) and low- (LS) sensitivity a4|32 nAChR using HEPES or phosphate ND-96 
buffer.
Responses were obtained from Xenopus oocytes under voltage clamp conditions (Vm = - 60 mV) 
using Xenopus oocytes expressed either HS (mRNA injected at a ratio of 1a:5p) or LS (mRNA 
injected at a ratio of 5a: 1(3) receptors. A) Dose-response curves resulting from co-application of
Zn2+ and ACh (EC75 concentration) on HS and HS(32D218A receptors in HEPES buffer. B) Dose-
response curves resulting from co-application of Zn2+ and ACh (EC75 concentration) on LS and 
LSp2D218A receptors in HEPES buffer. C) Dose-response curves resulting from co-application 
of Zn2+ and ACh (EC75 concentration) on HS and HS(32D218A receptors in phosphate recording 
buffer. D) Dose-response curves resulting from co-application of Z n + and ACh (EC75 
concentration) on LS and LSp2D218A receptors in phosphate recording buffer. Individual peak 
amplitudes were normalized to those obtained using a concentration of ACh equal to the ACh 
EC75 on the same oocyte. pECso, pICso and nH values (see Table 5.3) were determined using 
non-linear curve fitting as described in the methods. Data points represent at least 4 replicate 
values obtained from a minimum of two oocytes harvested from different frogs. Error bars indicate 
± SEM.
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Table 5.3. Summary of calculated results from Zn2+ concentration responses curve 
obtained by co-application of Zn2+ and ACh on high- (HS) and low- (LS) 
sensitivity a4p2 nAChR using HEPES or phosphate ND-96 buffer.
Receptor Buffer
pECso± SEM 
(EC50 pM)
lmax
pICso ± SEM 
(IC50 UM)
HS HEPES - -
4.9 ±0.3 
(13)
HS32D218A HEPES - -
3.6 ±0.5 
(250)
LS HEPES
4.0 ±0.7 
(100)
170% 2.9 ±2.7 (1260)
LSp2D218A HEPES
4.2 ± 0.4 
(63)
190% 3.2 ±0.6 (630)
HS Phosphate
7.1 ±0.9 
(0.079)
110%
4.7 ±1.1 
(20)
HSP2D218A Phosphate
3.6 ±0.5 
(250)
- -
LS Phosphate 3.8 ±0.8 (160) 140%
3.2 ±1.7 
(630)
LSp2D218A Phosphate - 0%
2.6 ± 0.6 
(2500)
Co-application of Zn2+ (0.001 pM -  1 mM) and 100 pM ACh in HEPES ND-96 recording 
solution on the HS receptor produced a bell-shaped dose-response curve (Figure 5.6B). Zn2+ 
potentiated ACh induced responses at concentrations < 300 pM. Zn2+ concentrations >300 pM 
inhibited ACh induced currents. On oocytes expressing LS(32D218A receptors, dose-response 
curves resulting from co-application of Zn2+ (0.001 pM - 1 mM) and 100 pM ACh in the HEPES 
ND-96 recording buffer showed no significant differences in the pEC50 ( p= 0.8896) or plC50 (p =
0.9054) when compared to wild-type LS receptors (Figure 5.6B and Table 5.3). The lmax appears 
to increase from 170% to 190% with the mutant, consistent with previous results (Moroni et al., 
2008). The increase in Zn2+ potentiation observed with the P2D218A is not likely explained by 
shifts in the ACh dose-response curve.
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5.4.5.3 Zn2+ Modulation of High- and Low-sensitivity a4/32 Receptors in Phosphate ND-96
Recording Buffer.
In phosphate ND-96 buffer, co-application of Zn+ and 10 pM ACh on the HS a4p2 
receptors produced a slight bell-shaped dose-response curve (Figure 5.6C and Table 5.3). 
Mutation of (32D218 to alanine resulted in an apparent rightward shift of the dose-response curve 
and enhancement of the observed potentiated lmax when responses were obtained in phosphate 
ND-96 buffer. The clear enhancement of potentiation was not observed in HEPES buffer. The 
inhibition observed in HEPES buffer for the P2D218A mutation could result from either inhibition 
by HEPES or saturation of a shared Zn2+/HEPES binding site by the high concentrations of 
HEPES present in the buffer. In phosphate buffer, this inhibition is not present thus potentiation is 
observed. It is unclear why potentiation is enhanced by the P2D218A mutation compared to wild- 
type when recorded in phosphate buffer but this could be the result of a differential rightward shift 
in the EC50 and IC50for Zn2+ potentiation and inhibition.
The concurrent application of Zn2+ (0.001 pM - 1 mM) and 100 pM ACh on oocytes 
expressing LS receptors produced bell-shaped dose-response curves in both the HEPES and 
phosphate ND-96 recording buffer. The pEC50 (p = 0.8394) and plC50 (p = 0.9204) values were 
not significantly different between the two buffers (Figure 5.6B and D and Table 5.3). Zn2+ 
potentiation was reduced in the phosphate buffer (140%) compared to the HEPES buffer (190%) 
(Figure 5.6D). In contrast, mutation of P2D218A produced dramatically different effects 
dependent on buffer composition. Mutation of p2D218 to alanine produced slight enhancement 
of potentiation when responses were recorded in HEPES buffer but abolished Zn2+ potentiation 
when using phosphate buffer. This is not easily explained by independent actions of HEPES or 
Zn2+ since simple additive effects would not likely produce these results. The data from both wild- 
type and mutant receptors recorded in both buffers suggest a possible synergistic activity of 
HEPES and Zn2+ that compensates for the effects of the P2D218A mutation. Loss of Zn2+ 
potentiation by the P2D218A mutation in phosphate buffer suggests a role for this residue in Zn2+ 
mediated potentiation of ACh induced currents on LS receptors. plC50 values found using HEPES 
or phosphate buffered ND-96 were not significantly different (p = 0.7593) (Figure 5.6 and Table
5.3). Moroni et al., (2008) previously suggested that the a+/a- interface contains the Zn2+ 
potentiation site. These results appear confounded by the presence of HEPES in the recording 
buffer. Our results suggest a role of the p+ face in Zn2+ mediated potentiation.
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5.5.1 HEPES Modulation of <*4p2 nAChR.
This study investigates the effects of HEPES on HS and LS a4p2 and a7 nAChRs. Our 
results demonstrate HEPES selectively potentiates the HS stoichiometry compared to the LS 
a4p2 and a7 nAChRs. The HS receptor is thought to have a (a4)2(P2)3 stoichiometry with a 
unique p+/p- binding cleft. The putative LS receptor is thought to have a (a4)3(P2)2 stoichiometry 
and does not have a p+/p- cleft although both HS and LS receptors contain a p+/a- binding cleft. 
Mutagenesis data showed that mutation of the P2D218 residue in the p+C-loop region abolished 
HEPES potentiation. These findings ascertain the HEPES potentiation site is located at the p+/p- 
cleft of the HS a4p2 receptor site and involves the p2D218 residue.
The first inhibitory phase of HEPES inhibition of the HS stoichiometry plateaus at a 
normalized response of one, suggesting HEPES can only inhibit the potentiated response at 
these concentrations (100 pM - 3 mM). The IC50s of the first (LS receptors) and second (HS 
receptors) HEPES inhibitory phases are similar and are unaffected by the P2D218A mutation. 
This could mean the inhibitory phases utilize similar mechanisms.
It is unclear from our data what the mechanism or binding site(s) are for HEPES 
inhibition. The two phase inhibition on the HS receptor suggests multiple mechanisms. Such 
mechanisms could include an allosteric inhibitory site, competition at the orthosteric site or open- 
channel block. Conceivably at least one inhibitory mechanism is competition at the orthosteric site 
since in the crystal structure of AChBP, HEPES was found to bind at the same location as other 
orthosteric ligands. In addition the IC50 values for HEPES inhibition are similar to that observed for 
HEPES binding to the AChBP. A second possibility is that HEPES is acting as an open-channel 
blocker at high concentrations. Hump currents, also known as rebound or tail currents, are inward 
currents which occur during the desensitized phase of the response on washout of the ligand and 
have been previously linked to open-channel block (Liu et al., 2008). At the concentrations tested, 
a possible tail current was seen at 300 pM HEPES. This could suggest that at high HEPES 
concentrations, open-channel block could be the inhibition mechanism of HEPES (Figure 5.1A 
and B).
5.5.2 HEPES Effects on <x7 nAChRs.
We also investigated the effects of HEPES on a7 nAChRs to determine if similar 
modulatory effects of HEPES were present. A small insignificant decrease was found in the Hill 
slope of the ACh dose-response experiments in the Phosphate buffer compared to HEPES 
buffer. The a7 ACh pEC50 values found using the HEPES and Phosphate buffer systems were not
5.5 Discussion.
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different from one another. In addition a7 receptors were not affected by application of HEPES. 
Due to seeing no effects of buffer composition on a7 nAChR we suggest that either HEPES or 
Phosphate buffer systems are adequate for investigating a7 nAChR.
5.5.3 HEPES as a Therapeutic Lead Drug.
Several ligands have different affinities and efficacies for the a4p2 stoichiometries 
including cytisine, ACh, nicotine and epibatidine (Moroni et al., 2006). To our knowledge, the S- 
enantiomer of mecamylamine (Taragacept® TC-5213) is the only ligand to show selective 
activation of the HS channels and inhibition of the LS channels (Taly et al., 2009). In the current 
study we show that HEPES is a selective PAM of HS receptors when compared to the LS 
stoichiometry and a7 nAChRs. Stoichiometric selective drugs based on HEPES could provide 
significant benefits for elucidation of mechanisms involving changes in expression or location of 
specific stoichiometries of a4p2 receptors. Such ligands could also prove useful in the diagnosis 
and treatment of CNS disorders. Our laboratory is currently engaged in structure function studies 
designed to develop novel analogs of HEPES for these purposes.
5.5.4 Mounting Evidence That Good’s Buffers interact with Physiological Systems.
Over the years, Good’s buffers have been shown to alter physiological systems. HEPES 
has been shown to stimulate the production of ATP and decrease the uptake of P-glycoprotein in 
Caco-2 and MDCK-MDR1 cells (Luo et al., 2010). The hyperpolarization-activated transient 
currents of human and rat 5-hydroxytryptamine transporters (SERT) expressed in Xenopus 
oocytes were blocked by HEPES with alterations in SERT kinetics (Li et al., 2002). The SERT 
currents decreased 10-50% by HEPES at concentrations greater than 1 mM. Additionally, 
HEPES has been shown to affect cell membrane (Poole et al., 1982) and block chloride ion 
channels (Yamamoto and Suzuki, 1987).
Tris buffer and similar compounds have been revealed to alter physiological responses. 
Studies suggest that Tris inhibits the function of enzymes such as aminopeptidase and alpha- 
amylase (Desmarais et al., 2002; Ghalanbor et al., 2008). In addition, Tris, TES and related buffer 
compounds have been shown to react with nerve agents to form new products (Gab et al., 2010).
To add to this growing list of the physiological and biochemical effects of Good’s buffer’s, 
the current study demonstrates alteration of nAChR function by HEPES and Tris. HEPES 
potentiates and inhibits ACh induced responses on a4p2 nAChRs in a stoichiometric dependent 
manner. We’ve also demonstrated that Tris inhibits ACh currents on both HS and LS a4p2 
receptor stoichiometries at concentrations > 3 mM. Application of 10 mM Tris inhibited dFBr 
potentiated ACh induced currents by > 50%.
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5.5.5 HEPES Competition with Other PAMs.
Positive allosteric modulators (PAMs) have recently become alluring targets in the search 
for potential therapeutic agents. PAMs generally function to increase the sensitive and/or efficacy 
of endogenous ligands such as ACh. Since many electrophysiological studies use a HEPES 
recording buffer, the discovery that HEPES is an allosteric modulator of a4(52 nAChR presents a 
concern regarding data interpretation. HEPES potentiation or inhibition may alter the responses 
of the compound in question. These concerns are especially pertinent with the study and 
development of other modulators.
We investigated the effects of buffer composition on the sensitive and efficacy of the 
PAMs dFBr and Zn2+. The affinities and efficacies of these PAMs were altered by Tris and 
HEPES buffers. A previous study comparing Tris and HEPES buffers showed that the GABAa 
PAM, thymol, displayed biphasic behavior in a HEPES buffer while only inhibition was seen when 
using a Tris buffer (Garcia et al., 2008). Similarly in our laboratory, dFBr appears to be more 
efficacious for the HS versus LS a4(32 receptors when using a HEPES buffer. But in the absence 
of HEPES no difference is evident. Despite the apparent difference in the dFBr and HEPES 
binding sites (dFBr to the p+/a-cleft and HEPES to the p+/p- cleft), the independent modulatory 
effects of dFBr and HEPES both alter the apparent efficacy, potency and inhibition of dFBr on the 
LS receptors. The complications arising from HEPES interaction with a4p2 receptors is further 
illustrated by our re-analysis of the effects of Zn2+ on HS and LS receptors. In their original study, 
Moroni et al. (2008) concluded that Zn2+ inhibited a4p2 receptors at the p+/a- binding interface 
while potentiating at the a+la- interface. This conclusion was based on the observation that Zn2+ 
was selective for the LS stoichiometry with a unique a+/a- cleft along with mutagenesis studies 
implicating p2D218 in inhibition and aH195 in potentiation. It is likely that HEPES inhibition of the 
HS receptor obscured the observation of Zn2+ potentiation. Since the HS receptor lacks the a+/a- 
binding cleft, it must be concluded that the a+la- cleft is not necessary for potentiation. With data 
obtained in the absence of HEPES, it seems more likely that the potentiation site is at the p+/a- 
cleft and the inhibitory site is at the P+/p- cleft. This also explains our observation that Zn2+ 
potentiation increases with the P2D218 mutation in phosphate buffer since p2 would be expected 
to alter both potentiation and inhibition.
5.5.6 Summary.
Our data have shown HEPES to be a potentially valuable lead molecule for a new class 
of stoichiometric selective ligands of a4(32 receptors. Continued work in this direction will likely 
elucidate features of both ligand and receptor responsible for this selectivity. In addition we have 
shown that HEPES buffer can interfere in physiological systems involving nAChRs and would
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recommend against using this buffer for the study of nAChRs. While phosphate buffer appears to 
be suitable in some cases, our discovery of changes induced in phosphate buffer on a7 receptors 
suggests caution in replacing HEPES with phosphate in all situations. While it might be tempting 
to switch to another Good’s buffer in place of HEPES, our data with Tris suggests that this may 
also be potentially troublesome. Many Good’s buffers share common structural features with 
HEPES and may exert effects on nAChRs. A though characterization of these buffers is currently 
being performed to identify suitable replacements.
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6.1 General Overview
Ligand gated ion channels (LGIC) are distributed throughout the peripheral and central 
nervous system (Taly et al., 2009) where they play a critical role in synaptic transmission at the 
junctions between nerve cells (synapses) and between nerve and muscle cells by regulating the 
passage of ions into the cell (Gotti et al., 2006). LGIC receptors are thus of critical importance to 
learning and memory, gene transcription and muscle contraction. The nicotinic acetylcholine 
receptor (nAChR) that is discussed in this thesis is one member of this Cys-loop super family of 
LGICs. Previous studies have demonstrated that dysregulation of nAChRs may underlie multiple 
neurological disorders including Alzheimer’s disease (Court et al., 2001; Nordberg, 2001), 
Schizophrenia (Adams and Stevens, 2007), Parkinson’s disease (Aubert et al., 1992), Autism 
(Martin-Ruiz et al., 2004; Lippiello, 2006) and nicotine addiction (Picciotto et al., 2001).
The development of novel ligands targeted at LGICs is thought to have high therapeutic 
potential for the treatment of neurological disorders. In particular, nAChR selective ligands could 
be useful in treating pathological conditions where nicotinic tone is altered. This thesis has 
focused on our research developing of a novel class of nicotinic receptor ligands typically 
described as positive allosteric modulators (PAMs). These ligands bind at an allosteric binding 
domain on nAChRs and enhance the endogenous neurotransmitter acetylcholine (ACh). This is in 
contrast to ligands that bind to the orthosteric site and either activate the receptor (competitive full 
and partial agonists) or block the binding of ACh (competitive antagonists). Many competitive 
ligands have been developed for nAChRs (for review see (Romanelli et al., 2007)), however 
positive allosteric modulators have been more elusive. Nonetheless, PAMs are likely to have 
many advantages over competitive ligands. Since PAMs typically alter responses elicited by the 
endogenous transmitter but are incapable of activating receptors directly they would enable 
retention of synaptic control via release of endogenous neurotransmitter. Additionally, some 
PAMs also preserve the overall response kinetics of the receptors while amplifying the peak 
responses. This is in contrast to competitive ligands which tend to block or desensitize receptors 
and reduce acetylcholine mediated synaptic currents. By PAMs exerting their effects only on ACh 
release and maintaining a normal, yet amplified signal (reviewed in (Bertrand and 
Gopalakrishnan, 2007)), the result of PAM action is likely to be similar to what might be obtained 
by increasing receptor numbers at the synapse, the basis of learning and memory. The success 
of a related class of PAMs for the GABAaR, the benzodiazepines, illustrates the potential value of 
this approach. Benzodiazepines are commonly used clinically for the treatment of seizure 
disorders. Discovery of nAChR PAMs could produce similar benefits in the treatment of other
CHAPTER 6: Discussion and Conclusions.
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neurological disorders such as Alzheimer’s disease where decline in nAChR numbers are 
evident.
Despite nAChRs wide distribution throughout the human body and the potential medical 
application, there are currently no allosteric modulators therapeutically used that selectively target 
nAChR subtypes. Based on preliminary molecular modeling and sequence comparisons between 
members of LGICs, we formed the general hypothesis that there are selective allosteric 
modulators for a4p2 nAChRs and they bind in a similar region as benzodiazepines on GABAaRs.
This thesis describes the discovery and development of two unique PAMs selective for 
the a4p2 nAChR subtype. The lead compounds desformylflustrabromine (dFBr) and 4-(2- 
hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES) were evaluated for their ability to 
potentiate a7 and both high- and low- ACh sensitivity a4p2 receptors. dFBr was previously 
shown to act as a selective a4p2 PAM with no potentiating action on the a7 subtype (Sala et al., 
2005; Kim et al., 2007). HEPES was previously thought to have no effect on nAChRs and is a 
common buffer in physiological preparations (Good et al., 1966) although it is observed bound to 
the orthosteric site in the crystal structure of the AChBP (Brejc et al., 2001).
Chapter 3 of this thesis presented data obtained in the first pharmacological 
characterization of synthetic dFBr, its effects on nAChR responses to partial and full agonists and 
its influence on receptor kinetics determined using two-electrode voltage clamp and human 
receptors expressed in Xenopus oocytes. Our studies show different degrees of potentiation for 
partial and full agonists and shed light on the mechanisms that may underlie the potentiating 
effect of dFBr. Chapter 4 describes a continuation of these studies aimed at identifying potential 
involvement of the plus face of the P2 subunit and the minus face of the a4 subunit in mediating 
the effects of dFBr.
In Chapter 5, we turned our attention to our second lead molecule, HEPES. We 
evaluated HEPES as a PAM for high and low ACh sensitivity a4p2 receptors. Our data show a 
selectivity of HEPES for the high-ACh sensitivity a4p2 receptor compared to the low-ACh 
sensitivity subtype. Since HEPES is commonly used as an electrophysiological buffer we also 
investigated other Good’s buffers as well as phosphate for effects on a4p2 and a l  receptor 
function. Our data suggest that phosphate recording buffers should be preferred over HEPES 
type buffers due to our observed potentiating and/or inhibitory action of these compounds on 
nAChRs. This is particularly true in the study of nAChR PAMs where HEPES type buffers may 
confound interpretation of electrophysiological data.
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6.1.1 Pharmacological Characterization of Synthetic dFBr.
The characterization of dFBr pharmacology described in chapter 3 was aimed at 
determining if the effects of dFBr were dependent on the type of stimulating agonist (partial or full) 
and on the order and timing of dFBr application. Effects of dFBr were examined using two- 
electrode voltage clamp and human a4p2 nAChRs expressed in Xenopus laevis oocytes. Our 
data indicate that responses to both partial and full agonists can be potentiated by dFBr. 
Responses to low-efficacy agonists were potentiated significantly more than responses to high- 
efficacy agonists (9.9 ± 0.05% versus 2.7 ± 0.01 fold change). The agonists ACh, choline and 
nicotine EC50 values were enhanced and reduced respectively with the co-application of dFBr. In 
contrast, antagonist plC50 values were unaffected by co-application of dFBr. The order of addition 
of dFBr did not appear to affect potentiation and pre-exposure to dFBr, and did not alter the rise 
time of the responses when compared to co-exposure with ACh. We also applied dFBr at 
different points during the ACh response curve. Our data indicate that dFBr could be applied at 
any point during the ACh-induced response and still elicit an amplified response. Addition of dFBr 
during the desensitizing phase of the response produced spikes equivalent in height to dFBr 
when co-applied with ACh, but required more rapid rise times to peak. This peak declined rapidly 
when compared to the original desensitized response amplitude on continuous application of 
dFBr. Thus, dFBr appears to “rescue” receptors from desensitization. While precise mechanisms 
await future single channel analysis, this data may indicate that dFBr shifts receptor equilibrium 
from a desensitized to an open conformation or, alternatively, permit receptors to enter an 
alternate open conformation.
We also investigated the inhibitory component of the biphasic dFBr potentiation/inhibition 
kinetics. In contrast to potentiation, inhibition of ACh-induced responses by dFBr was dependent 
on membrane potential suggesting it may involve open-channel block by dFBr and ACh. Our data 
indicates distinct mechanisms for the potentiation and inhibitory components of dFBr action. 
Since both potentiation and inhibition appear to be mediated by distinct mechanisms, it seems 
reasonable that alteration of the chemical structure of dFBr may lead to analogs capable of larger 
potentiation with little or no inhibitory action, or analogs with EC50 and IC50 values sufficiently 
different to permit tailoring of the potentiation effect by controlling dFBr concentration.
The results from the study have aided the field in understanding how a4p2 nAChR are 
modulated biphasically by dFBr. The ability of dFBr to modulate full and partial agonists 
especially with regards to ACh, nicotine and choline may be a useful quality in developing 
therapeutic treatment strategies for diseases such as Alzheimer’s disease, nicotine addiction and 
Autism. The enhancement of choline efficacy by dFBr further suggests that dFBr may be able to
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prolong a cholinergic response via choline. In this study we have begun to reveal the mechanism 
of dFBr potentiation and its ability to reactivate desensitized receptors. The ability of dFBr to 
reactivate desensitized receptors may be an appealing property especially with regards to 
smoking cessation, an addiction that up-regulates and desensitizes nAChR. The findings that 
dFBr inhibition involves open-channel block demonstrates that a single ligand can have several 
unique functions on a receptor. In addition, because the inhibition mechanism may be separate 
from the potentiation component, this suggests that the inhibitory actions of dFBr could be 
removed in future dFBr analogues. Although due to dFBr’s apparent ability to potentiate choline- 
evoked currents and thus alter the time course of cholinergic transmission, inhibition by dFBr may 
be an advantage to maintaining the temporal relationship.
6.1.2 Putative Binding Domain for Desformylflustrabromine.
In chapter 3, we investigated the involvement of non-orthosteric subunit interfaces of 
a4p2 receptors in the potentiation of ACh induced responses by dFBr. Amino acids on the non- 
orthosteric P2+ and a4- subunit faces were mutated to alanine and the receptors were 
expressed in Xenopus laevis oocytes. Residues were chosen for mutation based on sequence 
homology with amino acids identified as important for binding of benzodiazepine in the GABAa 
receptor. Selection of mutations and receptor locations were designed to test our hypothesis 
that dFBr binds at the subunit interfaces not utilized by binding ACh or competitive nAChR 
ligands (the non-orthosteric subunit interfaces). Acetylcholine and dFBr induced responses 
were recorded using two-electrode voltage clamp techniques. The effects of mutations can be 
classified into fundamentally three distinct categories:
1. Mutations that alter the dose response relationship for ACh in the absence of dFBr.
a. Low-sensitivity preparation: P2W176A, P2Y120A, p2Y127Aand a4K140A.
b. High-sensitivity preparation: P2W176A, P2D179A, P2D217A, P2Y120A, P2Y127A, 
O4K140A, o4W88A.
2. Mutations that alter the ability of dFBr to potentiate ACh induced responses with minimal 
effect on responses to ACh alone.
a. Low-sensitivity preparation: P2T177A, P2D179A and a4W88A.
b. High-sensitivity preparation: P2T177A, P2D116A and P2Y120A.
3. Mutations that had no effect on either ACh alone or ACh co-applied with dFBr.
a. Low-sensitivity preparation: P2D217A, P2D218A, P2D116A.
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b. High-sensitivity preparation: (B2D218A.
Mutations altering the ACh response in the absence of dFBr indicate a potential 
involvement of the mutated subunit faces (02+ or a4-) in mediation of the native ACh response. 
Since these subunit faces do not form part of the orthosteric site, our data suggest that 
conformational changes in these regions of the receptor may be involved in normal function of 
the receptor, a finding that has never before been demonstrated.
The novel discovery that allosteric clefts play a role in the ACh induced receptor 
conformational changes leading to activation and desensitization has not been previously 
demonstrated. One possibility for the basis of these effects might be that the C-loop within 
allosteric clefts moves as part of the conformational changes that occur on channel opening 
and/or desensitization. We hypothesize that this movement of the C-loop, possibly by closure 
similar to what occurs in the orthosteric cleft, might be involved in the conformational change 
leading to stabilization of a desensitized conformation. Mutations altering responses to ACh 
might also alter dFBr potentiation; however, since this effect would be obscured by the 
concurrent effects on ACh responses it is not possible to make any conclusions regarding dFBr 
interaction with these amino acids.
The second category of mutations that alter the effects of dFBr with little or no change 
in ACh dose response curves suggests that this set of mutations is involved in the interaction of 
dFBr with the receptor or with its effect on receptor function. The 02+ and a4- faces both 
appear to play a role in mediating dFBr’s effects. Our original hypothesis, that dFBr may bind at 
the non-orthosteric 02+ binding face, is supported by these data. The importance of this region 
in normal receptor function as illustrated by our data suggest that dFBr may alter receptor 
mechanism by either facilitating or inhibiting the normal function of the receptor at the 02+/a4- 
subunit interface. As described above, we hypothesize that movement of the C-loop in this 
region of the receptor may be involved in stabilization of the desensitized conformation of the 
receptor. If dFBr binding prevents C-loop closure, the desensitized conformation would likely be 
destabilized leading to a shift in equilibrium to the open conformation. Such an effect might 
explain the ability of dFBr to rescue desensitized receptors. Removal of dFBr might be 
expected to restore this equilibrium thus decreasing rapidly the number of receptors back to the 
unpotentiated levels we observe in experiments where dFBr is applied during the desensitizing 
phase of the response. Further studies to determine if dFBr actually binds to this region or 
simply alters the normal conformational changes that occur will require additional studies, 
perhaps using cysteine scanning mutagenesis and the substituted cysteine accessibility 
method (SCAM).
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6.1.3 Allosteric Modulation of High- and Low- ACh Sensitivity alpha4beta2 Nicotinic
Acetylchoiine Receptors by HEPES.
In Chapter 5, we present our discovery that 4-(2-hydroxyethyl)-1- 
piperazineethanesulfonic acid (HEPES) is a PAM selective for high ACh sensitive a4p2 
nAChRs. These experiments were prompted by our observation that mutation of P2D218A 
increased the potentiating effects of dFBr and our observation that HEPES was present in the 
orthosteric cleft of the homologous AChBP. We postulated that the enhancement of dFBr action 
might be the result of a blocking of the allosteric site by HEPES. If P2D218 interacted with 
HEPES but not dFBr, then mutation of P2D218 to an alanine might decrease affinity for 
HEPES, enabling dFBr to bind, producing an apparent enhanced effect by dFBr. The effects of 
HEPES were evaluated in phosphate buffered recording solutions using two-electrode voltage 
clamp techniques and a4p2 and a7 nAChR subtypes expressed in Xenopus laevis oocytes. 
Varying concentrations of HEPES co-applied with 10 pM ACh produced a bell-shaped dose- 
response curve on <34(32 nAChR expressed using the high-ACh sensitivity receptor preparation 
similar to the kinetics observed for dFBr. Co-exposure of 100 pM HEPES and 10 pM ACh 
produced responses potentiated 190% compared to ACh alone. When concentrations in 
excess of 100 pM were used, responses to ACh were inhibited by HEPES. Coincidentally, at 
concentrations of HEPES typically used in oocyte recording (5-10 mM), the potentiating effects 
of HEPES are matched by its inhibitory effects thus producing no apparent effect. This may 
explain why this effect had not previously been observed despite the common use of HEPES in 
recording media. Mutagenesis of (32D218 to alanine blocked the potentiating effects of HEPES 
suggesting it acts by binding to the plus face of the p2 subunit. In contrast to the high-ACh 
sensitivity a4p2 receptor preparation, receptors expressed using the low-ACh sensitivity 
preparations were not potentiated by HEPES. The remarkable selectivity of HEPES for a single 
receptor stoichiometry makes it of interest as a lead compound for highly selective PAMs but 
also an excellent research tool for the study of allosteric modulation in nAChRs. Understanding 
the selectivity of HEPES compared to dFBr may reveal new classes of PAMs with varied 
selectivity for different nAChR subtypes. The apparent competition between HEPES and dFBr 
strengthens the argument that dFBr is actually binding to subunit interfaces containing the plus 
face of the P2 subunit (our postulated dFBr binding site).
More recent data not presented in this thesis has continued our evaluation of Good’s 
buffers with similar in chemical structure. We have evaluated EPPS (3-[4-(2-Hydroxyethyl)-1- 
piperazinyljpropanesulfonic acid), PIPES (piperazine-N,N’-bis(2-ethanesulfonic acid), POPSO, 
MES (2-(N-morpholino)ethanesulfonic acid), MOPS (3-(N-morpholino)propanesulfonic acid),
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CHES (N-Cyclohexyl-2-aminoethanesulfonic acid), CAPS (N-cyclohexyl-3- 
aminopropanesulfonic acid) and CAPSO (N-cyclohexyl-2-hydroxyl-3-aminopropanesulfonic 
acid) on high- and low- ACh sensitivity preparations. The co-application of varying 
concentrations of the test compounds EPPS, POPSO, MOPS and CHES with 10 pM ACh on 
high-sensitivity receptors produced currents that were biphasically potentiated. Application of 
POPSO on low-sensitivity receptors produced a bell-shaped dose-response curve where 100 
pM ACh induced currents were both potentiated and inhibited. MES and CAPS inhibited ACh 
induced currents of receptors expressed in the high-sensitivity receptor preparation. Ligands 
MOPS, CAPS and CAPSO inhibited ACh induced currents on low-sensitivity receptors. EPPS, 
MES and CHES had no effect on ACh stimulated responses on low-sensitivity receptors while 
CAPSO had no influence on high-sensitivity receptors. PIPES was the only tested compound to 
have no effect on ACh induced currents on either receptor preparation. Tris inhibits both high 
(pICso = 2.0 ± 0.1; IC50 = 10 mM]) and low-sensitivity a4p2 nAChRs (plC5o = 2.2 ± 0.1; IC50 = 
6.8 mM). In contrast, no effect was observed for phosphate buffers.
While these experiments are incomplete and do not yet enable us to determine 
accurate structure function relationships, they do lay the groundwork for future studies to 
develop improved HEPES type PAMs. In addition, these new data suggest that HEPES type 
buffers are unsuitable for electrophysiological studies of nAChRs.
The effects of HEPES and Good’s buffers on nAChR function likely alters the 
interpretation of previous PAM studies due to the common use of HEPES as a buffering agent 
in electrophysiological recording buffers. From our experiments, it is clear that phosphate buffer 
represents the safest choice for performing electrophysiological studies of nAChRs. It is 
possible that similar effects of HEPES will be documented in the future for other LGIC receptor 
subtypes.
6.2 Future Directions.
The investigation of dFBr has so far focused on characterizing dFBr functionally and 
pharmacologically at the macroscopic level. The goal is to develop dFBr or an analogue of dFBr 
into a therapeutic ligand. For the therapeutic development of dFBr or a similar ligand to occur, 
further understanding how dFBr modulates the receptor at the microscopic and whole body 
system needs to be determined.
6.2.1 Single Channel Studies.
To investigate dFBr at the microscopic level, single channel and patch clamp techniques 
will be necessary. These techniques would elucidate the mechanisms of action of dFBr
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potentiation and inhibition by evaluating its effects on conformational stability on single receptor 
proteins. Single channel analysis is currently the most direct method available to obtain detailed 
information regarding the kinetic behavior of ion channels. Application of potentiating 
concentrations of dFBr and ACh could produce increases in the mean open times of the channel 
or, alternatively, alter the bursting frequency of the receptor compared to ACh only. These results 
would provide further evidence that the mechanism of dFBr potentiation involves stabilization of 
the open conformation of the receptor. Single channel studies would also be helpful in elucidating 
the mechanism of inhibition by dFBr. These experiments would need to be conducted at holding 
potentials where open-channel block by dFBr and ACh does not occur. Application of inhibiting 
concentrations of dFBr and ACh under these conditions might result in reduced open time 
probabilities or altered bursting rates. Combing these studies with site directed mutagenesis 
would likely provide novel insights into dFBr mechanisms at the single channel level and would 
also be extremely valuable at determining the role of the p2+/a4- interface in normal receptor 
function.
6.2.2 More Mutations and Scanning Cysteine Accessibility Method (SCAM).
Further work is needed to fully characterize the dFBr binding site. The work covered in 
this thesis provided the initial groundwork. Additional mutations that might provide insight into 
dFBr binding include: a4W82F, a4N86A, a4W88F, a4K90A, a4K90R, a4V135A, a4T136A, 
a4T136S, a4H137A, a4H137R, a4L138A, a4L138V, a4T139A, a4T139S, a4K140R, a4T152A, 
a4T152l, a4P153A, a4P153D, a4P154A, p2M126A, p2Y127A, p2T139S, p2S175A, p2S175T, 
P2W176F, P2T177A, p2T177S, p2T178A, P2Y178F, P2D179A, P2D179Q, p2N215A, p2N215E, 
P2D218Q, P2S219A, p2S219T, p2T220A, p2T220S, p2Y221A and p2Y221F. In addition, 
mutations that produced little or no effect on dFBr or ACh effects should be mutated to cysteine to 
determine if these would be suitable sites for SCAM. SCAM utilizes the ability to modify cysteine 
residues not involved in disulfide bonds with exogenous thiol reagents during the course of an 
experiment. Amino acids are substituting with cysteine then modified by the formation of thiol 
esters in the presence and absence of ligand. Changes in the rate of modification in the presence 
of the ligand help determine if the presence of the ligand alters the accessibility of the target 
amino acid. Decreased accessibility in the presence of dFBr would further support the hypothesis 
that the substituted amino acid is located within the ligand binding site. Ideally, cysteine mutations 
should be made on all key binding loops within the putative binding domain to confirm the location 
of the dFBr and HEPES binding domains. SCAM can also be used to identify portions of the 
receptor that move during the receptor cycle thus helping to identify the role of these regions in 
normal receptor functions. This approach could enable testing of the hypothesis that the C-loop of
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the (32+ face closes during receptor activation/desensitization and whether or not dFBr alters this 
closure.
6.2.3 The Development of the dFBr Binding Site on AChBP.
One of the goals of Dr. Marvin Schutle’s laboratory is to develop high throughput drug 
screening techniques. A potential candidate for a high throughput screening platform is the 
Acetylcholine Binding Protein (AChBP). Kinetic and affinity data for ligands interacting with the 
AChBP can be evaluated using Scintillation Proximity Assay (SPA) and Surface Plasmon 
Resonance (SPR). AChBP has similar pharmacology sensitivity to nAChR. The construction of 
AChBP proteins that are more similar to LGICs via mutagenesis may facilitate the drug screening 
process and lead to a better understanding of ligand binding sites.
One direction that the dFBr project can take is to develop an AChBP homologue that 
binds dFBr similarly to a4|32 nAChR. This would involve mutating AChBP residues to the 
equivalent of dFBr binding site residues. dFBr analogues could then be screened on the dFBr 
sensitive AChBP rapidly using techniques such as the SPR. This would greatly enhance the rate 
at which we are able to evaluate dFBr analogues and develop an understanding of this drug 
class. In addition, a dFBr sensitive AChBP homolog will be useful in studying the specific amino 
acid interactions that occur for the binding of dFBr to a4p2 nAChR. Crystal structures of the dFBr 
sensitive AChBP unbound and bound with dFBr could be resolved and be used to further 
understand the binding orientation and protein structural rearrangements induced by dFBr. The 
development of this protein will help verify binding site models of the a4p2 receptor and provide a 
platform for high throughput screening of the new dFBr class of modulatory agents.
6.2.4 Receptor Selectivity.
dFBr selectivity has been thoroughly investigated by us on a4p2 and a7 nAChR and by 
others on a3p2 receptors (Pandya and Yakel, 2011). The selectivity appears localized to 
receptors that contain the p2 subunit. However, many more subtypes of nAChR exists including 
the a3p2, a4p2, a3p4 subtypes. While Sala et al., (2005) evaluated several subtypes and 
suggested that dFBr was selective for a4p2 receptors, we observed differences in both potency 
and efficacy of synthetic dFBr compared to their results using dFBr purified from natural sources. 
This suggests that dFBr selectivity may be broader than was initially observed. Thus the true 
selectivity of dFBr is unknown. The effect of dFBr on other nAChR subtypes need to be 
evaluated. In addition, it would be interesting to determine if dFBr also interacts with other LGIC 
receptors. Our laboratory has performed preliminary studies indicating dFBr does not potentiate
218
serotonin responses on 5-HT3AR but the LGIC family is large and many other possibilities exist. 
The development of radiolabeled dFBr might facilitate these studies by enabling large receptor 
binding studies to be performed using high throughput approaches. The development of 
radiolabeled dFBr is currently underway in our collaborators’ laboratory.
6.2.5 dFBr Analogues.
The lead compound in these studies, dFBr, is a natural product and is unlikely to be 
suitable in its current form as a therapeutic agent. A number of potential problems are likely to be 
encountered when administering dFBr for the treatment of neurological disorders. These include 
poor pharmacokinetics, transit across the blood brain barrier (BBB), therapeutic efficacy and 
selectivity. To overcome these difficulties, a number of steps are typically involved in optimizing 
the structure of the ligand. These include:
1. Optimization of the pharmacophore structure (increased potency and selectivity).
2. Evaluation of biological distribution and optimization for target tissue (increased BBB transit 
and partitioning into brain).
3. Improved chemical stability in vivo (optimized pharmacokinetics).
4. Decreased toxicity (evaluation of non-LGIC effects -  selectivity).
5. Evaluation and enhancement of therapeutic efficacy.
The first step in this process involves evaluation in receptor expression systems as 
described in this thesis. Steps 2-5 involve the use of animal models and eventually human 
subjects. Each step involves numerous structurally varied analogs. This is likely to be a long 
process that will take place in several laboratories before commercially available compounds 
become available. We are currently in Stage 1 although interest by other laboratories and the 
recent release of synthetic dFBr by Tocris is likely to facilitate future animal studies. The release 
of synthetic dFBr is largely the result of our efforts and is based on the data presented in this 
thesis. We are also in the process of developing and characterizing dFBr analogues to optimize 
the dFBr pharmacophore. Our collaborators have synthesized 26 different analogues which we 
have analyzed. Results have shown that 12 of the 26 analogues potentiate a4(32 nAChRs 250­
290%. These 12 compounds selectively potentiated a4p2 and not a7 nAChR. An optimized 
ligand would be expected to have high selectivity for a4p2 receptors, higher potency, increased 
efficacy and lack of inhibitory effects. Improved characterization of the dFBr binding site is 
expected to enhance our ability to optimize the pharmacophore by enabling receptor homology 
modeling of the binding site and docking of potential ligands. This will lead to "rational drug
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design” for dFBr ligands. As we progress further toward ligands with better BBB transit, in vivo 
stability and therapeutic efficacy this fundamental data on dFBr’s requirements for selective 
interaction will guide further modification of the structure without loss of a4p2 selectivity.
6.2.6 Further Studies of HEPES Potentiation.
One unexpected finding that arose from the work in this thesis is the discovery that 
HEPES selectively modulates high ACh sensitive a4p2 receptors compared to low ACh sensitive 
a4|32 receptors and a7 nAChRs. This is one of the only ligands available that can selectivity 
modulate high ACh sensitive a4p2 receptors. To our knowledge, S-enantiomer of mecamylamine 
(TC-5213), is the only other ligand shown to show in vivo selective activation of the high- 
sensitivity channels and inhibition of the low sensitivity a4p2 nAChRs (Taly et al., 2009). The 
development of stoichiometric selective ligands would be useful in determining the distribution of 
these receptor populations throughout the central and peripheral nervous system in normal and 
diseased tissues. In addition such selective ligands could be highly valuable therapeutic ligands 
to treat disorders where dysregulation of one receptor stoichiometry occurs.
To develop HEPES or HEPES analogues as useful ligands, several steps are necessary. 
Like the path that dFBr has and will continue to travel, HEPES must also go through this process. 
This includes the development and evaluation of HEPES analogues on a4p2 and other nAChR 
subtypes, understanding of HEPES mechanisms, characterization of its binding site and testing in 
animal models and ultimately human subjects. One obstacle in the development of HEPES 
analogs is the low hydrophobicity of the parent compound, a problem not likely with dFBr analogs 
with a calculated LogP value of -4.87. This problem could make penetration of the BBB more 
difficult to engineer into HEPES compared to dFBr.
6.3 Summary.
The work described in this thesis has contributed significantly to advancement of our 
understanding of nAChR function in general and specifically to the development of an entirely 
new class of nAChR ligand. The long term impact is likely to be significant as this drug class is 
developed. In addition, the discovery of the effects of HEPES on nAChRs is likely to help prevent 
misleading experimental results due to the complicating factors of using HEPES in recording 
buffers. HEPES may additionally prove to be a valuable lead in the development of a new, even 
more selective ligand for characterization of a4p2 receptors in brain. This body of work also aided 
in the mechanistic understanding of how non-orthosteric clefts may be involved in the receptor 
mechanism.
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Therapeutic applications of the discoveries made in this thesis are also likely to be broad. 
Development of a novel a4(32 modulator has important application in the treatment of some of the 
most serious diseases facing us today. Alzheimer’s disease (Prevention, 2010a) and Autism 
(Prevention, 2010b) are rapidly increasing in our population and smoking continues to underlie 
some of the most debilitating diseases including cardiovascular disease, stroke and cancer 
(Prevention, 2010c). The development of new drugs to treat these diseases is crucial and 
compounds like dFBr and HEPES target the specific receptor identified as important in these 
disorders, the a4(32 receptors. We have begun the complicated endeavor of revealing the 
mechanism behind dFBr’s potentiation and inhibition actions on a4(32 receptors and we have 
located and characterized the a4p2 dFBr and HEPES binding sites. This will greatly facilitate the 
development of novel dFBr and HEPES analogues ultimately leading to a completely novel 
therapeutic agent.
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Appendix A.1 Response profiles for co-application of varying concentrations of dFBr 
and ACh for £2+ face B-ioop mutant receptors expressed using the low (LS) and high (HS) 
sensitive receptor preparations.
Xenopus oocytes were prepared using the high and low sensitive receptor preparations (HS 
mRNA injected at a ratio of 1a:5p; LS mRNA injection at a ratio of 5a:1p). Expressing oocytes 
were exposed to increasing concentrations of ACh and dFBr. A) Co-application of dFBr and 100 
pM ACh response traces for P2W176A receptors expressed via the low sensitive receptor 
preparation. B) Co-application of dFBr and 10 pM ACh response traces for P2W176A receptors 
expressed via the high sensitive receptor preparation. C) Co-application of dFBr and 100 pM ACh 
response traces for P2T177A receptors expressed via the low sensitive receptor preparation. D) 
Co-application of dFBr and 10 pM ACh response traces for P2D179A receptors expressed via the 
high sensitive receptor preparation. Response traces were recorded from a single oocyte. The 
solid bar above the response trace indicates the time the oocyte was exposed to co-application of 
varying concentrations of dFBr and ACh. For figures A, B and F, the response traces are offset 
for clarity.
Appendix A.2 Response profiles for co-application of varying concentrations of dFBr 
and ACh for P2+ face C-loop mutant receptors expressed using the low (LS) and high (HS) 
sensitive receptor preparations.
Xenopus oocytes were prepared using the high and low sensitive receptor preparations (HS 
mRNA injected at a ratio of 1a:5p; LS mRNA injection at a ratio of 5a:ip). Expressing oocytes 
were exposed to increasing concentrations of ACh and dFBr. A) Co-application of dFBr and 100 
pM ACh response traces for P2D217A receptors expressed via the low sensitive receptor 
preparation. B) Co-application of dFBr and 10 pM ACh response traces for P2D217A receptors 
expressed via the high sensitive receptor preparation. C) Co-application of dFBr and 100 pM ACh 
response traces for P2D218A receptors expressed via the low sensitive receptor preparation. D) 
Co-application of dFBr and 10 pM ACh response traces for (32D218A receptors expressed via the 
high sensitive receptor preparation. Response traces were recorded from a single oocyte. The 
solid bar above the response trace indicates the time the oocyte was exposed to co-application of 
varying concentrations of dFBr and ACh. For figure B, the response traces are offset for clarity.
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Appendix A.3 Response profiles for co-application of varying concentrations of dFBr 
and ACh for 02+ face A-ioop mutant receptors expressed using the low (LS) and high 
(HS) sensitive receptor preparations.
Xenopus oocytes were prepared using the high and low sensitive receptor preparations (HS 
mRNA injected at a ratio of 1a:5p; LS mRNA injection at a ratio of 5a: 1 p). Expressing oocytes 
were exposed to increasing concentrations of ACh and dFBr. A) Co-application of dFBr and 100 
pM ACh response traces for (32D116A receptors expressed via the low sensitive receptor 
preparation. B) Co-application of dFBr and 10 pM ACh response traces for 02D116A receptors 
expressed via the high sensitive receptor preparation. C) Co-application of dFBr and 100 pM ACh 
response traces for (32Y120A receptors expressed via the low sensitive receptor preparation. D) 
Co-application of dFBr and 10 pM ACh response traces for P2Y120A receptors expressed via the 
high sensitive receptor preparation. E) Co-application of dFBr and 100 pM ACh response traces 
for P2Y127A receptors expressed via the low sensitive receptor preparation. F) Co-application of 
dFBr and 10 pM ACh response traces for (32Y127A receptors expressed via the high sensitive 
receptor preparation. Response traces were recorded from a single oocyte. The solid bar above 
the response trace indicates the time the oocyte was exposed to co-application of varying 
concentrations of dFBr and ACh. For figures B, D and F, the response traces are offset for clarity.
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Appendix A.4 Response profiles for co-application of varying concentrations of dFBr 
and ACh for a4- face mutant receptors expressed using the low (LS) and high (HS) 
sensitive receptor preparations.
Xenopus oocytes were prepared using the high and low sensitive receptor preparations (HS 
mRNA injected at a ratio of 1a:50; LS mRNA injection at a ratio of 5a:10). Expressing oocytes 
were exposed to increasing concentrations of ACh and dFBr. A) Co-application of dFBr and 100 
pM ACh response traces for a4K140A receptors expressed via the low sensitive receptor 
preparation. B) Co-application of dFBr and 10 pM ACh response traces for a4K140A receptors 
expressed via the high sensitive receptor preparation. C) Co-application of dFBr and 10 pM ACh 
response traces for a4W88A receptors expressed via the high sensitive receptor preparation. 
Response traces were recorded from a single oocyte. The solid bar above the response trace 
indicates the time the oocyte was exposed to co-application of varying concentrations of dFBr 
and ACh. For figures A, B and C, the response traces are offset for clarity.
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